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Abstract 
The cell cycle is strictly regulated to ensure the precise transmission of genetic information 
from one cell to its daughter cells. The DNA damage response is one of these regulatory 
pathways and is activated in response to both intrinsic and extrinsic genotoxic stress. Once 
activated, downstream signalling disrupts normal cell cycle progression, causing arrest or 
alternatively, cell death. One of the cell cycle proteins, cyclin D1, has been suggested to play 
a crucial role in integrating the cell cycle machinery and the DNA damage response. This 
investigation demonstrates that cyclin D1 expression responds in a dose-dependent manner to 
the UV-mimetic DNA damaging agent, 4-nitroquinolin 1-oxide (4NQO). Immunoblotting 
experiments revealed a biphasic response of cyclin D1 expression to 4NQO:  cyclin D1 levels 
were largely unchanged following exposure of cells to low and high doses of 4NQO, whilst it 
was dramatically reduced after treatment with intermediate doses of 4NQO. The CDK 
inhibitor protein, p21, also responded in a dose-dependent manner, exhibiting elevated 
expression at low doses of 4NQO but was reduced or unchanged at intermediate and high 
doses, respectively. Exposure to IR or H2O2 triggered distinct responses by cyclin D1 and p21, 
indicating the likelihood that these DNA damaging agents activate distinct signalling 
pathways. Analyses of cellular responses by flow cytometry demonstrated that p21 expression 
primarily conferred resistance to damage-induced cell death whereas the level of cyclin D1 
expression correlated with the mode of cell death. 4NQO-induced cyclin D1 downregulation 
was proteasome-dependent but was resistant to deregulation of the majority of the key 
damage-regulating proteins. This investigation also revealed that other members of D-type 
cyclin family, cyclins D2 and D3, also exhibit distinct responses to various DNA damaging 
agents. Preliminary observations indicated that responses of the three D-cyclins were not 
interdependent and they may play distinct roles in the DNA damage response.   
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Chapter 1:  Introduction 
1.1 Cell cycle 
Proliferation of somatic cells consists of a series of carefully orchestrated events which 
collectively form a process called “the cell cycle”. The cell cycle can be divided into four 
stages; G1 (a first gap phase), S (where DNA is synthesised), G2 (a second gap phase) and M 
(where cells divide by mitosis); through which cells accurately duplicate their genomes and 
produce identical daughter cells. Progression through the cell cycle is regulated ultimately by 
extracellular signals such as growth factors, adhesion molecules and cytokines, which 
determine the balance between positive and negative regulators of cell cycle (Kato, 1999; 
Ekholm and Reed, 2000; Vermeulen et al., 2003; van den Heuvel, 2005). Mitogenic ligands 
arriving at the cell surface trigger a diverse array of intracellular signalling cascades typically 
involving surface-receptors and protein kinases (Pardee, 1989; Musgrove et al., 1994). These 
signals converge to upregulate proteins that are capable of driving cell cycle through G1 and 
towards DNA replication (Mann et al., 1997). Late in the G1 phase, cells undergo an 
irreversible transition and become committed to completing an entire round of cell cycle, 
independently of the presence of mitogenic stimuli. This crucial transition was first identified 
in 1974 and is referred to as the restriction (R) point (Pardee, 1974; Sherr, 1996; 
Blagosklonny and Pardee, 2002). In the absence of proliferative stimuli, cells exit cell cycle in 
G1 prior to the R point and establish a viable yet non-proliferative state known as quiescence 
(G0). Being the only phase of cell cycle responsive to extracellular signalling, the G1 phase 
plays the most critical role in determining the fate of a cell.  
 
Progression through the cell cycle is strictly regulated in such a way that the initiation of late 
events depends on the completion of early events (Hartwell and Weinert, 1989). Several 
classes of positive and negative regulators have been identified including, cyclins, cyclin-
dependent kinases (CDKs) and CDK inhibitors (CKIs). In addition to being the regulators of 
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cell cycle, the activities of these components of the cell cycle machinery are themselves under 
strict regulatory regimes.  
 
1.2 The Cell cycle machinery 
1.2.1 Cyclins  
Cyclins constitute a family of proteins whose primary function is to bind and activate cyclin-
dependent kinases. All cyclins contain a highly conserved stretch of approximately 100 amino 
acid residues known as “the cyclin box” that is required for interaction with CDKs 
(Kobayashi et al., 1992; Lees and Harlow, 1993; Morgan, 1997). The cyclin box assumes a 
unique tertiary structure, comprised of five tightly packed α-helices (Nugent et al., 1991; 
Brown et al., 1995; Jeffrey et al., 1995). The crystal structures of cyclins revealed that there 
are two cyclin box repeats localised near the middle to C-terminal region of cyclins. The N-
terminal cyclin box exhibited high sequence conservation amongst cyclins A, B, E and H. On 
the other hand, the C-terminal fold appeared topologically similar but showed significant 
sequence divergence (Brown et al., 1995; Jeffrey et al., 1995; Noble et al., 1997; Honda et al., 
2005; Petri et al., 2007).  
 
Cyclins were originally identified as proteins whose expression levels oscillated in a cell 
cycle-dependent manner in sea urchin eggs (Evans et al., 1983; Hunt, 2004). In mammalian 
cells, at least 14 types of cyclins have been identified, 7 of which have been implicated in cell 
cycle regulation as summarised in Table 1. Programmed synthesis and proteolysis ensure 
accumulation of a specific type of cyclin during a strictly defined window within the cell 
cycle. Such regulation allows for phase-specific activation of particular cyclin-CDK 
complexes (Glotzer et al., 1991; Pines, 1995; Sanchez and Dynlacht, 2005). The D-type and 
E-type cyclins are often referred to as G1-cyclins since their activities are required for  
 N. Suwaki 
Page | 19  
 
 
Table 1  Human cyclins and their primary binding partners identified to date. 
The proposed activities associated with the named cyclin-CDK complexes are 
indicated with appropriate reference.  
Cyclins CDK Activity Reference 
Cyclin A CDK2, CDK1 S, G2/M phase (Minshull et al., 
1990; Lew et al., 
1991; Desai et al., 
1992) 
Cyclin B CDK1 Mitosis 
Cyclin C CDK3, 8 
G0/G1 transition 
Transcription 
(Barette et al., 2001; 
Ren and Rollins, 2004) 
Cyclin D CDK4, CDK6 G1 phase 
(Matsushime et al., 
1992; Matsushime et 
al., 1994) 
Cyclin E CDK2 G1/S phases (Koff et al., 1992) 
Cyclin F - 
Nuclear localisation of cyclin B1 
during G2/M phase. 
(Bai et al., 1994; 
Kong et al., 2000) 
Cyclin G - 
Apoptosis? 
DNA damage? 
(Bates et al., 1996; 
Okamoto and Prives, 
1999) 
 
Cyclin H CDK7 
CDK-activating kinase, 
Active throughout cell cycle 
(Harper and Elledge, 
1998; Kaldis, 1999) 
Cyclin I - DNA damage? (Jensen et al., 2000) 
Cyclin J  Drosophila embryogenesis 
(Kolonin and Finley, 
2000) 
Cyclin K CDK9 Transcription (Baek et al., 2007) 
Cyclin L CDK11 mRNA splicing (Loyer et al., 2008) 
Cyclin T CDK9 Transcription (Wei et al., 1998) 
Cyclin S - Long-term memory 
(Edelheit and Meiri, 
2004) 
 
progression through G1 phase and an activation of a key transcription factor E2F (Dynlacht et 
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al., 1994; Black and Azizkhan-Clifford, 1999; Hengstschlager et al., 1999). Activation of E2F 
enables expression of components of the cell cycle machinery that are required for DNA 
synthesis (Muller et al., 2001; Dimova and Dyson, 2005). G1/S cyclins, comprising of E-and 
A-cyclins bound to CDK2, promote the completion of the G1/S transition and initiation of 
DNA synthesis in S phase (Coverley et al., 2002; Woo and Poon, 2003). The activities of 
cyclin A-CDK1/2 and cyclin B-CDK1 complexes regulate mitotic entry and completion of 
cell division (Pines, 1995; Nigg et al., 1996; Sanchez and Dynlacht, 2005; De Boer et al., 
2008).  
 
1.2.1.1 D-type cyclins 
In mammals, there are three D-cyclins, namely D1, D2 and D3, encoded by individual genes. 
They share an average of 57% sequence identity over their entire sequences whereas within 
the conserved cyclin box motif, up to 78% sequence identity is observed (Inaba et al., 1992; 
Xiong et al., 1992). Distinct members of D-cyclins are expressed in a tissue-specific manner. 
Cyclin D1 is predominantly found in fibroblasts whereas lymphocytes preferentially express 
cyclins D2 and D3 (Ando et al., 1993; Tam et al., 1994; Kaplan et al., 2005). Furthermore, 
different D-cyclins were shown to be expressed at particular stages during the development of 
various organs in mice (Sun et al., 1996; Yang et al., 2006b). Due to its nearly ubiquitous 
expression and the highest incidence of deregulation observed in cancer cells, cyclin D1 is the 
best characterised of the three members of the D-cyclins.  
 
D-cyclins are relatively unstable proteins with half lives of less than 30min (Diehl et al., 1997; 
Diehl et al., 1998). They differ from other cell cycle cyclins as their expression is regulated by 
extracellular signals rather than a phase-specific manner (Pardee, 1989; Sherr, 1995). In the 
presence of a mitogenic stimulus, D-cyclin levels are maintained relatively high throughout 
the cycle although a number of groups reported a small reduction during S phase (Stacey, 
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2003; Guo et al., 2005b; Yang et al., 2006a; Alao, 2007). A withdrawal of mitogenic stimulus 
results in a rapid degradation of D-cyclins (Matsushime et al., 1991; Guo et al., 2005a). Such 
property enables D-cyclins to act as sensors which link extracellular signals to the regulation 
of the cell cycle machinery (Diehl, 2002; Liang and Slingerland, 2003; Musgrove, 2006). As 
shown in Figure 1.1, cyclin D1 accumulation is achieved via at least three distinct Ras-
oncogene regulated signalling cascades (Peeper et al., 1997; Hitomi and Stacey, 1999; 
Musgrove, 2006). Firstly, an activated Ras induces a mitogen activated protein kinase (MAPK) 
cascade consisting of MAPK kinase (MEK), and extracellular signal-regulated kinase (ERK); 
leading to a transactivation of cyclin D1 gene (Aktas et al., 1997; Weber et al., 1997). 
Secondly, Ras activates phosphoinositol-3 kinase (PI3K) subsequently inducing protein 
kinase B (PKB)/Akt activity. PKB/Akt activation results in an elevated level of D-cyclin 
mRNA translation via promoting the activity of ribosomal protein S6 kinase 1 (S6K1) 
(Cantley, 2002; Liang and Slingerland, 2003; Koziczak and Hynes, 2004; Musgrove, 2006). 
Finally, the PI3K-PKB/Akt-pathway can also lead to inhibition of glycogen synthase kinase 
3β (GSK3β) whose activity is required for degradation of D-cyclins (Diehl et al., 1997; Diehl 
et al., 1998; Takahashi-Yanaga and Sasaguri, 2008).  
 
Degradation of cyclin D1 is initiated by a phosphorylation of the T286 residue. The 
phosphorylation promotes an association between cyclin D1 and a nuclear exportin, CRM1, 
which shuttles cyclin D1 to the cytoplasm (Diehl et al., 1997; Diehl et al., 1998). In the 
cytoplasm, the phosphorylated T286 mediates the interaction of cyclin D1 with the F-box 
subunit of the E3-ligase complex, known as the Skp2-Cul1-F-box
Fbx4-αBcrystallin
 (SCF
Fbx4-
αBcrystallin
) complex (Alt et al., 2000; Lin et al., 2006; Alao, 2007; Barbash et al., 2007). The 
interaction between another subunit of the SCF
Fbx4-αBcrystallin
 complex, Cul1, and cyclin D1 
further assists the ubiquitination event (Maeda et al., 2001). Subsequently, cyclin D1 becomes 
degraded via proteasome-dependent pathway. There are a number of other pathways by which 
cyclin D1 appears to be degraded. For instance, degradation of free cyclin D1 was shown to 
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depend on ubiquitination but not on the phosphorylation of T286 residue (Germain et al., 
2000). An alternative protein kinase, Mirk/Dyrk1B, whose expression is prominent in 
quiescent cells, was shown to bind to cyclin D1 instigating a phosphorylation of cyclin D1 at 
T288. This modification was also able to destabilise cyclin D1 (Zou et al., 2004).  
 
1.2.1.2  Multifaceted role of D-cyclins in mammalian cells 
The primary function of D-cyclins is the activation of its cognate CDK partners, CDK4 and 
CDK6, and subsequent inactivation of retinoblastoma proteins (pRb, p107, p130) by 
phosphorylation (Matsushime et al., 1992; Meyerson and Harlow, 1994). pRb was the first 
tumour suppressor to be identified and is found mutated in a rare paediatric eye tumour, 
retinoblastoma. It consists of 928 amino acids with the so called A-box, B-box and a spacer (S) 
region forming the “pocket” domain. The B-box contains several highly conserved residues 
such as Y709, Y756 and N757. These residues are involved in interactions between pRb and 
“pocket binding proteins” including histone deacetylases (HDACs), components of SWI/SNF 
nucleosome remodelling complex, D-cyclins and several oncogenes, most of which bear a 
conserved LxCxE motif (Dowdy et al., 1993; Lee et al., 1998; Harbour and Dean, 2000a; 
Kim et al., 2001). pRb exerts its cell cycle inhibitory functions via two distinct mechanisms, 
keeping a tight control at the R-point of cell cycle. Firstly, pRb physically interacts with E2F 
transcription factors via the pocket region, impeding the ability of E2Fs to transactivate gene 
expression (Flemington et al., 1993; Helin et al., 1993). As a result, E2F transcription factors 
are unable to induce expression of proteins that are important for S phase entry and DNA 
synthesis such as cyclin E, cyclin A, DNA polymerase α, and proliferating cell nuclear antigen 
(PCNA) (Ohtani et al., 1995; Dyson, 1998; Black and Azizkhan-Clifford, 1999; Muller and 
Helin, 2000). Secondly, through interactions mediated by the pocket region, pRb can recruit 
SWI/SNF and HDAC1 to promoters with E2F-binding sites to form a single complex, E2F-
pRb-SWI/SNF/HDAC1 (Trouche et al., 1997). This complex subsequently confers a “closed” 
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conformation on chromatin, reducing access to the transcriptional machinery and hence 
inhibiting expression from E2F-responsiove promoters (Harbour and Dean, 2000c; Zhang et 
al., 2000).  
 
Cyclin D-CDK4/6 holoenzymes activated at G1 phase of cell cycle initiates an inactivation of 
pRb by phosphorylating specific sites out of 16 identified target sites such as S780, S795 and 
T826 (Kitagawa et al., 1996; Zarkowska and Mittnacht, 1997; Lundberg and Weinberg, 1998). 
Physical interactions between D-cyclins as well as CDK4 with pRb have been demonstrated 
to promote this phosphorylation (Dowdy et al., 1993; Ewen et al., 1993; Kato et al., 1993; 
Wallace and Ball, 2004). The current model suggests that these initial phosphorylations 
induce a conformational change in the A-/B-boxes of pRb, exposing an additional 
phosphorylation site, S567, which lies within the S-region. Subsequent phosphorylation of 
S567 by another G1-cyclin-CDK complex, cyclin E-CDK2, induces a large conformational 
change, disrupting the interaction between pRb and E2F (Harbour et al., 1999; Adams, 2001).  
 
Whilst pRb remains as the best characterised substrate of cyclin D-CDK4/6 holoenzymes, a 
number of potential targets have been identified more recently. For instance, signal 
transducers of transforming growth factor-β (TGF-β), Smad2 and Smad3, are subject to 
repressive phosphorylation by cyclin D-CDK4 and cyclin E/A-CDk2 (Matsuura et al., 2004). 
Cyclin D-CDK4 activities also appear to regulate the activity of a bone- and cartilage–specific 
transcription factor, Runx2 (Shen et al., 2006) as well as a CDK inhibitor, p21 (unpublished 
data, Child and Mann). In addition to a CDK-activatory function, it has become apparent that 
D-cyclins possess cellular functions independent of CDKs. Cyclin D1 positively regulates 
transcription of estrogen responsive element genes by mediating a ligand-independent binding 
of estrogen receptor α (ERα) and steroid receptor coactivators (Zwijsen et al., 1997; Zwijsen 
et al., 1998). A physical interaction between cyclin D1 and p300/CBP-associated factor 
(P/CAF) which contains an intrinsic histone acetyl-transferase activity can further assist 
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transactivation (Bernards, 1999; McMahon et al., 1999). On the other hand, binding of D-
cyclins to other transcription factors such as STAT3, b-Myb and cyclin D-binding Myb-like 
protein (DMP1), results in inhibition of their activities in a CDK-independent manner (Hirai 
and Sherr, 1996; Bienvenu et al., 2001; Fu et al., 2004; Inoue et al., 2007).  
 
1.2.2 Cyclin-dependent kinases (CDKs) 
CDKs belong to a family of serine/threonine protein kinases that form heterodimeric 
holoenzyme with cyclins. They target a consensus five amino acid motif, S/T-P-X-K/R, found 
in their substrates. A proline residue at the +1 site is absolute requirement although the 
positive residue at +3 site is sometimes absent (Stevenson-Lindert et al., 2003; Ubersax et al., 
2003; Takada et al., 2004). Expression levels of CDKs remain relatively constant throughout 
cell cycle and phase-specific activation of distinct CDKs are ensured by oscillating levels of 
their regulatory cyclin subunit (Glotzer et al., 1991; Ekholm and Reed, 2000). Mammalian 
CDKs were identified either as cyclin-binding protein kinases that were closely related to 
CDC2 of Schizosaccharomyces pombe (S.pombe) or CDC28 of Saccharomyces cerevisiae (S. 
cerevisiae) (Norbury and Nurse, 1989; Meyerson et al., 1992; Bullrich et al., 1995). To date, 
up to 12 CDKs have been discovered and at least 7 of them have been implicated in cell cycle 
control whilst others are involved in transcriptional and developmental regulation (Pines, 
1994; Morgan, 1997; Vahteristo et al., 2001; Vermeulen et al., 2003) The activities of cell 
cycle CDKs are tightly regulated by an array of post-translational modifications and 
interactions with positive and negative regulators as discussed below.  
 
1.2.2.1 Positive regulators of CDKs 
(a) Cyclins 
Binding of a cyclin to CDK induce a partial activation of the latter by triggering a large 
conformational change. CDKs are composed of a β-sheet-rich N-terminal lobe and a C-
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terminal lobe rich in α-helix with a catalytic cleft found in between the two. Several 
conserved residues in the N-terminal lobe have been identified to mediate an interaction with 
cyclins (De Bondt et al., 1993; Jeffrey et al., 1995). Upon binding of a cyclin, the highly 
conserved PSTAIRE motif of the CDK rotates about the axis and becomes shifted into the 
catalytic cleft, positioning a catalytic residue, E51, to align with D145 and K33 (Jeffrey et al., 
1995; Morgan, 1997). The T-loop of the CDK, containing a conserved threonine residue 
found phosphorylated in fully active CDK, also interacts with cyclin. The interaction moves 
the T-loop away from the entrance of the catalytic cleft allowing binding of substrates and the 
activatory phosphorylation site becomes accessible (De Bondt et al., 1993; Jeffrey et al., 1995; 
Pavletich, 1999). In addition, it has been suggested that cyclins partly control the subcellular 
localisation of cyclin-CDK complexes (Yang and Kornbluth, 1999). Distinct molecular 
mechanisms of nuclear trafficking have been proposed for different cyclin-CDK complexes. 
Subcellular localisation of cyclin A- and cyclin B- complexes are regulated by the N-terminal 
region of the cyclins whilst cyclin E appears to mimic classical nuclear localisation signal-
containing proteins, directing an association of the cyclin-CDK complex with nuclear 
trafficking proteins such as importin α/β (Pines and Hunter, 1994; Moore et al., 1999). Others 
demonstrated that phosphorylation of cyclin D1 or cyclin B1 promotes their interaction with 
the nuclear exporter, CRM1 (Diehl et al., 1998; Yang et al., 1998; Alt et al., 2000). Whilst 
most cyclins can direct nuclear transport without forming a complex with a CDK, the ability 
of cyclin A to regulate subcellular localisation of the complex depends on its interaction with 
CDK2 (Maridor et al., 1993; Jackman et al., 2002).  
 
(b) Activatory phosphorylation by CDK-activating kinase (CAK) 
Full activation of a CDK requires phosphorylation at a conserved threonine residue, T160 (in 
human CDK2), mediated by CDK-activating kinase (CAK) (Lorca et al., 1992; Brown et al., 
1999; Kaldis, 1999; Stevenson et al., 2002). The exact role of this modification during 
activation varies amongst cyclin-CDK complexes. In some cases, such as cyclin A-CDK1 
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complexes, this phosphorylation is a pre-requisite for stable complex formation whereas most 
cyclins and CDKs exhibit high affinity interactions in the absence of this phosphorylation 
(Ducommun et al., 1991; Desai et al., 1995). In mammalian cells, the cyclin H-CDK7 
complexes together with a third protein, MAT-1, function as CAK (Harper and Elledge, 1998). 
Following an initial conformational change associated with cyclin binding as discussed above, 
CAK-dependent phosphorylation of the T-loop threonine induces further conformational 
changes in the T-loop and C-terminal lobe of a CDK, completing the rearrangement of 
catalytic residues to their active orientations for full activation of the holoenzymes (Jeffrey et 
al., 1995; Russo et al., 1996b; Pavletich, 1999).  
 
1.2.2.2 Negative regulators of CDKs 
(a) INK4 family of CDK inhibitors (CKIs) 
Members of the INK4 family of CKIs are specific inhibitors of cyclin D-associated kinase 
activities. Four members of the INK4 family, p16
INK4a
, p15
INK4b
, p18
INK4c
 and p19
INK4d
, share a 
common structural unit known as ankyrin repeats, which form L-shaped domains (Serrano et 
al., 1993; Hirai et al., 1995). The crystal structures of p16
INK4a
- and p19
INK4d
-bound CDK6 
revealed that the binding of an INK4 inhibitor induces allosteric changes in the CDK, rotating 
the N-terminal lobe away from and its C-terminal lobe. This misalignment of the two lobes 
distorts the ATP-binding site and subsequently inhibits kinase activity (Brotherton et al., 1998; 
Russo et al., 1998). It is generally believed that INK4 inhibitors compete with D-cyclins for 
binding to CDK4/6 as INK4-CDK complexes are often isolated as heterodimers (Sherr et al., 
1994; McConnell et al., 1999; Vidal and Koff, 2000). However, the amino acid residues 
responsible for mediating p16
INK4a
/p19
INK4d
 interactions with CDK4/6 do not overlap those for 
cyclin-CDK (Jeffrey et al., 1995; Coleman et al., 1997; Brotherton et al., 1998; Russo et al., 
1998). To support this view, a ternary complex between INK4 and cyclin-CDK4 complex can 
be obtained in vitro (Serrano, 1997).  
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(b) Cip/Kip family of CKI 
The CDK interacting protein/cyclin dependent kinase inhibitory protein (Cip/Kip) family of 
CDK inhibitors has three members, p21
Cip1/Waf1
, p27
Kip1
 and p57
Kip2
 (referred to as p21, p27 
and p57 hereafter), and show a broader target range when compared to INK4 inhibitors 
(Harper et al., 1993; Xiong et al., 1993; Polyak et al., 1994b; Toyoshima and Hunter, 1994; 
Lee et al., 1995; Matsuoka et al., 1995). The three members are structurally related and show 
up to 44% sequence identity in their N-terminal regions whilst their C-terminal regions 
exhibit divergence in length, sequence and function (Russo et al., 1996a; Nakayama, 1998). 
p21 is a p53-responsive gene and is often upregulated during a DNA damage response and 
can cause cell cycle arrest (el-Deiry et al., 1993; el-Deiry et al., 1994). p27 expression, on the 
other hand, is responsive to anti-proliferative signals such as cell-cell contact and TGF-β and 
is found at reduced levels during proliferation (Pagano et al., 1994; Polyak et al., 1994a; Sa et 
al., 2005). p57 is often found coexpressed with p27 in many organs although studies using 
knockout mice suggested that p57 is likely to play a crucial role in early organogenesis that 
cannot be complemented by p27 (Lee et al., 1995; Matsuoka et al., 1995; Nakayama, 1998). 
p57 is the least studied Cip/Kip proteins of the three.  
 
Cip/Kip inhibitors associate with different CDKs with varying affinities. They are potent 
inhibitors of CDK2, CDK3, CDK4 and CDK6 kinases but are less effective towards CDK1 
and CDK5 and do not associate with CDK7 (Gu et al., 1993; Polyak et al., 1994a; Toyoshima 
and Hunter, 1994; Harper et al., 1995; Lee et al., 1995; Blain, 2008). The crystal structure of a 
ternary complex comprising cyclin A-CDK2-p27 revealed that p27 binds to both cyclin and 
CDK, utilising its highly flexible and extended structure (Russo et al., 1996a). A large 
conformational changes in CDK2, induced by the binding of p27, inhibits CDK2 kinase 
activity by three mechanisms; (1) a structural rearrangement of the N-terminal lobe of CDK2, 
destabilising any bound ATP from the catalytic cleft, (2) p27 inserts a small 310-helix to the 
catalytic cleft to mimic ATP and (3) binding of p27 to a peptide-binding groove of cyclin A 
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blocks substrate interactions (Russo et al., 1996a; Pavletich, 1999). Furthermore, binding of a 
Cip/Kip inhibitor was shown to interfere with activatory phosphorylation of CDK by CAK 
(Smits et al., 2000).   
 
Although initially identified as inhibitors, Cip/Kip proteins are frequently found in complex 
with active cyclin-CDK complexes in proliferating cells (Zhang et al., 1994; Harper et al., 
1995; Cheng et al., 1999; Sherr and Roberts, 1999; Blain, 2008). In particular, it has been 
suggested that the formation of stable cyclin D-CDK4 complexes are promoted by Cip/Kip 
proteins (LaBaer et al., 1997; Cheng et al., 1999; Sugimoto et al., 2002; Bagui et al., 2003). 
How p21 and p27 switch between these diametrically opposing roles in cell cycle control is 
unknown. The “stoichiometry model” proposed that p21 and p27 act as inhibitors once their 
cellular concentration exceeded a certain threshold (Zhang et al., 1994; Harper et al., 1995). 
However, this model contradicted an observation that a single molecule of p21 or p27 can 
cause complete inhibition of cyclin-CDKs (Russo et al., 1996a; Hengst et al., 1998). Recently, 
it was suggested that the phosphorylation status at two tyrosine residues of p27 may 
determine its ability to inhibit or activate cyclin-CDK complexes (Blain, 2008; James et al., 
2008). This hypothesis appears promising as differential phosphorylation status of p21 can 
regulate its multifaceted functionalities (Jarviluoma et al., 2006).  
 
(c) Inhibitory phosphorylation of CDKs 
Cyclin-CDK complexes can be inhibited by post-translational modification of a conserved 
tyrosine residue, Y15 and, to a lesser extent, T14 (Norbury et al., 1991; Gu et al., 1992; 
Morgan, 1995). These residues are located within a glycine-rich loop of CDK (GXGTYG) 
and are phosphorylated by Wee1 and Myt1. As they protrude over the ATP-binding regions 
within the catalytic cleft, it is believed that the phosphorylation of these residues physically 
blocks ATP binding to cyclin-CDK complexes (De Bondt et al., 1993; Jeffrey et al., 1995). 
The CDC25 family of protein phosphatases is responsible for removing these phosphate 
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groups to activate CDKs during cell cycle. In mammals, three CDC25 isoforms have been 
identified; CDC25A, CDC25B, and CDC25C (splice variant 1, 2, and 3). Generally, CDC25A 
regulates entry and progression through S phase by activating of cyclin E/A-CDK2 and 
CDC25B and CDC25C have been implicated in the regulation of cyclin B/CDK1 and thus 
controlling G2-M transition (Donzelli and Draetta, 2003; Boutros et al., 2006; Karlsson-
Rosenthal and Millar, 2006). 
 
1.3 The DNA damage response 
1.3.1 Overview of the DNA damage response 
The strict and timely regulation of the cell cycle as described above enables ordered 
progression, orchestrating events in a timely manner to achieve the faithful transmission of 
genetic material. However, our genomes are under constant attack from both intrinsic and 
extrinsic sources of damage, such as ultraviolet (UV) light, ionising radiation (IR), reactive 
oxygen species (ROS) and a wide array of DNA modifying/damaging chemicals, that are able 
to induce DNA lesions at any point during cell cycle (Hoeijmakers, 2001; Sancar et al., 2004). 
To protect our genome, cells have developed mechanisms through which they detect the 
presence of DNA lesions and rapidly induce global cellular responses including a transient 
and/or permanent cell cycle arrest, DNA repair and cell death, collectively known as the DNA 
damage response. The types of cellular responses triggered by the DNA damage are believed 
to be dependent on types and levels of DNA abrasions (Zhou and Elledge, 2000; Carr, 2002; 
Kastan and Bartek, 2004).  
 
1.3.2 Components of the DNA damage response 
The components of the DNA damage response form a hierarchy of signalling cascades. They 
are composed of three classes of signalling molecules; sensors, transducers and effectors; 
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although the classification of upstream regulators is arguable (Hoeijmakers, 2001; McGowan 
and Russell, 2004; Niida and Nakanishi, 2006; Harper and Elledge, 2007). Sensor elements 
govern the initial events in DNA damage-induced signalling. Our understanding of how these 
sensor proteins detect the structural changes in DNA locally and translate it to an activation of 
global cellular response is limited. However, a number of proteins have emerged as prominent 
candidates for this task. Ataxia-telengiectasia mutated (ATM) and ATM and Rad3-related 
(ATR) belong to a family of phosphoinositol 3-kinase related kinases (PIKK) and are both 
activated by DNA damage. ATM is primarily activated in response to double-strand DNA 
strand breaks (DSB) whilst ATR is found activated in response to single-strand DNA strand 
breaks (SSB) and stalled replication forks (Abraham, 2001; Shiloh, 2001; Nyberg et al., 2002; 
Yang et al., 2003). The observations that both ATM and ATR can interact with damaged DNA 
led to the hypothesis that they are directly activated upon recruitment to the site of damage 
and thus act as sensors (Suzuki et al., 1999b; Guo et al., 2000; Yang et al., 2004). Others have 
suggested that ATM and ATR are activated through mediator proteins that can direct a 
formation of a multi-protein complex at the site of damage. For instance, ATM-interacting 
proteins include Mre11-Rad50-Nbs1 (MRN) complex, mediator of DNA damage checkpoint 
1 (MDC1) and p53-binding protein 1 (53BP1), whereas ATR can associate with ATR-
interacting protein (ATRIP), Claspin, Rad17-replication factor C (RFC)-like complex, and 
Rad9-Rad1-Hus1 complex, to name a few (Cortez et al., 2001; Bermudez et al., 2003; Chini 
and Chen, 2003; Lin et al., 2004). In this model, ATM and ATR are classified as signal 
transducers and mediator proteins rather than sensors of DNA damage.  
 
Upon activation, ATM and ATR phosphorylate two of the main downstream signal 
transducers, checkpoint kinases 1 and 2 (Chk1 and Chk2) (Matsuoka et al., 1998; Ahn et al., 
2000; Guo et al., 2000; Liu et al., 2000; Zhao and Piwnica-Worms, 2001). They play an 
important role of relaying DNA damage signalling from damage sites to the effector proteins 
including the components of cell cycle, DNA repair, and cell death pathways, to bring about a 
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“pan-cellular” response (Bartek and Lukas, 2003; Lukas et al., 2004; Niida and Nakanishi, 
2006; Chen and Poon, 2008). Deciphering DNA damage responses associated with various 
DNA damaging agents is an extremely challenging task due to a sheer volume of potential 
substrates identified for these upstream regulators. For example, there are several hundreds of 
potential phosphorylation target sites identified for ATM and ATR whilst the number of 
recognised substrates for Chk1 and Chk2 continues to grow (Kurz and Lees-Miller, 2004; 
Kim et al., 2007; Matsuoka et al., 2007; Stokes et al., 2007). The importance of DNA damage 
response is apparent as a failure in this pathway results in genomic instability which is a 
hallmark of cancer. Indeed, many cancer cells and cancer-prone genetic disorders show 
defects in one or more components of the DNA damage response (Weinert and Lydall, 1993; 
Kastan and Lim, 2000; Wang, 2000; Hoeijmakers, 2001).  
 
1.3.3 DNA damage response and cell cycle 
Normal proliferating cells are only able to withdraw from the cell cycle during G1 phase prior 
to the R-point (Pardee, 1974). The effector components of the DNA damage response, 
however, interact with the cell cycle machinery and enable cells to perturb their progress at 
any point during cell cycle, allowing damaged DNA to be repaired prior to cell cycle 
progression. A number of well-established pathways are briefly discussed below.  
 
1.3.3.1 G1 arrest: ATM/ATR-Chk2/Chk1-p53/MDM2-p21 pathway 
Mammalian cells acquiring DNA damage during G1 phase of the cell cycle temporarily or 
permanently arrest in G1 via the ATM/ATR-Chk2/Chk1-p53/MDM2-p21 pathway. Active 
ATM/ATR and Chk2/Chk1 phosphorylate p53 at multiple target sites in the N-terminal 
domain, particularly at Ser 15 and Ser 20, respectively (Canman et al., 1994; Chehab et al., 
1999; Lakin and Jackson, 1999; Tibbetts et al., 1999; Shieh et al., 2000; Saito et al., 2002; 
Chen and Poon, 2008). This phosphorylation interferes with the binding between p53 and an 
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ubiquitin ligase responsible for its rapid turnover, MDM2, and thus stabilises p53 expression. 
In addition, the upstream kinases also phosphorylate MDM2 directly, leading to inactivation 
of p53-degradation pathway (Maya et al., 2001). p53-dependent transactivation results in an 
accumulation of p21 which subsequently inhibits the G1-cyclin-CDK complexes whose 
activities are required for the G1/S transition (Siliciano et al., 1997; Jabbur et al., 2000; 
Bartek and Lukas, 2001). Furthermore, p21-dependent inhibition of G1-cyclin-CDK 
complexes maintains pRb in an active form which contributes to a sustained G1 arrest by 
repression of E2F activities (Garner and Raj, 2008).  
 
1.3.3.2 S phase arrest: ATM/ATR-Chk2/Chk1-CDC25A pathway 
An alternative downstream target of Chk1/Chk2 is CDC25A, whose activity is required for 
activation of S-cyclin-CDK complexes. Following DNA damage induced by UV or IR, a 
rapid degradation of CDC25A is observed in ATM/ATR-Chk2/Chk1-dependent manner 
(Mailand et al., 2000; Falck et al., 2001; Sorensen et al., 2003). This is accompanied by 
inhibition of its downstream target, CDK2. As the activities of cyclin E-CDK2 and cyclin A-
CDK2 complexes are required for efficient DNA synthesis and progression through S phase, 
reduced CDC25A activities result in S phase arrest (Shirahige et al., 1998; Costanzo et al., 
2003; Xiao et al., 2003).   
 
1.3.3.3 G2/M arrest: Inhibition of cyclin B-CDK1 complexes 
DNA damage-induced G2/M arrest predominantly results from inhibition of cyclin B-CDK1 
complexes. Both p21 and other members of the CDC25 family, CDC25B/C have been 
implicated in establishing G2/M arrest downstream of ATM/ATR and Chk1/Chk2 (Peng et al., 
1997; Bunz et al., 1998; Niculescu et al., 1998; Chan et al., 2000; Bulavin et al., 2001; 
Walworth, 2001; Karlsson-Rosenthal and Millar, 2006). Firstly, a number of evidence 
suggested that the p53-dependent induction of p21 interfere with the activation of cyclin B-
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CDK1 complexes by blocking the activatory phosphorylation of the complex by CAK (Smits 
et al., 2000; Baus et al., 2003; Charrier-Savournin et al., 2004). Secondly, DNA damage-
induced degradation of CDC25B/C was also observed, leading to accumulation of inactive 
phospho-Y15 CDK1 (Furnari et al., 1997; Rhind et al., 1997; Sanchez et al., 1997; Graves et 
al., 2000; Chen et al., 2002).  
 
1.4 Thesis 
1.4.1 DNA damaging agents 
Molecular and cellular responses mounted by cells as a result of activation of DNA damage 
response are dependent on the types and levels of DNA damage imposed (Kaufmann and 
Paules, 1996; Zhou and Elledge, 2000). However, defining precisely the types and amount of 
DNA lesions associated with a single DNA damaging agent is difficult as it frequently causes 
more than one types of damage including strand breaks, base modifications and cross-linking 
to name a few. Furthermore, the potency of an agent often varies amongst cell types. In this 
thesis, four commonly used DNA damaging agents were employed: UV, IR, 4-nitroquinoline 
1-oxide (4NQO) and H2O2.   
 
1.4.1.1  IR and H2O2 
IR can impose DNA damage by two distinct mechanisms: (1) chemical modification by a 
direct ionisation of DNA and (2) by generating potent ROS such as a hydroxyl radical (·OH) 
(Leach et al., 2001; Lomax et al., 2002). H2O2 is a source of ·OH and hence induces similar 
types of DNA damage as IR (Loft and Poulsen, 1996; Patrzyc et al., 2001). DNA lesions 
incurred by IR and H2O2 include base modification, SSB, and DSB. A single ·OH often target 
guanine and to a lesser extent thymidine and can induce formation of “DNA tandem lesions” 
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where a ·OH -adduct formed at one base triggers an electron/proton transfer amongst 
nucleobases in the vicinity. As a result, an initial DNA lesion is amplified to form a cluster of 
damaged residues and/or strand breaks (Siddiqi and Bothe, 1987; Chatgilialoglu and O'Neill, 
2001; Dizdaroglu et al., 2002; Lomax et al., 2002). Such damage imposed by IR or H2O2 are 
potent activators of ATM and Chk2 as well as DNA repair pathways including base excision 
repair and DSB repair pathways (Taylor and Lehmann, 1998; Bakkenist and Kastan, 2003; 
Buscemi et al., 2004). 
 
1.4.1.2 UV and 4NQO 
UV induces damage to cellular chromophores, such as DNA, that are able to absorb energy 
from UV radiation leading to formation of pyrimidine dimers and base modifications. The 
presence of such modifications imposes a structural constraint on DNA, interfering with 
replication and transcription which often leads to further damage by strand breaks (Berlingin 
et al., 1992; Kim et al., 1995; Kaufmann and Paules, 1996; Sinha and Hader, 2002; Latonen 
and Laiho, 2005). These events consequently result in the activation of the DNA damage 
response components, ATR and Chk1 (Guo et al., 2000; Heffernan et al., 2002; Unsal-
Kacmaz et al., 2002; Paulsen and Cimprich, 2007). An environmental carcinogen, 4NQO, is 
often referred to as a UV-mimetic, primarily due to its ability to impose DNA damages that 
are repaired by nucleotide excision repair (NER), the same repair pathway that is responsible 
for removing UV-induced damage (Wolff et al., 1977; Zelle and Bootsma, 1980; Yang et al., 
1991; Jones et al., 1992; Taylor and Lehmann, 1998). Upon cellular uptake, 4NQO undergoes 
metabolic activation leading to the generation of the active species, acetoxy-4-aminoquinolin 
1-oxide (Ac-4HAQO) (Figure 1.2) (Kawazoe and Araki, 1967; Nagao and Sugimura, 1976; 
Demeunynck et al., 1981; Galiegue-Zouitina et al., 1983). Ac-4HAQO binds to guanine or 
adenine to form bulky base adducts, dGuo-C8-AQO, dGuo-N2-AQO, and dAdo-N6-AQO 
(Bailleul et al., 1984; Galiegue-Zouitina et al., 1985; Galiegue-Zouitina et al., 1986). These 
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modifications give rise to base-pair change mutations (Nagao and Sugimura, 1976; Fronza et 
al., 1992). The intermediates such as 4-hydroxyaminoquinolin 1-oxide (4-HAQO) and various 
other 4NQO derivatives have also been shown to cause DNA lesions and mutations (Stich et 
al., 1971; Bailleul et al., 1981; Nunoshiba and Demple, 1993). Furthermore, activation of 
4NQO to 4HAQO contributes to the generation of ROS leading to an oxidative damage of 
DNA such as strand break (Speelman et al., 1983; Fronza et al., 1992; Nunoshiba and Demple, 
1993; Arima et al., 2006)  
 
1.4.2 Role of cyclin D1 in DNA damage response 
Amongst various cell cycle proteins implicated in the DNA damage response, a dramatic 
clearance of cyclin D1 following exposure IR, UV, and H2O2 has been reported (Hiyama and 
Reeves, 1999; Agami and Bernards, 2000; Miyakawa and Matsushime, 2001; Barnouin et al., 
2002; Fasanaro et al., 2006). Although different molecular mechanisms appear to be 
responsible for the degradation process in each case, reduced cyclin D1 levels are 
predominantly associated with enforced G1 arrest. Moreover, there is evidence of both 
positive and negative roles of cyclin D1 in apoptosis (Dobashi et al., 1998; Dobashi et al., 
1999; Katayama et al., 2001; Tabbi et al., 2002; Dobashi et al., 2004; Retzer-Lidl et al., 2007; 
Thoms et al., 2007a; Thoms et al., 2007b), suggesting that cyclin D1 may have functions in 
the DNA damage response additional to its critical role in cell cycle regulation. This may 
explain the association of cyclin D1 deregulation with a wide range of cancers including those 
of breast, neck and head (de Jong et al., 1998; de Jong et al., 1999; Hardisson, 2003).  
 
In this thesis, the potential roles of cyclin D1 in the DNA damage response were explored 
with the following objectives:  
1) Determination of cyclin D1 responses to various DNA damaging agents (4NQO, 
H2O2, UV and IR) and identification of the DNA damage-responsive cell cycle 
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proteins in mammalian cells.  
2) Assessment of cellular responses associated with DNA damage-induced cyclin 
D1 response in mammalian cells.  
3) Investigation of upstream and downstream regulators of the cyclin D1 response to 
DNA damage.  
4) Comparison of DNA damage-induced responses of the three members of D-type 
cyclins in mammalian cells.  
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Figure 1.1 Ras-mediated intracellular signalling cascades regulate cyclin D1 
expression level at various levels 
 A schematic diagram of a Ras-dependent signalling cascade which ultimately leads to an 
upregulation of cyclin D1.When activated, a signal transducer protein, Ras, induces cyclin D1 
transcription via a MAPK signalling cascade composed of Raf-MEK-ERK. Ras also induces a 
PI3K-Akt/PKB signalling which subsequently direct an upregulation of cyclin D1 by either 
enhancing cyclin D1 mRNA translation or by inhibition of cyclin D1 degradation via an 
inactivation of GSK3β.  
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Figure 1.2  Mechanism of activation of 4NQO to Ac-4HAQO 
Upon cellular uptake, 4NQO undergoes a series of reductions to form an intermediate 
4HAQO, generating ROS during the reaction. 4HAQO is then converted to its ultimate 
carcinogenic form, Ac-4HAQO, via an intermediate diacetyl-4-hydroxyaminoquinolin 1-
oxide (di-Ac-4HAQO).  
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Chapter 2:  Materials and Methods 
2.1 Chemicals 
All chemicals were purchased from Amersham Pharmacia, BDH Merck, Calbiochem, GE 
Healthcare, Gibco, Invitrogen, Melford Laboratories, MilliPore, Molecular Probe, National 
Diagnostics, Pharmacia, Sigma-Aldrich UK, TAAB Laboratories Equipment and VWR 
International. Enzymes and antibodies were obtained from BD Biosciences, BD Pharmingen, 
Biosource International, Boehringer Mannheim, Helena Biosciences, Santa Cruz 
Biotechnology, Cancer Research UK and New England Bio Labs.  
 
2.2 Buffers and Solutions 
The most commonly used buffers and solutions are listed below (Table 2).  
Table 2  Compositions of buffers and solutions employed. 
Buffer A  
(subcellular localisation) 
10mM Tris-HCl pH8.0 / 10mM KCl, 1.5mM 
MgCl2 / 0.34M sucrose / 10% (v/v) glycerol / 
1mM DTT / 0.1mM PMSF 
Coomassie brilliant blue staining solution 
0.25% (w/v) Coomassie blue dye / 10% (v/v) 
methanol / 10% (v/v) acetic acid 
Carbonated Electrophoresis transfer 
buffer 
3mM Na2CO3 / 10mM NaHCO2 / 0.01% (w/v) 
SDS / 10% (v/v) methanol 
Destaining solution 10% (v/v) acetic acid / 10% (v/v) methanol 
DNA denaturing solution 2N HCl / 0.5% (v/v) Triton X-100 
DNA ligation buffer 
500mM Tris-HCl pH7.6 / 100mM ATP / 10mM 
MgCl2 / 10mM DTT / 50µg/ml BSA  
Electrophoresis transfer buffer (ETB) 
25mM Tris-base / 190mM glycine / 0.01% (w/v) 
SDS / 10% (v/v) methanol 
Gene Clean Washing solution  
10mM Tris-HCl pH7.5 / 50mM NaCl / 2.5mM 
EDTA / 50% (v/v) ethanol 
GST Tween based wash buffer  20mM Tris-HCl pH8.0 / 0.1% (v/v) Tween 20 / 
 N. Suwaki 
Page | 40  
 
100mM NaCl / 1mM EDTA 
HEPES Buffered saline (HBS) solution 
59mM HEPES pH7.04 / 280mM NaCl / 10mM 
KCl / 1.5mM Na2HPO4 /12mM Dextrose  
K-buffer 
25mM Tris-HCl pH8.0 / 5mM MgCl2 / 0.1mM 
EGTA pH7.5 / 0.1% (v/v) β-mercaptoethanol 
Luria Broth Media 
1%(w/v) bactitryptone / 1%(w/v) NaCl / 
0.5%(w/v) bactoyeast extract pH7.0 
Ligation Buffer 
10mM ATP / 50mM Tris-HCl pH 7.6 / 1mM 
MgCl2 / 1mM DTT / 50μg/ml BSA 
NETN buffer 
20mM Tris-HCl pH8.0 / 0.5% (v/v) Nonited-40 / 
100mM NaCl / 1mM EDTA 
Phosphate buffered saline (PBS) 
140mM NaCl / 3mM KCl / 10mM Na2HPO4 / 
20mM KH2PO4 
Phosphate buffer saline Tween (PBST) 
140mM NaCl / 3mM KCl / 10mM Na2HPO4 / 
20mM KH2PO4 / 0.1% (v/v) Tween 20 
RIPA buffer 
50mM Tris-HCl pH8.0 / 150mM NaCl / 0.1% 
(v/v) Nonited-40 / 0.128%(w/v) sodium 
deoxycholate / 0.1% (v/v) SDS 
Tris-Acetate Buffer (TAE) 
40mM Tris-acetate pH8.5 /  
1mM EDTA pH8.0 
TAE loading buffer 
40mM Tris-acetate pH8.5 / 1mM EDTA  pH8.0 / 
0.04%(w/v) bromophenol blue / 2% (w/v) Ficoll 
SDS-PAGE loading buffer 
64mM Tris-HCl pH 6.8 / 9.6% (v/v) glycerol / 
2% (w/v) SDS / 5% (v/v) β-mercaptoethanol / 
0.1% (w/v) bromophenol blue 
SDS-PAGE running buffer 
25mM Tris-base / 190mM glycine / 0.1% (w/v) 
SDS 
Solution I (DNA preparation) 
25mM Tris-HCl pH8.0 / 50mM glucose / 10mM 
EDTA pH8.0 
Solution II (DNA preparation) 200mM NaOH / 1% (w/v) SDS 
Solution III (DNA preparation) 3M potassium acetate / 5M glacial acetic acid 
Sub G1 wash buffer 192mM Na2HPO4 / 4mM citric acid pH7.8 
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2.3 Antibodies 
The primary antibodies used in this project are as followings: retinoblastoma (554162) from 
BD Pharmingen; phosphospecific antibodies for retinoblastoma Rb-pSer807/811 PAb hu and 
Rb-pT821 PAb hu from BioSource International; FLAG (M2) from Sigma; cyclin D1 (72-
13G; A-12), cyclin D3 (D-7), cyclin E1 (HE-12; M-20), CDC2 p34 (17), CDK2 (M2), CDK4 
(DCS-35), p27(C-19), p21 (C-19-G) and p16 (JC8) from Santa Cruz Biotechnology; Histone 
H2A.X-Ser139 (2577) and caspase-3 (9662) from New England BioLabs; and cyclin A2 
(E23-1), cyclin B1 (V152), cyclin D2 (DCS3.1), and α-Tubulin (TAT-1) were kind gifts from 
Dr Gordon Peters from CRUK LRI London, UK.  
 
2.4 Plasmids 
Following constructs were used in this study (Table 3). 
Table 3  Plasmid list 
Plasmid Origin 
pcDNA3 - 2xFLAG human cyclin D1 D. Mann, unpublished data 
pcDNA3 - 2XFLAG human cyclin D1 R29A/L32A D. Mann, unpublished data 
pcDNA3 - 2xFLAG human cyclin D1  T156A D. Mann, unpublished data 
pcDNA3 - 2xFLAG human cyclin D1 T286A D. Mann, unpublished data 
pGEX-KG –pRb (792-973) 
A kind gift from WG Kaelin Jr; 
(Adams et al., 1999) 
 
 
2.5 Recombinant DNA techniques 
2.5.1 Enzymatic manipulation of DNA 
DNA digests were carried out in a total volume of 10-20μl, using up to 5μg DNA and 10 units 
of each restriction enzyme in appropriate buffer (Boehringer Mannheim). Samples were 
incubated at 37
o
C for 30-60min.  
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2.5.2 Agarose electrophoresis 
Digested DNA was separated by agarose gel electrophoresis. Electrophoresis was carried out 
at 80mAmp of constant current. Resolved DNA fragments were visualised by ethidium 
bromide staining under UV light and, if appropriate, the required DNA fragment was excised 
for purification.  
 
2.5.3 GeneClean DNA purification 
The samples were incubated in an equal volume of 6M NaI at 65
o
C for 5min. 5μl of 
Glassmilk (Boyle and Lew, 1995) was added to the sample and incubated on ice for 5min. 
The DNA-bound Glassmilk mixture was centrifuged for 1min at 13,000rpnm and the 
supernatant was removed. Impurities were removed by washing the pellet twice in wash 
solution as instructed above. DNA was eluted from the Glassmilk by resuspending the pellet 
in 20μl of sterile water and incubating at 65oC for 5min. The eluent was obtained by brief 
centrifugation and an aliquot of the supernatant solution was used for ligation.  
 
2.5.4 JetSorb DNA purification 
For the purification of DNA fragment smaller than 500 base pairs, the JetSorb DNA gel 
extraction was performed according to the manufacturer’s instruction (Genomed).  
 
2.5.5 DNA ligation  
Purified DNA fragments and 10ng of appropriately digested plasmid vector were incubated in 
the ligation buffer at room temperature for at least 1h with 10 units of T4 DNA ligase 
(Fermentas). Ligated products were GeneCleaned prior to the transformation by 
electroporation.  
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2.5.6 Transformation by electroporation 
DNA samples were mixed with an aliquot of electrocompetent E.coli DH5α cells. 
Electroporation was performed using a BioRad Gene Pulser set at 2.25kV, 25μF. Luria Broth 
(LB) media was added and the mixture was plated on agar dishes containing appropriate 
antibiotics for selection. Plates were incubated at 37
o
C for 12h for the selection of 
transformants.  
 
2.6 Preparation of plasmid DNA 
2.6.1 Small scale preparation of plasmid DNA (mini prep.) 
Transformant colonies were selected and grown in 2ml LB supplemented with appropriate 
antibiotics for 8-16h at 37
o
C with constant shaking. Cells were pelleted by centrifugation 
(13,000rpm for 20s). The pellet was resuspended in 100μl Solution I. 200μl Solution II and 
150μl Solution III were added sequentially and mixed gently by inversion. Bacterial debris 
was removed by centrifugation (13,000rpm for 3min). DNA was obtained by ethanol 
precipitation followed by centrifugation (13,000rpm for 3min). Extracted DNA was 
resuspended in 50μl of sterile water. 
 
2.6.2 Large scale preparation of plasmid DNA (maxi prep.) 
200µl of the corresponding culture from small scale preparation was used to inoculate 200ml 
of LB supplemented with appropriate antibiotics overnight at 37
o
C with constant shaking.  
The culture was centrifuged for 6min at 5,000rpm at 4
o
C. The pellet was resuspended in 10ml 
Solution I by vortexing. 15ml Solution II and 20ml Solution III were added sequentially and 
mixed by inversion. The suspension was centrifuged for 5min at 9,000rpm at 4
o
C and the 
supernatant solution was filtered and mixed with 45ml isopropanol. The sample solution was 
mixed and centrifuged for 10min at 9,000rpm at 4
o
C. The pellet was dissolved in 3ml sterile 
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water. 4ml 5M LiCl was added and the mixture was incubated on ice for 5min. The 
precipitated RNA was removed by centrifugation of the solution at 13,000rpm for 5min. The 
supernatant was collected and mixed with 14ml absolute ethanol. Following a 5min 
incubation on ice, the mixture was pelleted by centrifugation (5min, 5,000rpm, 4
o
C). The 
pellet was briefly dried, resuspended in 500μl sterile water and digested with 0.1μg RNase A 
for 15min at 37
oC. DNA was precipitated by adding 600μl 20% (w/v) polyethylene glycol 
(PEG) 4000/2.5M NaCl solution and incubating on ice for 5min. The sample was centrifuged 
for 5min at 13,000rpm and the pellet was resuspended in 500μl sterile water. DNA was 
extracted by adding 500μl phenol/chloroform (1:1) and mixing, followed by 5min 
centrifugation at 13,000rpm. The aqueous fraction was retained and the trace of phenol was 
removed by adding an equal volume of chloroform followed by centrifugation for 1min at 
13,000rpm. DNA was precipitated from the aqueous phase by brief incubation with 10% (v/v) 
3M sodium acetate (pH5.2) and two volumes of absolute ethanol. After mixing by inversion, 
the sample was centrifuged briefly at 13,000rpm. The DNA precipitation was resuspended in 
50-100μl sterile water and the concentration determined by measurement of optical density 
(OD) at 260nm.  
 
2.7 Protein Analysis 
2.7.1 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
Slab gel electrophoresis was performed as described in (Laemmli, 1970). All the protein 
samples were separated on gels composed of 10% stacking gel and resolving gel prepared at 
7%, 10%, 12% or 15% (w/v) acrylamide to suit the experimental design.  
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Composition of gel mixture  
Stacking gel mixture Resolving gel mixture 
Component To make up 5ml 
mixture 
(ml) 
Component To make up 10ml 
mixture 
Acrylamide 
Mixture*  
0.85 Acrylamide 
Mixture*  
As appropriate 
2M Tris-HCl  
pH 6.8 
0.625 2M Tris-HCl  
pH 8.8 
1.9 
10% (w/v) SDS 0.05 10% (w/v) SDS 0.2 
 
* Acrylamide mixture: 30% (w/v) acrylamide : 0.8% (w/v) Bis-acrylamide stock solution 
(37.5:1) (National Diagnostics) 
  
Each mixture is made up to the appropriate volume with sterile water and the polymerisation 
of the gel mixtures were induced by addition of ammonium persulphate and NNN’N’-
tetramethylethylediamine (TEMED).  Cell lysates were harvested in SDS-PAGE sample 
buffer and heated to 100
o
C for 10min in a hot block before loading onto the gel. Samples 
were electrophoresed at constant voltage of 200V to appropriate distance in the SDS-PAGE 
running buffer.  
 
2.7.2 Electrophoretic transfer protocols and immunostaining 
For immunoblot analysis, SDS-gels were electroblotted to polyvinylidene difluoride (PVDF) 
membrane (MilliPore) for 75min at 400mA constant current in electrophoresis transfer buffer 
(ETB) or carbonated electrophoresis transfer buffer. The PVDF membrane was incubated 
overnight in 5% non-fat dried milk dissolved in PBST with appropriate primary antibodies. 
The blot was given brief wash with PBS followed by three 10min washes with PBST before 
being re-incubated for 45min in blocking solution containing a secondary antibody (α-mouse, 
α-rabbit or α-goat conjugated to horseradish peroxidase (HRP) as appropriate) at room 
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temperature. The blot was washed as before and with additional two 5min washes in PBS. 
Protein samples bound by antibodies were visualised by the Luminol reaction as described by 
the manufacturer (MiliPore). The membrane was developed using Fuji Film Image Reader 
LAS – 3000. The image was then analysed using Advanced Image Data Analyser (AIDA) 
V.3.52.  
 
2.7.3 Quantification of the band intensities 
The band intensities measured by the AIDA programme for each protein was normalised for 
the loading, using α-tubulin blot:  
𝐵𝑎𝑛𝑑 𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 𝑜𝑓 𝑎 𝑝𝑟𝑜𝑡𝑒𝑖𝑛 𝑠𝑎𝑚𝑝𝑙𝑒
𝐼𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 𝑜𝑓 𝑡ℎ𝑒 𝛼 − 𝑡𝑢𝑏𝑢𝑙𝑖𝑛 𝑜𝑓 𝑡ℎ𝑒 𝑝𝑟𝑜𝑡𝑒𝑖𝑛 𝑠𝑎𝑚𝑝𝑙𝑒 𝑜𝑓 𝑖𝑛𝑡𝑒𝑟𝑒𝑠𝑡
 
 
The relative protein expression was then calculated as following:  
𝐼𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 𝑜𝑓 𝑎 𝑝𝑟𝑜𝑡𝑒𝑖𝑛 𝑏𝑎𝑛𝑑 𝑓𝑟𝑜𝑚 𝑎 𝑠𝑎𝑚𝑝𝑙𝑒 𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑤𝑖𝑡ℎ 4𝑁𝑄𝑂
𝐼𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 𝑜𝑓 𝑡ℎ𝑒 𝑝𝑟𝑜𝑡𝑒𝑖𝑛 𝑏𝑎𝑛𝑑 𝑓𝑟𝑜𝑚 𝑎 𝑛𝑜𝑛 − 𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 𝑠𝑎𝑚𝑝𝑙𝑒
× 100 (%) 
 
2.8 In vitro and in vivo expression of recombinant proteins 
2.8.1 Expression and purification of Glutathione-S-Transferase (GST) fusion 
proteins  
20μl of an appropriate overnight recombinant bacterial culture was diluted to 10% volume 
with fresh LB supplemented with 50µg/ml carbenicillin (Melford Laboratories) and then 
incubated at 37
o
C for 1h. 1mM isopropyl-beta-D-thiogalactopyranoside (IPTG) was added to 
induce protein expression. The sample was incubated for 4h with constant shaking, at 37
o
C. 
The bacterial culture was centrifuged at 5,000rpm for 6min at 4
o
C and resuspended in 10ml 
NETN prior to sonication (Sonics Vibracell set at 20Watts for 45s) and the mixture was 
centrifuged for 5min at 5,000rpm. The supernatant solution was added to 100μl glutathione 
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(GSH)-Sepharose beads (Pharmacia), which had been equilibrated in NETN. The sample was 
mixed by inversion and incubated with mixing for 1h at 4
o
C. The GSH-Sepharose beads were 
washed 3 times in NETN and the samples were stored at -20
o
C following the addition of an 
equal volume of 80% (v/v) glycerol. For the purification of the GST-full length pRb 
recombinant protein, the IPTG-induction was carried out overnight at 30
o
C and the NETN 
buffer was replaced with Tween based buffer (0.1% (v/v) Tween 20, 20mM Tris-HCl pH8.0, 
0.1M NaCl, 1mM EDTA) to improve the yield.  
 
The presence of the recombinant protein in each purified sample was confirmed by subjecting 
20μl of the purified sample to SDS-PAGE on a 10% polyacrylamide gel. The protein bands 
were visualised by incubating gels with the staining solution for 1h with constant shaking. 
Protein bands were detected by washing off excess stain solution in the destaining solution for 
8-16h. 
 
2.8.2 Eluting GST-fused protein off GSH-beads 
The GST-fused recombinant protein preparation was washed twice in 100mM Tris pH8.0. The 
washed GST-beads were incubated in double the volume of an eluting solution (20mM 
reduced glutathione beads (BDH Biochemicals), 100mM Tris-HCl pH8.0) at the room 
temperature for 10min, with occasional vortex for mixing. The eluting mixture was 
centrifuged at 8,000 rpm for 10s and the supernatant was kept as the eluted recombinant 
protein.  
 
2.8.3 Dialysis of the recombinant protein preparations 
Dialysis membrane (VWR International) was cut to appropriate size and washed in distilled 
water. The recombinant protein preparations were poured into the dialysis membrane and the 
both ends of the membrane were sealed using dialysis clips. The recombinant protein 
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preparations were dialysed against 1 litre 1:1 PBS / Glycerol for 4h with stirring at 4
o
C. The 
recombinant protein preparation was dialysed for another 4h or overnight in fresh dialysate.   
 
2.8.4 Determination of protein concentration by Bradford assays 
Bradford assays (200μl) were performed in microtitre dishes by mixing 1 to 10μl of protein 
sample and 20% (v/v) Bradford Reagent (Sigma). The OD was measured at 595nm and the 
protein concentration was determined using a standard curve generated with serial dilutions of 
BSA. 
 
2.8.5 Protein Expression in Sf9 cells 
Sf9 cells were maintained at 27
o
C in Grace’s Complete Insect Media, supplemented with 10% 
foetal bovine serum (FBS). 2.5 x 10
5
cells were infected using 0.5ml of appropriate virus 
suspension and harvested 72h later. Infected cells were centrifuged for 5min at 1,000rpm, 4
o
C. 
Each pellet was resuspended in 100μl K-buffer and placed on ice for 10min with occasional 
vortex. The suspension was centrifuged 2min at 13,000rpm. The supernatant solution was 
stored at -20
o
C after addition of SDS-PAGE sample buffer and used for immunoblot assays.  
 
2.9 Investigation of cellular response to DNA damage in mammalian cells 
2.9.1 Growth and Maintenance of mammalian cells 
All the mammalian cells used were maintained in a humidified atmosphere containing 5% 
carbon dioxide at 37
o
C. unless otherwise stated. Cells were cultured in either Dulbecco’s 
modified Eagle’s medium DMEM (Sigma) or Roswell Park Memorial Institute (RPMI) 1640 
medium (Sigma) supplemented with 10% serum and antibiotics where necessary. The culture 
components for the cell lines used in this project are as listed below (Table 4).  
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Table 4  List of mammalian cells used in this investigation 
Cell line Description Base 
media 
Serum 
(10% v/v) 
Antibiotics 
AT5BI VA  SV40-transformed human ataxia 
telangiectasia (AT) complementation 
group D 
DMEM FCS - 
C57BL MEF C57BL mouse embryonic fibroblast 
(primary) 
DMEM FCS - 
C57BL 3T3 C57BL mouse embryonic fibroblast 
(immortalised) 
DMEM FCS - 
C57BL cyclin 
D1
-/-
 MEF 
C57BL MEF derived cyclin D1 
knockout cell line 
DMEM FCS - 
C57BL cyclin 
D1
-/-
 3T3 
C57BL MEF derived cyclin D1 
knockout cell line (immortalised) 
DMEM FCS - 
C57BL p21
-/-
 
3T3 
C57BL MEF derived p21 knockout cell 
line 
(Deng et al., 1995) 
DMEM FCS - 
EH1 U2OS cells expressing p16
INK4a
 under 
IPTG-inducible promoter 
(McConnell et al., 1999) 
DMEM FCS Geneticin 
(300µg/ml) 
Hygromycin 
(150µg/ml) 
HeLa Human cervix epitheloid carcinoma DMEM FCS - 
MCF7 Human breast adenocarcinoma DMEM FCS - 
MRC5 CV1  SV40-transformed Human lung 
fibroblast 
DMEM FCS - 
MOLT 4 Human acute T lymphoblastic 
leukaemia 
RPMI FCS - 
NIH 3T3 NIH mouse embryonic fibroblast  
contact inhibited 
DMEM NCS - 
D1 inducible 
3T3 
Swiss 3T3 derivative with IPTG-
inducible expression of FLAG-tagged 
human cyclin D1 
DMEM NCS Geniticin 
(300µg/ml) 
Hygromycin 
(150µg/ml)  
D1 wt 3T3 NIH 3T3 derivative with constitutive 
expression of FLAG-tagged human 
cyclin D1 wild type 
DMEM NCS Puromycin 
(5µg/ml) 
D1 RXXL 3T3 NIH 3T3 derivative with constitutive DMEM NCS Puromycin 
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expression of FLAG-tagged human 
cyclin D1with double mutation (R29A 
& L32A) 
(5µg/ml) 
D1 T156A 3T3 NIH 3T3 derivative with constitutive 
expression of FLAG-tagged human 
cyclin D1 with a point mutation 
(T156A) 
DMEM NCS Puromycin 
(5µg/ml) 
D1 T286A 3T3 NIH 3T3 derivative with constitutive 
expression of FLAG-tagged human 
cyclin D1 with a point mutation 
(T286A) 
DMEM NCS Puromycin 
(5µg/ml) 
D3 inducible 
3T3 
Swiss 3T3 derivative with IPTG-
inducible expression of FLAG-tagged 
human cyclin D3 
DMEM NCS Geniticin 
(300µg/ml) 
Hygromycin 
(150µg/ml) 
Saos-2 Human osteosarcoma DMEM FCS - 
Swiss 3T3 Swiss mouse embryonic fibroblast 
contact inhibited. 
DMEM NCS - 
Swiss-PI3K Swiss 3T3 cells engineered to express 
constitutively active PI3K (Prasad, 
2003). 
DMEM NCS Puromycin 
(5µg/ml) 
SVts8 Immortal cell line derived from TIG-3 
after transfection with
 
SV40 tsT antigen. 
(Tsuyama et al., 1991). Cells were 
normally grown at a permissive 
temperature (34
o
C). The temperature 
sensitive large T-antigen was inhibited 
by culturing cells at a non-permissive 
temperature (38.5
o
C) for 15h.   
DMEM FCS Penicillin 
(100units/ml) 
Streptomycin 
sulphate 
(100µg/ml) 
U2OS Human osteosarcoma DMEM FCS - 
XP12RO  SV40-transformed human 
complementation group A xeroderma 
pigmentosum fibroblast 
DMEM FCS - 
WI38 Human lung fibroblast 
(primary) 
DMEM FCS - 
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2.9.2 Transfection of mammalian cells with DNA plasmids 
Calcium phosphate mediated DNA transfections of mammalian cells were performed as 
follows. For each φ 90mm dish, 400μl DNA solution containing 8-24μg plasmids plus 0.2M 
CaCl2 was bubbled through 400μl 2X HEPES buffered saline. After 15min incubation at room 
temperature, the transfection mixture was added to the cells. Transfected cells were washed 
briefly with 3ml of serum free DMEM 24h later and subsequently incubated in appropriate 
media for further 24h before processing.  
 
2.9.3 DNA damaging agents and chemical inhibitors 
4-Nitroquinoline 1-oxide was dissolved in absolute ethanol at 40mM. Aliquots of 1ml were 
kept at -20
o
C in the dark. H2O2 was kept at 4
o
C in a coloured bottle. Various chemical 
inhibitors such as SAPK2/p38
MAPK 
inhibitor (SB203580), Chk1 inhibitor (SB218078) and 
Chk2 inhibitor II, MG-132, and ALLN, were dissolved in dimethyl sulphoxide (DMSO) and 
stored according to manufacturers’ instructions.  
 
2.9.4 Treatment of cells with DNA damaging agents and chemical inhibitors 
Cells were seeded at a known density on φ 90mm dish with 8ml of culture media 24h prior to 
use. Cells were treated with 4NQO or hydrogen peroxide for 30min, followed by a brief wash 
in PBS and exchange of culture media. Alternatively cells were exposed to 256nm UV using 
the UVP CX-2000 Crosslinker or IR by MDS Nordan Gamma Cell 3000. The effects of 
chemical inhibitors were assessed by pre-treating the cells for 30min with appropriate amount 
of inhibitors prior to the treatment with DNA damaging agents. Cells were harvested at 
various time points and processed further according to the experimental plan.  
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2.9.5 Determination of cell viability by MTS assay 
NIH 3T3 cells were seeded at the density of 2,000 cells per well on a 96-well tissue culture 
plate. 24h post-plating, cells were subjected to a range of 4NQO doses for 30min. Then the 
cells were incubated at 37
o
C for 3h. The MTS assays were then carried out using CellTiter 
96® AQueous One Solution Cell Proliferation Assay (Promega) as directed by the manufacturer.  
 
2.9.6 Flow cytometry: Investigation of membrane integrity by dual staining with Yo-
Pro-1® and Propidium Iodide (PI) 
For distinguishing between cells undergoing apoptosis and necrosis, dual staining of live cells 
with Yo-Pro-1® and PI was carried out. Cells were trypsinised and collected in 5ml of 
DMEM/10% serum solution. Cells were centrifuged at 1,000rpm for 5min. Cells were washed 
twice in ice-cold PBS. Cell pellet was re-suspended in 1ml of PBS and stained with 0.1µM 
Yo-Pro-1® (Molecular Probe) and 0.1µg/ml PI for 30min on ice. Stained samples were then 
analysed on the BD FACS Calibur system (BD Biosciences).  
 
2.9.7 Flow cytometry: Fixation of the cells for analysis by fluorescent activated cell 
sorter (FACS) 
In preparation for some of the flow cytometry analysis, cells were fixed in 70% (v/v) ethanol 
before staining with appropriate reagents. Cells were trypsinised and collected in 5ml 
DMEM/10% serum. Cells were centrifuged at 2,500rpm for 5min at 4
o
C. Supernatant was 
aspirated and the cells were washed once in ice-cold PBS. The pellet was fixed by adding 70% 
ethanol drop-by-drop while vortexing. Samples were kept on ice for at least 30min before 
processing further, or kept at 4
o
C up to 4 weeks before being processed.  
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2.9.8 Flow cytometry: Cell cycle (Sub-G1) analysis  
For analysis of sub-G1 population, samples were washed twice in 2ml sub-G1 wash buffer.  
Cells were centrifuged at 2,500rpm for 3min. The cell pellet was treated with 100ug/ml 
ribonuclease A for 10minutes and was stained with 50µg/ml PI for 30min on ice. Cells were 
analysed by BD FACSCalibur analyser (Becton Dickenson Biosciences) using the laser 
excitation at 488nm. 10,000 events per sample were collected and DNA profiles of the cells 
were analysed with the FlowJo software version 7.2.2 (Tree Star Inc.).  
 
2.9.9  Flow cytometry: Bromodeoxyuridine (BrdU) incorporation assay  
Cells were treated with a DNA damaging agent as described before and were incubated for 3h 
with last 30minutes in the presence of 10µM BrdU. Cells were harvested and fixed in 70% 
(v/v) ethanol. The fixed cells were centrifuged at 2,500rpm for 3min at 4
o
C and the 70% 
ethanol was removed. Cells were resuspended in 1ml of denaturing solution (2N HCl, 0.5% 
(v/v) Triton X-100), and incubated at room temperature for 30min. The denaturing solution 
was removed and replaced with 1ml of the neutralising solution (0.1M Tris, pH 8.5). Cells 
were washed in 1ml of blocking solution (0.5% (v/v) Tween 20, 1% (w/v) BSA, in PBS) and 
the pellet was collected by centrifugation as above. 20μl of FITC-conjugated BrdU antibody 
(BD 347583) was added directly to the cell pellet. After 30min incubation at room 
temperature the cells were washed once in the blocking solution. Subsequently, cells were 
resuspended in 1ml of PBS containing 5μg/ml of PI. DNA profiles of the cells and the BrdU 
incorporation levels were analysed by FACSCalibur analyser. 20,000 events per sample were 
collected. Using the FlowJo software, each sample was analysed by plotting FITC-
fluorescence (i.e. BrdU staining) against PI fluorescence (i.e. DNA content). BrdU positive 
cells were scored as the population of cells with FITC-fluorescence higher than that of the G1 
or G2/M population.  
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2.9.10 Localisation of cellular protein by immunostaining assay  
Cells were grown to 80% confluence in φ 90mm tissue culture dishes containing coverslips 
(13mm diameter). Cells were fixed on coverslips by gently adding appropriate volume of 4% 
formaldehyde solution (TAAB Laboratories Equipment) for 10min. Coverslips were washed 
three times in PBS for 5min. Cells were permeabilised by incubating with either ice cold 
methanol or 0.2% (v/v) Triton X-100/ PBS for 10min, depending on the primary antibody. 
Coverslips were incubated with blocking solution (5% (v/v) BSA in PBS) for 1h followed by 
three washes in PBS as before. Coverslips were stained with primary antibody for 1h in a 
humid chamber. 1:50 and 1:1000 dilution was used for antibodies against cyclin D1 and 
FLAG-tag , respectively. Coverslips were washed as before and were incubated with anti-
mouse secondary antibody, diluted at 1:3000, for 45min. Following the PBS washes as before, 
the coverslips were placed on a slide with 4',6-diamidino-2-phenylindole (DAPI)-Mowiol 
mountant. The stained cells were visualised and the images were captured using the Axiocam 
software on a Zeiss Axiovert 200M inverted microscope. For quantitation of the 
immunofluorescence, 150-200 cells in random fields of view across the entire coverslip of 
each sample were scored. For the observation of nuclear condensation, cells were fixed on 
coverslips as described above and were placed on a slide with DAPI-Mowiol mount without 
incubations with antibodies. 
 
2.9.11 Immunoprecipitation (IP) assay 
Cells from four 90mm dishes per sample were used in the IP assay. Cells were scraped in 
300μl per dish of RIPA buffer and collected into an Eppendorf tube. The cells were 
homogenised by passing through 23 gauge syringe five times and were incubated on ice for 
15min. The cell lysate was centrifuged at 14,000 rpm for 10min in a pre-cooled centrifuge at 
4
o
C. The supernatant was transferred into a new Eppendorf tube. 100μl of the lysate was 
taken as the whole cell lysate sample. The remaining of the lysate was placed in an Eppendorf 
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tube containing 50μl of protein G (GE Healthcare) beads that were pre-equilibrated with RIPA 
buffer. 2μg per IP sample of an appropriate antibody was added. The sample was incubated 
with mixing for 2h at 4
o
C. The protein G beads were washed 3 times in RIPA buffer by brief 
centrifugation at 8,000rpm and were resuspended in 50μl of 2X SDS-PAGE loading buffer. 
For IP-kinase assays, the protein G beads were washed twice in K-buffer volume β-
mercaptoethanol) immediately after the 3 washes RIPA buffer.  
 
2.9.12 Kinase assay 
For in vitro kinase assays, 15μl of IP samples (containing cyclin/CDK complex), 1µM ATP, 
1µM MgCl2, 5μl of recombinant protein (eluted and dialysed, approximately 1-2μg protein), 
1μCi γ-[32P]-ATP and K-buffer to 25μl were mixed and incubated at 30oC. Reactions were 
terminated after 45min using 5X SDS-PAGE sample buffer, unless stated otherwise. Assay 
samples were resolved on a 10% polyacrylamide gel by SDS-PAGE. Gels were fixed in 
destaining buffer for 10min followed by autoradiography or quantitation using 
phosphorimager. 
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Chapter 3:  DNA damage-induced responses by cell cycle 
proteins in NIH 3T3 cells 
3.1 Introduction 
In addition to being the cellular sensor of mitogenic stimuli and hence the positive regulator 
of cell cycle, cyclin D1 has been implicated in the DNA damage response. Rapid clearance of 
cyclin D1 in the cells exposed to a number of DNA damaging agents including IR, UV and 
H2O2 have been reported previously (Agami and Bernards, 2000; Miyakawa and Matsushime, 
2001; Barnouin et al., 2002). One of the consequences of such degradation is G1 cell cycle 
arrest. Other evidence showed that over-expression of cyclin D1 or CDK4 sensitise cells to a 
DNA damage-induced apoptotic cell death while another report demonstrated that the loss of 
cyclin D1 is required to induce efficient DNA repair process following DNA damage (Pagano 
et al., 1994; Dobashi et al., 1998; Dobashi et al., 1999; Katayama et al., 2001; Dobashi et al., 
2004; Retzer-Lidl et al., 2007). Collectively, these reports suggest that cyclin D1 levels may 
play a decisive role in regulating the cellular events after DNA damage is inflicted.  
 
To dissect the role of cyclin D1 in the DNA damage response, molecular changes in NIH 3T3 
cells treated with 4NQO were investigated. In addition to cyclin D1, responses of other key 
components of the cell cycle machinery were also examined. The 4NQO-induced molecular 
responses were compared with those associated with UV, H2O2 and IR. This chapter presents 
the results from the initial investigations to systematically study the inter-relationship between 
the DNA lesions imposed by various DNA damaging agents and the molecular responses of 
the key cell cycle regulatory proteins especially focusing on cyclin D1.  
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3.2 Results 
3.2.1 Comparison of cyclin D1 response to 4NQO and H2O2 in NIH 3T3 cells 
The changes in cyclin D1 expression triggered by 4NQO-induced DNA damage were 
assessed by immunoblotting lysates of the mouse fibroblast cell line, NIH3T3, treated with a 
range of 4NQO doses as described (Materials and Methods). Five independent experiments 
consistently showed that cyclin D1 responds to 4NQO treatment in a dose-dependent manner 
(Figure 3.1). At a low dose of 4NQO (2.5µM), cyclin D1 expression remained unchanged. 
Moderate doses of 4NQO (10µM-75µM) reduced the cyclin D1 level to approximately 10% 
of the control samples within 3h of exposure. The level of a house-keeping protein, α-tubulin, 
remained constant in the samples treated with up to 100µM of 4NQO, excluding the facile 
explanation of protein loss through cell death. Interestingly, at a high dose of 4NQO (200µM), 
cyclin D1 levels were similar to that of untreated cells; α-tubulin was slightly reduced in level 
compared to control cells, suggesting potential protein loss through cell death (Figure 3.1). 
Quantification using the AIDA programme revealed that approximately 80% of cyclin D1 
expression was maintained following exposure to 200µM 4NQO (Figure 3.1b).  
 
To determine whether this biphasic response in cyclin D1 levels triggered by 4NQO treatment 
was common to all DNA damaging agents, the immunoblotting experiment was repeated 
using H2O2. In line with the previous reports, exposure of cells to increasing doses of H2O2 
resulted in a gradual degradation of cyclin D1 in a dose-dependent manner (Figure 3.2) 
(Barnouin et al., 2002; Fasanaro et al., 2006). When compared with the cyclin D1 degradation 
caused by 4NQO exposure, H2O2 triggered a less dramatic reduction of cyclin D1 expression. 
1mM H2O2 was required to trigger an 80% reduction in cyclin D1 expression while 10µM 
4NQO was sufficient to lower the cyclin D1 expression to a similar level. Moreover, the 
maintenance of the cyclin D1 level following exposure to high doses of 4NQO could not be 
reproduced using up to 5mM H2O2, at which dose the α-tubulin signal was reduced suggesting 
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that there was a loss of protein potentially by cell death (data not shown). These data indicate 
that 4NQO and H2O2 trigger different responses by cyclin D1.  
 
3.2.2 Response by other cell cycle proteins in NIH 3T3 cells 
In an attempt to understand the molecular responses to 4NQO treatment further, the levels of 
other cell cycle regulators following exposure of NIH 3T3 cells to 4NQO or H2O2 were 
examined by immunoblotting. Cyclin A2, cyclin E1, CDK1, CDK2, and CDK4 did not 
exhibit dose-dependent changes in expression levels with either of the DNA damaging agents 
tested (Figure 3.3) whereas changes in expression levels of cyclin B1 and p27 appeared 
variable each time (data not shown). Although the majority of cell cycle proteins examined 
here did not change expression levels in response to 4NQO- or H2O2- induced DNA damage, 
the CDK inhibitor, p21, exhibited a strong dose-dependent response to both of the DNA 
damaging agents (Figure 3.3).  
 
Differential phosphorylation of p21 has been shown to partly regulate the opposing functions 
of p21 (Child and Mann, 2006). The phosphorylation of S130 of p21 produces a slower 
migrating species of p21 on SDS-PAGE gel (Jarviluoma et al., 2006) and is visible in the 
immunoblot presented in Figure 3.3. 4NQO or H2O2 treatment altered both the expression 
level and phosphorylation status of p21. Exposure to 25µM or greater doses of H2O2 resulted 
in an accumulation of both forms of p21 in a dose-dependent manner (Figure 3.3b). On the 
other hand, 4NQO induced a biphasic response in p21; treatment with a low dose of 4NQO 
induced a dramatic 6-fold increase in p21 expression, at medium doses the p21 level declined 
by 80% and with high doses the level was similar to that in the untreated control cells (Figure 
3.3a). The S130 phosphorylated form of p21 was only present in the control and the sample 
treated with the low dose (2.5µM) of 4NQO. Combined with the difference in the cyclin D1 
response caused by the two DNA damaging agents, these data support the notion that the 
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DNA damaging agents induce distinct responses in the levels of two key cell cycle regulators.  
 
3.2.3 Generality of the cyclin D1 and p21 response to 4NQO 
In order to test the generality of the 4NQO-induced biphasic response of cyclin D1 and p21 
observed in NIH 3T3 cells, the response of these proteins in two other cell lines were tested. A 
normal human fibroblast, WI38, and a human osteosarcoma cells, U2OS, were treated with 
4NQO and the responses of cyclin D1 and p21 were examined by immunoblotting as before. 
The ability of U2OS cells to maintain cyclin D1 expression appeared slightly inferior to NIH 
3T3 and WI38 (Figure 3.4). Nonetheless, the characteristic biphasic response of cyclin D1 
was readily reproducible in both cell lines (Figure 3.4). The dramatic accumulation of p21 
observed in response to 2.5µM of 4NQO was absent in both cell lines. The medium to high 
doses of 4NQO triggered similar changes in the p21 levels as was observed in NIH 3T3 cells 
(Figure 3.4). These data suggest that the 4NQO-induced biphasic response of cyclin D1 is 
likely to be a universal response whereas p21 response may exhibit certain tissue or species 
specificities in expression following DNA damage.  
 
3.2.4 Responses of cyclin D1 and p21 to other DNA damaging agents in NIH 3T3 
cells 
Miyakawa and Matsuhime (2001) and Agami and Bernard (2000) previously reported that 
cyclin D1 is downregulated in response to UV and IR, respectively. To determine the 
responses of cyclin D1 and p21 to other DNA damaging agents, NIH 3T3 cells were exposed 
to various doses of UV and IR. Cells were harvested 3h after exposure and the responses of 
cyclin D1 and p21 were analysed by immunoblotting as before. In line with previous 
observations, cyclin D1 was indeed downregulated following exposure to UV and IR in NIH 
3T3 cells (Figure 3.5). Whereas increasing doses of IR caused a gradual decrease in cyclin D1 
level, UV treatment induced a dose-dependent biphasic response which resembled the 
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response observed after the 4NQO treatment. As can be seen in Figure 3.5a, cyclin D1 
expression was maintained at a similar level to the control sample in response to up to 50J/m
2
 
UV. A dramatic clearance of cyclin D1 expression was observed following exposure to 500-
2500J/m
2
 UV. In a similar manner to the response triggered by high doses of 4NQO, high 
doses of UV (5000-7000J/m
2
) resulted in a maintenance of cyclin D1 expression. Such 
maintenance of cyclin D1 expression following high doses of UV have not been reported 
before. UV exposure also caused a similar p21 response as observed after 4NQO treatment; 
p21 accumulated in response to a low dose of UV (15J/m
2
), medium doses of UV (500-
2500J/m
2
) led to a clearance of p21 and high doses of UV did not seem to have an apparent 
effect on p21 expression (Figure 3.5a). Whilst UV seemed to trigger similar responses of 
cyclin D1 and p21 as 4NQO induced DNA damage, IR-induced cyclin D1 and p21 responses 
shared similar features to those caused by H2O2 treatment. As presented in Figure 3.5b, 
increasing doses of IR induced a gradual decrease of cyclin D1 and an accumulation of p21. 
Like in the case with H2O2-associated responses, biphasic responses of cyclin D1 or p21 were 
not observed by increasing the IR dose up to 80Gy, at which dose a loss of α-tubulin signal – 
possibly by cell death – was observed (data not shown).  
 
3.2.5 Impact of cyclin D1 and p21 changes induced by DNA damage response at 
molecular level 
As a first step to determining the effect of the 4NQO-induced response on cell cycle 
progression, the phosphorylation status of pRb in the NIH3T3 cells treated with 4NQO or 
H2O2 was examined by electrophoretic mobility shift assay. Depending on the level of 
phosphorylation, pRb shifts from an active hypophosphorylated form to an inactive 
hyperphosphorylated form (Mittnacht, 1998). In the samples treated with H2O2, the pRb 
population gradually shifted from hyper- to hypo-phosphorylated forms with increasing doses 
of H2O2. pRb remained hyperphosphorylated up to 25µM of H2O2 (Figure 3.6b). At 50-
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100µM of H2O2, where p21 was induced and cyclin D1 level began to decline (Figures 3.2, 
3.3b), hyper- and hypophosphorylated forms of pRb co-existed in the population (Figure 3.6b). 
At doses higher than 100µM, only the hypophosphorylated form of pRb was detected. On the 
other hand, 4NQO treatment of NIH 3T3 cells resulted in more complex changes in pRb 
phosphorylation. In the samples treated with 2.5µM of 4NQO, where cyclin D1 was 
maintained and p21 accumulation was observed, both hyper- and hypophosphorylated forms 
of pRb were detected (Figure 3.6a). For the samples treated with 10-75µM of 4NQO, where 
both cyclin D1 and p21 levels were reduced, the pRb ran slightly above the 
hypophosphorylated form. In response to 100-200µM of 4NQO, where both cyclin D1 and 
p21 levels were maintained at the similar levels as the control, pRb migrated in between the 
hyper- and hypo-phosphorylated forms of pRb. When compared with cyclin D1 levels 
observed in these 4NQO-treated NIH 3T3 cells (Figure 3.1), the presence of cyclin D1 and 
that of intermediate pRb species seemed to correspond to a certain extent, suggesting that 
cyclin D1-associated kinase activity may be responsible for the presence of the partially 
phosphorylated form of pRb.   
 
To dissect the ambiguous changes in the pRb phosphorylation pattern induced by 4NQO, the 
pRb kinase activities were directly examined by IP followed by in vitro kinase assay. To 
observe the changes in the pRb kinase activities, NIH 3T3 cells were treated with 4 doses of 
4NQO: 0µM, 2.5µM, 50µM and 200µM: to represent control, low, medium and high doses, 
respectively. Three hours after treatment, Cyclin D-CDK4 and cyclin E/A-CDK2 complexes 
were isolated by IP through their CDK subunits. The kinase activities associated with each 
immunocomplex were measured in vitro, against a recombinant pRb fragment (Rb 792-973) 
or histone H1. After several attempts, it became evident that the kinase activity associated 
with CyclinD-CDK4 complex could not be detected through this method whilst the activity of 
cyclin E-CDK2 was successfully measured. The CDK2- associated activity was reduced by 
approximately 70% in response to the low dose of 4NQO (Figure 3.7). Medium and high 
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doses of 4NQO almost halved the kinase activity associated with CDK2, with 200µM sample 
retaining slightly less kinase activity (Figure 3.7). As the immunoblotting showed, CDK2 
present in the 4NQO-treated NIH 3T3 cells exist as two forms with distinct electrophoretic 
mobilities (Figure 3.7a). The faster migrating form of the CDK2 represents the active form 
which is phosphorylated at T160 on its activation loop and the slow migrating form represents 
the inactive CDK2 (Gu et al., 1992; Brown et al., 1999). Considering that similar levels of 
both forms of CDK2 were maintained following 4NQO exposure, it appears that the 4NQO-
induced DNA damage response is unlikely to regulate CDK2 activity via regulation of T160 
phosphorylation (Figure 3.7a). Furthermore, the expression levels of neither cyclin E1 nor 
cyclin A2 responded to the 4NQO treatment (Figure 3.3a). Collectively, these results suggest 
that any changes in the CDK2-associated kinase activity are likely to be due to the interaction 
of the complex with other proteins, such as CKIs, or inhibition by covalent modifications 
other than phosphorylation of T160 (see 3.3 Discussion).   
 
Although the CDK2-associated kinase activity in cells treated with a low dose of 4NQO was 
reduced substantially (Figure 3.7b), the electrophoretic mobility shift assay for pRb presented 
in Figure 3.6a showed the presence of hyperphosphorylated pRb in this sample. As described 
earlier, the functional inactivation of pRb requires kinase activities of both CDK2- and 
CDK4/6-associated complexes (Lees et al., 1991; Hatakeyama et al., 1994; Lundberg and 
Weinberg, 1998). Moreover, three groups have demonstrated that the CDK4-dependent 
phosphorylation of pRb is responsible for mobility shift of pRb (Kato et al., 1993; Resnitzky 
and Reed, 1995; Knudsen and Wang, 1996). The presence of hyperphosphorylated pRb, 
therefore, indicates that the CDK4-associated activity may be preserved in the sample. 
 
As an alternative approach to IP-kinase assay, the effect of 4NQO exposure on the CDK4-
associated kinase activity can be monitored by assessing the phosphorylation status of pRb at 
CDK4 specific target sites. S807 and S811 are two known phosphorylation sites specific to 
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the cyclin D-CDK4 complex (Knudsen and Wang, 1996; Zarkowska and Mittnacht, 1997). 
Immunoblotting with a phosphospecific antibody revealed that the phosphorylation pattern at 
these sites mostly followed the dose-dependent changes in the cyclin D1 expression, 
suggesting that the CDK4-associated kinase activities changed with cyclin D1 expression in 
4NQO-treated NIH 3T3 cells (Figures 3.1, 3.8). Moreover, all the pRb phosphorylated at 
S807/S811 sites co-migrated with the hyperphosphorylated pRb (i.e. the pRb in the non-
treated sample), suggesting that the population of pRb that migrated in between hyper- and 
hypophosphorylated forms of pRb as observed in Figure 3.6a were not phosphorylated at 
S807 or S811 sites. The experiment was repeated using a phosphospecific antibody that 
detects phosphorylation of pRb at one of the CDK2-specific sites, T821. Unlike 
phosphorylation of CDK4-specific sites, T821 phosphorylation following 4NQO exposure did 
not exhibit prominent dose-dependency. Although in vitro kinase assays showed that the 
CDK2-associated kinase activities were substantially reduced following 4NQO exposure 
(Figure 3.7b), changes in the levels of T821 phosphorylation were limited. In fact, pRb 
phosphorylation at T821 sites in 50µM and 200µM seemed unaffected compared to the non-
treated sample despite the 50% reduction of the CDK2-associated kinase activities as 
presented in Figure 3.7b. These results seemed to imply either that the halved CDK2-
associated kinase activity was sufficient to fully phosphorylate pRb at this site or unknown 
kinases were able to phosphorylate pRb at T821. The pRb species phosphorylated at T821 
also co-migrated with the hyperphosphorylated form, similarly to those phosphorylated at 
CDK4-specific target sites (Figure 3.7). Together, these results demonstrated that the partially 
phosphorylated forms of pRb observed in Figure 3.6a are likely to be phosphorylated at 
phosphorylation sites other than S807, S811 and T821.  
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3.2.6 Changes in pRb phosphorylation status in response to the 4NQO-induced DNA 
damage response 
To investigate the relationships between the cyclin D1 and p21 expression levels and pRb 
phosphorylation status in the DNA damage response further, EH1 cells, a stable clone of 
U2OS cells that expresses p16
INK4a
 under the control of an IPTG-inducible promoter was 
employed (McConnell et al., 1999). EH1 cells were treated with 4 doses of 4NQO in the 
presence and absence of IPTG. The changes in the expression of cyclin D1 and p21, as well as 
the phosphorylation status of pRb in each sample were studied by immunoblotting (Figure 
3.9).  
 
McConnell et al., (1999) showed that when the p16
INK4a
 expression was induced, the activities 
of CDK4/6 were inhibited in the EH1 cells. The dose-dependent changes in cyclin D1 
expression levels induced by 4NQO was unaffected by the inhibitory effect of p16
INK4a
, 
indicating that the changes in expression levels of cyclin D1 were independent of CDK4/6-
associated kinase activities (Figure 3.9a). The induction of p16
INK4a
 expression stabilised and 
somewhat induced the expression of p21 which is in agreement with observations made by 
Aboussekhra and colleagues (Al-Mohanna et al., 2004). pRb phosphorylation status was 
dramatically different in IPTG-induced and uninduced EH1 cells. In the absence of IPTG, 
cells proliferated normally as indicated by the presence of hyperphosphorylated pRb (Figure 
3.9b). Upon induction of p16
INK4a
, pRb became hypophosphorylated, consistent with the study 
reported by McConnell et al. (1999). Interestingly, the pRb in cells treated with 200µM of 
4NQO, where cyclin D1 was maintained, was partially phosphorylated despite the induction 
of p16
INK4a
 and the maintenance of p21, both of which are able to inhibit the kinases 
responsible for pRb phosphorylation. These observations give rise to three possible 
explanations; (1) Cyclin D1 maintained following exposure to 200µM 4NQO was shielded 
from the inhibitory effects of p16
INK4a
 and p21, (2) CKIs were inactivated as a result of the 
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DNA damage response or (3) Other kinases were able to phosphorylated pRb following DNA 
damage.  
 
In addition to the regulation of pRb function by cyclin D-associated kinase activities, Müller 
and colleagues have demonstrated the ability of pRb in regulating the expression of cyclin D1 
by showing that transfection of functional pRb into pRb deficient tumour cells induces cyclin 
D1 expression (Muller et al., 1994). To determine whether the partial phosphorylation of pRb 
observed in cells treated with 200µM 4NQO was the cause or the consequence of cyclin D1 
maintenance, D1wt 3T3 cell line, a stable NIH3T3 cell clone that expresses human cyclin D1 
under the control of CMV promoter, was generated (Materials and Methods). This cell line 
allows the expression of ectopic cyclin D1 to remain after the imposition of quiescence as the 
expression is driven by cytomegalo virus (CMV) promoter ((Fitzsimons et al., 2002). Thus, 
D1wt 3T3 cell line is suitable for studying the 4NQO-induced changes in cyclin D1, in the 
absence of pRb phosphorylation.  
 
Firstly, the integrity of the DNA damage response in the novel cell line was tested. Treatment 
of asynchronous D1wt 3T3 with a range of 4NQO dosages resulted in the biphasic response 
by both endogenous and exogenous cyclin D1 as well as p21 (Figure 3.10a). This indicated 
that the DNA damage response is intact, at least in terms of cyclin D1 and p21 expression, in 
the presence of ectopic cyclin D1. It also suggested that the 4NQO-induced changes in cyclin 
D1 expression levels were regulated post-transcriptionally. D1wt 3T3 cell line appeared 
slightly more sensitive to 4NQO compared to NIH 3T3, with the maximum degradation of 
cyclin D1 achieved in response to 10-25µM 4NQO rather than 25-50µM. However, 50µM 
4NQO was still able to impose a substantial reduction of cyclin D1. Therefore the subsequent 
experiments were carried out with the 4 doses of 4NQO – 0, 2.5, 50 and 200µM – as chosen 
previously. To assess the 4NQO-induced cyclin D1 response in the presence of 
hypophosphorylated pRb, D1wt 3T3 cells were quiesced by serum starvation over 3 nights. 
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Despite the presence of ectopic cyclin D1, the cells were quiesced successfully following the 
serum starvation and approximately 95% of cells accumulated in the G0/G1 peak (Figure 
3.10c). This observation agrees with Resnitzky and Reed’s report which showed that 
expression of cyclin D1 alone could not induce proliferation in quiescent cells (Resnitzky and 
Reed, 1995). Furthermore, Cheng and colleagues demonstrated that ectopically expressed 
cyclin D1 is unable to form an active complex with CDK4 in the absence of serum 
stimulation possibly due to the presence of a high level of p27 (Cheng et al., 1998).  
 
Figure 3.10b shows that although the level of p21 was reduced in the quiescent cell 
population, the dose-dependent induction of p21 could still be observed at 3h post-exposure. 
Moreover, the biphasic response of cyclin D1 was intact even though the pRb remained 
hypophosphorylated up to 3h after the treatment at all the 4NQO doses tested. Taken together 
with the results from the EH1 cell line, partially phosphorylated pRb is not required for the 
maintenance of cyclin D1 following the 4NQO exposure. Furthermore, the presence of 
partially phosphorylated pRb appeared to be serum dependent.  
 
3.3 Discussion 
The findings from the initial investigations into the potential role of cyclin D1 in the DNA 
damage response are presented in this chapter. By screening for cell cycle regulators that 
respond to the DNA damaging agents, 4NQO and H2O2, unique dose-dependent responses by 
cyclin D1 and p21 have been identified. Consistent with previous reports, treatment with 
H2O2 resulted in a classic DNA damage response where cyclin D1 levels declined and p21 
accumulated with an increasing dose (Chen et al., 1998; Chen et al., 2000; Barnouin et al., 
2002; Fasanaro et al., 2006). On the other hand, both cyclin D1 and p21 exhibited unique 
biphasic responses to 4NQO treatment where at a low dose (2.5µM) cyclin D1 levels were 
unchanged but p21 was induced strongly within 3h of exposure; at intermediate doses (10-
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75µM) both cyclin D1 and p21 levels were reduced dramatically; at high doses (100-200µM) 
little change in cyclin D1 or p21 expression was observed (Figures 3.1a, 3.3a). Failure to 
reproduce this biphasic response using a lethal dose of H2O2 suggested that the 4NQO-
induced responses by cyclin D1 and p21 represent a novel DNA damage response that has not 
been reported before. Further studies demonstrated that UV and IR, both of which are well 
established DNA damaging agents, induced similar responses of cyclin D1 and p21 to 4NQO 
and H2O2, respectively. Although both UV- and IR-induced DNA damage have been shown to 
trigger cyclin D1 degradation previously, this is the first time where UV-induced DNA 
damage was shown to activate dose-dependent biphasic response of cyclin D1 (Hiyama and 
Reeves, 1999; Agami and Bernards, 2000; Miyakawa and Matsushime, 2001).   
 
The 4NQO-induced response of cyclin D1 was readily reproduced in cell lines other than NIH 
3T3 cells as presented in Figure 3.4. A human osteosarcoma cell line, U2OS, that retains fully 
functional p53 and pRb but lacks the expression of CDK4-inhibitor, p16
INK4a
 (Diller et al., 
1990; Park et al., 2002), was also able to reproduce the biphasic response of cyclin D1 albeit 
with slightly different sensitivity. This implies that the DNA damage response by cyclin D1 is 
independent of the ability of p16
INK4a
 to dissociate cyclin D1 from CDK4 although 
requirement for the inhibition of CDK4-associated kinase activity by other CKI cannot be 
ruled out at this stage. Unlike the universality exhibited by the cyclin D1 response, p21 
accumulation induced by a low dose of 4NQO was absent in the two human cell lines tested 
here. Comparable with the result presented here, Lee and colleagues have demonstrated that 
p21 in human cells are more sensitive to UV-induced degradation than p21 in mouse cells 
(Lee et al., 2006). Furthermore Xie and the colleagues have demonstrated that the kinetics at 
which p21 is induced in response to DNA damage varies amongst cell lines (Xie et al., 2002). 
Such species and cell specific differences in the p21 response may partly explain the 
discrepancies between previously reported p21 responses to DNA damage. While p21 is 
mainly induced in response to DNA damage caused by IR (Canman et al., 1994; Di Leonardo 
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et al., 1994; el-Deiry et al., 1994; Siliciano et al., 1997), the reports on UV-induced response 
by p21 have been rather puzzling. Several groups have shown that irradiation with UV results 
in upregulation of p21 in both p53-dependent and independent manners (Poon et al., 1996; 
Loignon et al., 1997; Haapajarvi et al., 1999; Hiyama and Reeves, 1999; Jabbur et al., 2000). 
Others reported a down-regulation of p21 in response to UV in a dose-dependent manner 
(Allan and Fried, 1999; Bendjennat et al., 2003; Lee et al., 2006; Lee et al., 2007). The 
involvement of p21 in DNA damage-induced repair is another contentious property of the 
CKI (Cooper et al., 1999; Fukami-Kobayashi and Mitsui, 1999; Stivala et al., 2001; Perucca 
et al., 2006). Such pleiotropic properties of p21 in the DNA damage response resemble its 
functions in cell cycle regulation. It may play an important role in determining the cellular 
response to DNA damage alongside cyclin D1.  
 
To determine the impact of DNA damage-induced changes in cyclin D1 and p21 expression 
levels, the G1/S transition status was examined at molecular level. As described above, the 
progression of cells through G1 to S phase of the cell cycle is governed primarily by the 
activities of the pRb tumour suppressor and E2F transcription (Helin et al., 1993; Black and 
Azizkhan-Clifford, 1999; Harbour and Dean, 2000c). The growth suppressive activity of pRb 
is dependent on the kinase activities of G1 cyclin/CDK complexes (Connell-Crowley et al., 
1997; Ezhevsky et al., 1997; Leng et al., 1997; Ezhevsky et al., 2001). The crucial roles 
played by the G1 cyclin/CDK complexes were demonstrated by a number of groups; 
overexpression of cyclin D1 and cyclin E accelerated the G1 phase of cell cycle (Musgrove et 
al., 1994; Resnitzky and Reed, 1995; Imoto et al., 1997; Kamalati et al., 1998), 
immunodepletion of cyclin D1 or dominant negative mutation of CDK2 inhibited G1-S phase 
progression (Lees et al., 1991; Lundberg and Weinberg, 1998) and loss of pRb expression 
rendered cyclin D1 dispensable for regulation of G1-S transition (Lukas et al., 1995; Keenan 
et al., 2004). Furthermore the enhanced cell growth associated with overexpression of 
cyclin/CDK complexes was overcome by expression of p21 (Horton et al., 1995), indicating 
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the close functional relationships between these proteins.  
Changes in cyclin D1 and p21 expression levels induced following exposure of NIH 3T3 cells 
to 4NQO and H2O2 were reflected in the alteration of pRb phosphorylation status, which is 
indicative of changes in the G1-S phase transition (Figure 3.6). The reduced expression of 
cyclin D1 and concomitant increase in the CDK inhibitor, p21, following exposure to H2O2 
presented in Figure 3.2a resulted in the mobility shift of pRb from the hyper- to 
hypophosphorylated form (Figure 3.6b). This indicated that the cyclin D1 reduction was 
associated with loss of kinase activity, most likely that of CDK4 as previously reported (Chen 
et al., 1998; Barnouin et al., 2002). Following the lack of CDK4-dependent pRb 
phosphorylation, cyclin E-CDK2 complexes would fail to phosphorylate pRb as their pRb 
kinase activities are dependent on the presence of partial phosphorylation of pRb by cyclin D-
CDK4 complexes (Lundberg and Weinberg, 1998). Moreover, loss of cyclin D1 is linked to 
the redistribution of CKIs to cyclin E-CDK2 complexes (Poon et al., 1996; He et al., 2005; 
Alao et al., 2006a) and the induction of p21 would complete the inactivation of G1-cyclin 
kinase activities. Taken together, the H2O2-associated responses observed at the molecular 
level point towards the well-documented induction of the G1/S cell cycle arrest through the 
p53-p21-pRb pathway (Dulic et al., 1994; Kaufmann and Paules, 1996). 
 
The 4NQO-induced changes in pRb phosphorylation status appeared much more intricate. 
The assessment of CDK4- and CDK2-associated kinase activities in vitro did not unveil an 
explanation to this observation. The kinase activity associated with CDK2 following 4NQO 
exposure was generally reduced although the expression of activating subunits, cyclin E and 
cyclin A, or the phosphorylation of T160 by cyclin H-CDK7 complex appeared unaffected. 
The dramatic reduction of CDK2-associated kinase activity in response to a low dose of 
4NQO was likely to be at least partially due to the substantial accumulation of p21. Reduced 
CDK2 kinase activity in NIH 3T3 cells treated with medium doses of 4NQO was probably 
due to redistribution of p27 following rapid degradation of cyclin D1. A similar phenomenon 
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was observed in response to UV-induced DNA damage where low doses of UV (up to 50J/m
2
) 
but not high doses caused p21 accumulation. In the case of a UV-induced response, CDK2 
inhibition was achieved by loss of activating cyclins in response to high doses of UV (Poon et 
al., 1996). In the case of the response induced by high doses of 4NQO, however, alternative 
regulatory mechanisms for CDK2 must exist as p21 accumulation,  and degradation of cyclin 
D1, E or A was absent in these samples. A number of groups have demonstrated that cyclin 
D1 can sequester CDK2 in inactive complexes that cannot be activated by cyclin H-CDK7, 
which may provide a way of fine-tuning the level of G1-kinase activities (Dulic et al., 1993; 
Higashi et al., 1996).  Although a formation of such complex is possible, CDK2 in the 4NQO-
treated NIH 3T3 cells were phosphorylated at the threonine residue. Thus, further 
investigation is required to determine the mechanism by which CDK2 is inhibited after the 
treatment with a high dose of 4NQO.  
 
Electrophoretic mobility shift assays using a phosphospecific antibody for CDK4-specific 
phosphorylation sites on pRb demonstrated that phosphorylation of S807/S811 sites seemed 
to follow the 4NQO-induced changes in cyclin D1 expression (Figure 3.8). Furthermore, the 
pRb species phosphorylated at S807/811 sites migrated together with the 
hyperphosphorylated form of pRb (Figure 3.8). This observation endorses previous reports 
which demonstrated that the phosphorylation of pRb at the CDK4-specific target sites, S807 
and S811, were responsible for the mobility shift of pRb to the hyperphosphorylated form 
(Kato et al., 1993; Knudsen and Wang, 1996). Use of another phosphospecific antibody which 
detects the phosphorylation of CDK2-specific site, T821, revealed that the phosphorylation of 
pRb at this site remained mostly unaffected by the 4NQO-induced DNA damage response 
(Figure 3.8). Interestingly, T821-phosphorylated pRb also co-migrated with 
hyperphosphorylated form of pRb (Figure 3.8). Collectively, these results indicated that the 
pRb population that migrates between the hyper- and hypo-phosphorylated forms of pRb 
observed following 4NQO exposure was not phosphorylated at S807/811 or T821.  
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The pRb population with an intermediate electrophoretic mobility was previously observed 
when the cyclin E/CDK2-associated kinase activity was inhibited by over-expression of a 
kinase inactive mutant CDK2 (Leone et al., 1997; Lundberg and Weinberg, 1998). Indeed, the 
appearance of pRb with a perturbed electrophoretic mobility seemed to correspond with the 
loss of CDK2-associated kinase activities as shown in Figures 3.6 and 3.7. They found that 
this partially phosphorylated form of pRb displayed reduced nuclear localisation whilst 
preserving the ability to bind and inhibit E2F-1, suggesting that the pRb was not 
phosphorylated at S780, a CDK4-specific site which was shown to interfere with E2F-1 
binding ability of pRb (Kitagawa et al., 1996; Lundberg and Weinberg, 1998). The 
observations of the molecular responses in 4NQ-treated EH1 and D1 wt 3T3 cells suggested 
that the presence of a partially phosphorylated form of pRb was serum dependent although the 
CDK4-associated kinase activity may be dispensable. Perhaps, there are yet unidentified 
kinases that are able to phosphorylated pRb at sites which confer the unique electrophoretic 
mobility to the pRb.  Previously, a CDC2-related serine/threonine kinase, CDK9, has been 
shown to form a complex with T-cyclins and directly interact with pRb in vivo (Simone et al., 
2002). CDK9 is able to phosphorylate pRb at some of the serine residues that are 
phosphorylated by CDK4, in vitro (Grana et al., 1994; De Luca et al., 1997; Simone et al., 
2002). Another report demonstrated that checkpoint kinases 1 and 2 (Chk1 and Chk2) were 
able to phosphorylate pRb at S612, which is normally a CDK2-target site, in response to DNA 
damage (Inoue et al., 2007). Alternatively, an exposure to a high dose of 4NQO may have 
altered the activities of protein phosphatase 1 (PP1), a phosphatase responsible for promoting 
dephosphorylation of pRb. A number of reports have indicated the involvement of PP1 in the 
DNA damage response (Wang et al., 2001; Tang et al., 2008).  
 
For a long time, pRb was the only known substrate of the cyclin D1-CDK4 complexes. 
However, a number of other proteins have been identified as potential substrates more 
recently. For example, Matsuura and colleagues demonstrated that the TGF-β signal 
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transducers, Smad2 and Smad3, are negatively regulated by phosphorylation dependent on the 
kinase activities of cyclin D-CDK4 and cyclin E/A-CDK2 complexes (Matsuura et al., 2004). 
Furthermore, cyclin D-associated kinase activities have also been implicated in regulation of 
transcription factors, DMP1 (cyclin D-interacting Myb-like protein) and Runx2 (Hirai and 
Sherr, 1996; Bodner et al., 1999; Shen et al., 2006), as well as a CKI, p21 (unpublished data, 
Child and Mann). Therefore, changes in cyclin D1 and p21 levels following exposure to DNA 
damaging agents could have more profound effect in terms of cellular responses.  
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a. 
 
 
b.  
 
Figure 3.1 Characterisation of 4NQO-induced changes in cyclin D1 expression in 
NIH 3T3 cells 
Asynchronously growing NIH 3T3 cells were treated with varying doses of 4NQO and lysed 
3h post-exposure. (a) The levels of cyclin D1 expression were examined by immunoblotting. 
The α-tubulin expression was also assessed as a loading control. (b) Cyclin D1 levels from 
immunoblotting assays were quantified using AIDA software and were normalised against α-
tubulin levels, as described (Materials and Methods). The relative protein expression was 
calculated from five independent experiments. The error bars represent the standard error.   
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a. 
 
b. 
 
Figure 3.2 Characterisation of H2O2-induced changes in cyclin D1 expression in 
NIH 3T3 cells 
Asynchronously growing NIH 3T3 cells were treated with varying doses of H2O2 and lysed 
3h post-exposure. (a) The level of cyclin D1 expression was examined by immunoblotting. 
The level of the α-tubulin, was used to monitor protein loading. (b) Cyclin D1 from the 
immunoblotting assay was quantified using AIDA software and normalised against α-tubulin 
levels, as described (Materials and Methods). The relative protein expression was calculated 
from three independent experiments. The error bars represent the standard errors 
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a. 
 
 
Figure 3.3  Assessment of the cell cycle protein expression in NIH 3T3 following 
exposure to DNA damage agents 
Changes in the expression level of cell cycle proteins in response to different doses of DNA 
damaging agents were examined by immunoblotting. (a) Asynchronously growing NIH3T3 
cells were treated with 0- 200µM 4NQO and harvested 3h post-exposure. Expression levels of 
six cell cycle proteins were investigated by immunoblotting. The level of α-tubulin was also 
assessed as a loading control.  
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b. 
 
 
 
Figure 3.3 cont.  Assessment of the cell cycle protein expression in NIH 3T3 
following exposure to DNA damage agents.  
(b) Asynchronously growing NIH3T3 cells were treated with 0-1000µM H2O2 and harvested 
3h post-exposure. Expression levels of six cell cycle proteins were investigated by 
immunoblotting. The α-tubulin expression was also assessed to monitor protein loading.  
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b. 
 
 
Figure 3.4 Testing the generality of 4NQO-triggered response by cyclin D1 and p21 
Asynchronously growing U2OS and WI38 cell lines were treated with 4NQO and harvested 
3h post-exposure. Protein expression of cyclin D1 and p21 in (a) U2OS and (b) WI38 cell 
lines were assessed by immunoblotting. The α-tubulin expression levels were monitored to 
assess protein loading.  
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Figure 3.5  Characterisation of cyclin D1 and p21 responses following exposure of 
NIH 3T3 cells to UV or IR 
Asynchronously growing NH 3T3 cells were treated with (a) UV or (b) IR and harvested 3h 
after exposure. Changes in the expression levels of cyclin D1 and p21 were assessed by 
immunoblotting. α-tubulin level was also examined to monitor protein loading.  
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b. 
 
 
Figure 3.6 Characterisation of the effect of the DNA damage response on pRb 
phosphorylation status by electrophoretic mobility shift assay  
Asynchronously growing NIH 3T3 cells were treated with (a) 4NQO or (b) H2O2 and 
harvested 3h post-exposure as described before. Protein samples were separated on a 7% 
SDS-PAGE gel to isolate the differentially phosphorylated forms of pRb. The bands were 
visualised by immunoblotting with a pan-pRb antibody. Protein sample from quiescent NIH 
3T3 cells served as a control for hypophosphorylated pRb. Hyper- and hypo-phosphorylated 
forms of pRb are indicated with black and white triangles, respectively.  
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Figure 3.7  Changes in the CDK2-associated kinase activities following exposure to 
4NQO 
(a) Asynchronously growing NIH 3T3 cells were treated with 4 doses of 4NQO and 
expression levels of cyclin E and CDK2 were assessed by immunoblotting as control for the 
total protein levels. Cyclin E/A-CDK2 complexes was isolated from 4NQO-treated NIH 3T3 
cells by IP using an antibody against CDK2 at 3h post-exposure. The negative control 
contained no antibody. The kinase activity was measured in vitro using histone H1 as 
substrate. (b) The CDK2-associated kinase activities were quantified by phosphorimaging. 
The bar chart represents the mean values and error bars indicate the range of activities 
obtained from two independent experiments.  
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Figure 3.8  Phosphorylation of pRb at CDK4-specific target sites 
The lysates of 4NQO-treated NIH3T3 cells were separated by 7% SDS-PAGE for 
electrophoretic mobility shift assay. The phosphorylation status of the CDK4-specific 
(S807/811) and the CDK2-specific (T821) sites on pRb was examined using phosphospecific 
antibodies. Lysate of quiescent NIH 3T3 (G0) was used as a negative control.  
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Figure 3.9  pRb phosphorylation status and 4NQO induced cyclin D1 and p21 
responses in the presence and absence of p16
INK4a
 
Asynchronously growing EH1 cells were treated with 4 doses of 4NQO in the presence and 
absence of IPTG. (a) Expression levels of cyclin D1, p21, p16
INK4a
 and α-tubulin were 
examined by immunoblotting assay. (b) Changes in the phosphorylation status of pRb were 
assessed by electrophoretic mobility shift assay using a pan-pRb antibody. Black and white 
triangles indicate hyper- and hypo-phosphorylated forms of pRb, respectively.  
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Figure 3.10  4NQO - induced cyclin D1 and p21 responses in quiescent D1wt 3T3 
cells 
For description see below.  
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c.  
 
 
Figure 3.10 cont.  4NQO - induced cyclin D1 and p21 responses in quiescent D1wt 
3T3 cells 
To study the cyclin D1 and p21 response to 4NQO in quiescent cells, a stable cell clone – D1 
wt3T3 – that constitutively expresses human cyclin D1 under the CMV promoter was 
generated from NIH 3T3 cells. (a) Asynchronously growing D1wt 3T3 cells were treated  
4NQO and the responses of endogenous cyclin D1 (white triangle), exogenous cyclin D1 
(black triangle) and p21 were studied by immunoblotting. The α-tubulin expression level was 
assessed as a loading control. (b) D1wt 3T3 cells were quiesced by serum starvation and were 
treated with 4NQO as before. Changes in the protein expression were tested by 
immunoblotting assays. (c) The DNA profiles of asynchronous and serum starved D1 wt 3T3 
population were obtained by PI staining and flow cytometry as described (Materials and 
Methods).   
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Chapter 4:  Investigation of cellular responses to 4NQO-
induced DNA damage in NIH 3T3 cells  
4.1 Introduction 
The outcomes of the DNA damage response are thought to be dependent on the types and 
levels of damage imposed (Zhou and Elledge, 2000; Carr, 2002; Kastan and Bartek, 2004). 
When repairable, the DNA damage signalling leads to activation of the repair processes whilst 
temporarily inducing arrests of cell cycle as described before (Introduction 1.3). Alternatively, 
when DNA repair is not favourable, cells carrying damaged DNA are removed by cell death.  
There are mainly two types of cell death; apoptosis and necrosis. Apoptosis, also known as “a 
programmed cell death”, is comprised of a sequence of characteristic events including, 
chromatin condensation (Gorczyca, 1999; Huppertz et al., 1999), loss of mitochondrial 
membrane potential, nuclear fragmentation and preservation of plasma membrane integrity 
through these processes (Jin and El-Deiry, 2005; Roos and Kaina, 2006; Elmore, 2007; Taylor 
et al., 2008). On the other hand, necrotic cell death, commonly known as “an accidental cell 
death”, is characterised by cell swelling, an early loss of plasma membrane integrity and 
subsequent inflammatory response (Blagosklonny, 2000; McHugh and Turina, 2006). For a 
long time, necrosis was considered as uncontrolled process. However, recent findings have 
shown that a number of protein molecules, such as RIP-1 and cyclophilin D, are involved in 
the regulation of necrotic cell death but not of apoptotic cell death (Baines et al., 2005; 
Nakagawa et al., 2005; Festjens et al., 2006; Festjens et al., 2007). These findings led to 
suggestions that necrosis may also be a programmed cell death which is differentially 
regulated from apoptosis (Zong and Thompson, 2006; Golstein and Kroemer, 2007).  In 
addition, with recent advance in the understanding of cell necrobiology, more types of cell 
death such as autophagy, oncosis and cytoplasmatic cell death have been described (Van 
Cruchten and Van Den Broeck, 2002). Some cellular events are associated with more than one 
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mode of cell death and interplay of signalling pathways between different types of cell death 
have also been reported (Kim et al., 2006; Tsujimoto et al., 2006). As a result, definition of 
each type of cell death has become rather unclear in literatures. To avoid ambiguity, cells were 
classified apoptotic when they exhibited the characteristic features such as nuclear 
fragmentation, chromatin condensation, caspase activation and maintenance of membrane 
integrity whilst dying cells that lacked these features were classified necrotic in this project.  
 
4.2 Results 
4.2.1 4NQO induces long-term changes in cyclin D1 and p21 levels in NIH 3T3 cells 
To determine whether the 4NQO-induced responses of cyclin D1 and p21 would have any 
impact on the outcomes of the DNA damage response, the long-term responses of cyclin D1 
and p21 were assessed in NIH 3T3 cells. Cells were exposed to low (2.5µM), medium (50µM) 
and high (200µM) doses of 4NQO and harvested at longer time points for immunoblot as 
described before (Materials and Methods). It was revealed that the unique responses of these 
proteins induced by 4NQO persisted up to 48h post-exposure (Figure 4.1). Cyclin D1 in the 
cells treated with a high dose of 4NQO became undetectable at later time points most likely 
due to a loss of cellular material as indicated by the declining level of a structural protein, α-
tubulin. The response of p21 was also maintained up to 48h after exposure. The p21 
accumulation triggered by a low dose of 4NQO intensified with time and reached its peak 
level at 16h post-exposure. The p21 level began to decline at 24 – 48h time points although it 
remained elevated compared to the non-treated control sample. A medium dose of 4NQO 
induced a degradation of p21 and the level remained low throughout the course of this assay. 
Finally, the p21 level was sustained at a similar level as the control sample in response to an 
exposure to a high dose of 4NQO and it only declined with a lowering level of α-tubulin. 
Together, these results demonstrate that the 4NQO-induced changes in cyclin D1 and p21 
levels represent long-term responses to DNA damage and thus they are likely to affect the 
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outcome of cellular responses following 4NQO treatment.  
 
4.2.2 Viability of the cells after DNA damage by 4NQO exposure 
To understand the roles of cyclin D1 and p21 in DNA damage response, cellular responses 
associated with different doses of 4NQO were assessed. Firstly, viabilities of the 4NQO-
treated cells were assessed by PI-exclusion assay using flow cytometry. The PI dye is 
positively charged and is actively excluded from live cells that have intact plasma membranes. 
Non-viable cells often have a reduced or defective membrane transport activity and 
sometimes their membranes can be physically disrupted. Thus non-viable cells can be 
positively stained with PI (Darzynkiewicz, 1997; Vitale et al., 1998; Elmore, 2007).  
 
At 3h post-treatment, less than 10% of the cells were positively stained with PI in response to 
all the doses tested (Figure 4.2), suggesting that although changes in the levels of cyclin D1 
and p21 were apparent within 3h of exposure to 4NQO, the subsequent cellular responses 
may take longer to be established, at least for the cell death response. At 24 and 48h after 
exposure, the proportion of cells positively stained with PI increased in a dose-dependent 
manner (Figure 4.2). Following treatment with a low dose (2.5µM) of 4NQO, less than 20% 
of cells were stained positively with PI up to 48h post-exposure. Thus, the majority of these 
cells seemed to have retained an intact plasma membrane throughout the course of this 
experiment. Medium and high doses of 4NQO rendered their plasma membranes permeable 
to PI in 20% and 40% of cell population, respectively, within 2h. By 48h, the proportion of PI 
positive cells increased by 2-3 fold, inducing cell death in up to 60% and 80% of the 
population (Figure 4.2). Similar results were obtained using a trypan blue assay (data not 
shown). Taken together, these observations demonstrate that 4NQO doses greater than 50µM 
exerted cytotoxic effects, inducing a substantial level of cell death in NIH 3T3 cells in both 
time and dose-dependent manners. At lower doses, on the other hand, the majority of the 
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population survived the 4NQO-induced damage. A similar dose-dependent loss of cellular 
viability was detected at an earlier time point by monitoring the metabolic activities of 
mitochondria as a marker. CellTiter96
®
 AQueous Assay (Promega), also known as the MTS 
assay, is a colourimetric assay which measures the activity of mitochondrial enzymes. 
Metabolically active mitochondria are able to convert a tetrozolium compound [3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] (MTS) 
to a purple coloured formazan product (Cory et al., 1991). Six independent MTS assays 
highlighted a dose-dependent cytotoxic effect of 4NQO in NIH 3T3 cells within 5h of 
exposure (Figure 4.3). Viabilities of 4NQO-treated NIH 3T3 cells gradually decreased with an 
increasing dose of 4NQO as indicated by a decreasing detection of formazan products (Figure 
4.3).  
 
Collectively, the PI exclusion and MTS assays both indicated that 4NQO treatment induced a 
dose-dependent loss of viability in NIH 3T3 cells. Mitochondrial dysfunction and loss of 
cellular membrane integrity are characteristics associated with both apoptotic and necrotic 
cell death (Taylor and Lehmann, 1998; Tsujimoto et al., 2006). Considering that different 
doses of 4NQO induced distinct molecular responses, it is possible that the changes in cyclin 
D1 and p21 may play a role in determining the mode of cell death activated following 4NQO 
exposure. To probe this hypothesis, a number of characteristic features specific to a type of 
cell death have been examined.  
 
4.2.3 Characteristic features accompanying cell death induced by  4NQO ; 
Apoptosis vs. Necrosis 
In an attempt to distinguish the type of cell death induced by 4NQO, Yo-Pro-1
®
 dye 
(Molecular Probe) was used in conjunction with PI in an immunofluorescent analysis of 
4NQO-treated cells by flow cytometry. Yo-Pro-1
®
  is a non-cytotoxic dye that can stain early 
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apoptotic cells as well as necrotic cells but not viable cells (Idziorek et al., 1995). A dual 
staining with PI and Yo-Pro-1
®
 enables a differentiation between apoptotic (Yo-Pro-1
®
 
positive; PI negative) and late apoptotic/necrotic (Yo-Pro-1
®
 positive; PI positive) cells. With 
an increasing doses of 4NQO, mixed populations of single (i.e. apoptotic) and double positive 
cells (i.e. late apoptotic/necrotic) were detected (data not shown). Although this suggested that 
4NQO-induced DNA damage may activate both apoptotic and necrotic cell death, an accurate 
quantification of Yo-Pro-1
®
 signal was hindered by a strong autofluorescent property of 
4NQO-treated NIH 3T3 cells.  
 
An alternative dye, 4',6-diamidino-2-phenylindole (DAPI), was employed to stain nuclei of 
4NQO-treated NIH 3T3 cells and the changes in nuclear morphology were observed under the 
fluorescent microscope as described (Materials and Methods). This revealed that whereas the 
nuclei of cells treated with 0 or 2.5µM 4NQO remained spherical, the nuclei of cells treated 
with 50 and 200µM 4NQO were smaller and somewhat flattened in shape (Figure 4.4). 
Furthermore, a medium dose of 4NQO (50µM) in particular induced a nuclear condensation 
as can be observed from an enhanced fluorescent signals of the nuclei at 48h post-exposure. 
Nuclear condensation, as mentioned before, is one of the characteristics associated with 
apoptotic cell death. In order to assess whether 4NQO-treatment, particularly at a medium 
dose, can induce apoptotic cell death in NIH 3T3 cells, the presence of another apoptotic 
cellular event was probed in 4NQO-treated NIH 3T3 cells.  
 
One of the key events during apoptosis is the activation of cysteine-dependent aspartate 
directed proteases, caspases.  To date, 14 mammalian caspases and over 400 of their 
substrates have been identified (Shi, 2002; Chowdhury et al., 2006; Taylor et al., 2008). 
Caspases are produced as catalytically inactive zymogens and upon activation of apoptosis, 
they undergo proteolytic activation (Shi, 2004a; Shi, 2004b; Jin and El-Deiry, 2005). Caspase-
3 is one of the frequently activated executioner caspases in apoptotic cells. Amongst a number 
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of known functions, it has been implicated in activation of caspase-activated DNA 
endonuclease (CAD) by cleaving its inhibitor, ICAD (Porter and Janicke, 1999; Sarkaria et al., 
1999). The activation of CAD subsequently leads to DNA fragmentation which is a hallmark 
of apoptosis. Thus, caspase-3 activation could be used as an indication for the onset of 
apoptotic cell death pathway. Figure 4.5 presents the changes in the levels of procaspase-3 (i.e. 
inactive full length caspase-3) and active caspase-3 detected in the 4NQO-treated NIH 3T3 
cells at indicated time points. Up to 8h post-exposure, only the inactive form of caspase-3 (i.e. 
procaspase-3) was detectable in all samples. The active form of caspase-3 was absent in cells 
treated with 2.5µM (low dose) 4NQO within the time scale of this experiment. Active 
caspase-3 was first detected at 16h after an exposure to 50µM (medium dose) 4NQO. The 
level of active caspase-3 in this sample increased with time and seemed to reach its maximum 
at 48h of exposure. In cells treated with 200µM (high dose) 4NQO, the activation of caspase-
3 appeared to have taken place at a later time point compared to that in the 50µM sample. A 
relatively low level of active caspase-3 was observed at 24h following an exposure to a high 
dose of 4NQO. It increased up to a similar level as 50µM sample within 48h. In both samples, 
the level of procaspase-3 decreased concomitantly with an increasing detection of the active 
caspase-3 in all samples (Figure 4.5).  
 
As can be seen, exposure to a medium dose of 4NQO induced caspase-3 activation at an 
earlier time point than a high dose of 4NQO. Previous investigations with PI-exclusion and 
MTS assays, however, suggested that the incidence of cell death increased proportionally to 
the doses of 4NQO, in other words, it is proportional to the level of DNA damage. Taken 
together, these observations seemed to indicate that medium doses of 4NQO induced cell 
death with apoptotic characteristics whereas high doses of 4NQO predominantly induced a 
non-apoptotic mode of cell death, possibly necrosis. Thus, it is possible that the difference in 
the molecular responses triggered by these doses of 4NQO could be responsible for 
distinguishing the types of cell death pathways activated following DNA damage.  
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4.2.4 Flow cytometry analysis of 4NQ- induced cellular responses in NIH 3T3 cells 
Cellular responses to 4NQO-induced DNA damages in NIH 3T3 cells were studied further 
using flow cytometry analysis. NIH 3T3 cells were treated with 8 different doses of 4NQO; 0, 
2.5, 10, 25, 50, 75, 100 and 200µM; as previously used in the immunoblotting assays. At 24 
and 48h after 4NQO exposure, cells were harvested and fixed in 70% ethanol. They were 
stained with PI and analysed by flow cytometry. To enable the detection of potential DNA 
fragmentation associated with apoptosis, sub-G1 buffer was used during processing as 
described in Materials and Methods.  
 
Initially, 4NQO-treated NIH 3T3 cells were collected and analysed at 3h post-exposure. At 
this time point, no prominent changes in DNA profiles were observed in response to any of 
the 4NQO doses tested (data not shown). At 24 and 48h after exposure, however, the DNA 
profiles of 4NQO-treated NIH 3T3 cells were substantially different from the control sample, 
suggesting that progression through the cell cycle has been perturbed by the activation of 
DNA damage response (Figure 4.6a). Changes in the distribution of cells between different 
phases took place in both dose- and time-dependent manners. In response to a low dose 
(2.5µM) of 4NQO, cells accumulated in S and G2/M phases of cell cycle at 24h after 
exposure. An asynchronous distribution of cells was restored within 48h of treatment, 
implying that the cellular responses induced by 2.5µM 4NQO were transient. Furthermore, no 
notable accumulation of cells with a sub-G1 content of DNA was observed, suggesting that an 
exposure to a low dose of 4NQO did not trigger cell death (Figure 4.6). This was consistent 
with the maintenance of membrane integrity (Figure 4.2) and the lack of caspase-3 activation 
(Figure 4.5) as observed before. Collectively, these observations seemed to indicate that the 
DNA damage imposed by a low dose of 4NQO induced transient arrests at S and G2/M phase 
in NIH 3T3 cells, most probably to allow time for DNA repair prior to re-entering cell cycle. 
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In response to medium doses (10 - 75µM) of 4NQO, a prominent increase in the G1 
population was observed whilst the G2/M population was almost undetectable at 24h after the 
treatment. The G1 arrest persisted up to 48h post-exposure, with a steady increase of cells 
with sub-G1 DNA content (Figure 4.6). At 24h, where active caspase-3 was readily detectable 
(Figure 4.5), up to 15% of cells were found in the sub-G1 region of the DNA profiles (Figure 
4.6). The sub-G1 population increased by 2-fold within 48h of 4NQO exposure, coincident 
with the increased proportion of dead cells observed by PI-exclusion assays (Figure 4.2). 
Taken together, these observations suggested that the DNA damage incurred by medium doses 
of 4NQO triggered a strong G1 arrest as well as apoptotic cell death. Cellular responses 
associated with NIH 3T3 cells treated with high doses (100-200µM) of 4NQO resembled 
those observed in response to medium doses of 4NQO, in terms of the distribution amongst 
cell cycle phases; a G1 arrest persisted up to 48h after damage and sub-G1 population 
increased with time (Figure 4.6). Notably, the proportion of the sub-G1 population associated 
with cells treated with high doses of 4NQO remained lower than that of cells treated with 
medium doses at all time points examined here (Figure 4.6b). This seemed to agree with a late 
activation of caspase-3 in response to treatment with a high dose of 4NQO compared to a 
medium dose of 4NQO (Figure 4.5), further supporting the hypothesis that the high doses of 
4NQO mainly induced non-apoptotic cell death.  
 
The effect of the 4NQO-induced DNA damage response on the progression of cells through 
G1/S transition was examined further by BrdU-incorporation. To assess the cellular responses 
triggered by none, low, medium and high doses of 4NQO, NIH 3T3 cells were treated with 
0µM, 2.5µM, 50µM and 200µM 4NQ, respectively. A low dose of 4NQO caused little 
reduction in the level of BrdU incorporation compared to the non-treated sample at 3h post-
exposure (Figure 4.7). BrdU incorporation was abolished almost completely in response to 
medium and high doses of 4NQO. Although a G1 arrest only became apparent at later time 
points in the DNA profiles, these observations indicated that medium and high doses of 
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4NQO triggered a rapid inhibition of DNA synthesis within 3h of exposure.  
 
4.2.5 Phase-specific response 
The lack of changes in the DNA profiles at early stages of DNA damage responses (data not 
shown) despite a palpable inhibition of DNA synthesis as observed from the BrdU 
incorporation analysis (Figure 4.7) suggested that cell cycle arrests induced by 4NQO 
exposure are not confined to a particular stage of cell cycle. To assess 4NQO-induced 
responses at different stages of the cell cycle, NIH 3T3 cells were enriched in G1, S and 
G2/M phases of cell cycle prior to 4NQO treatment. To achieve synchronisation, NIH 3T3 
cells were first arrested in G0 by serum starvation for 72h. Cells were then stimulated to re-
enter cell cycle by re-introduction of serum. The G1-, S- and G2/M-enriched population of 
cells were obtained after 10, 18, and 22h after addition of serum, respectively.  Each cell 
population was exposed to none, low (2.5µM), medium (50µM) and high (200µM) doses of 
4NQO and the progress of each population through cell cycle was monitored up to 24h post-
exposure.  
 
In the absence of 4NQO-induced damage, the G1-enriched population progressed into the S 
phase and began to regain asynchrony 24h after stimulation (Figure 4.8a). In response to low 
and high doses of 4NQO, cells remained arrested in G1 phase up to 24h post-exposure (Figure 
4.8b, d). The DNA profile of cells treated with 50µM 4NQO at 3h post-exposure appeared 
similar to that of an asynchronous population (Figure 4.8c). However, DNA profiles collected 
from the later time points revealed that the cells were arrested in G1 up to 24h after exposure, 
indicating that the sample collected at 3h after damage was probably not fully quiescent prior 
to serum re-introduction. An accumulation of sub-G1 population was detected in cells treated 
with a medium dose of 4NQO but was absent from the rest of the samples at 24h time point, 
consistent with the previous observations (Section 4.2.4). Collectively, these results 
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demonstrated that the cells in G1 respond by cell cycle arrest to all the doses of 4NQO tested 
here. A G1 arrest of cells in response to a low dose of 4NQO was not detected in the assays 
using asynchronous NIH 3T3 cells (Figures 4.6, 4.7), highlighting the limitation of data 
obtained from studies using an asynchronous population of cells.  
 
The S phase -enriched population of NIH 3T3 cells entered G2/M phases within 3h and 
regained an asynchronous distribution of cells 12h later in the absence of 4NQO (Figure 4.9a). 
In response to medium and high doses of 4NQO, cells remained arrested in the S phase up to 
24h post-exposure and a similar proportion of sub-G1 population was observed in both 
samples (Figure 4.9c, d). In response to a low dose of 4NQO, on the other hand, the S phase-
enriched population continued to progress to late-S and G2/M phases of cell cycle albeit at a 
slower rate than the non-treated cell population (Figure 4.9b). This observation seems to be in 
an agreement with the transient response observed earlier in the asynchronous cells (Figure 
4.6). It is likely that a low dose of 4NQO induced a repairable level of DNA damage and thus 
cells underwent DNA replication slowly to accommodate for the repair process to take place. 
In this model, incorporation of BrdU would be maintained to the similar level observed in the 
non-treated cells even if the cells were arrested in G1, as both DNA replication and repair 
processes involve DNA synthesis (Figure 4.7).  
 
For the G2/M phase-enriched population, cells were treated with 4NQO at 22h post-serum 
stimulation. In response to all doses of 4NQO, cells remained arrested up to 12h post-
exposure (Figure 4.10b, c, d). At 24h after exposure, however, a small shift from the late S to 
G2/M was observed. The population treated with a low dose of 4NQO exhibited the most 
notable shift (Figure 4.10b). Whereas this progress of cells through G2/M phase coincided 
with an appearance of sub G1 population in cells treated with medium and high doses of 
4NQO, no sub G1 population was observed in the cells treated with a low dose of 4NQO. 
This may be an indication that cells are less capable of mounting cell cycle arrests at later 
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stages of the cell cycle in response to DNA damage.  
 
4.2.6 Cell cycle analysis of H2O2-treated NIH 3T3 cells by flow cytometry 
The cellular responses following exposure to H2O2 were analysed and compared with that of 
4NQO. The H2O2-treated NIH 3T3 cells responded by a temporal accumulation of cells in 
G2/M phase which resembled the response of cells to 2.5µM 4NQO (Figure 4.11). The G2/M 
population increased in a dose-dependent manner; a moderate increase was observed in 
response to 100µM H2O2 whilst over 60% of the cell population was found in the  G2/M peak 
of the DNA profile in response to 1000µM H2O2 (Figure 4.11). Concomitantly with the 
increase in the G2/M population observed with an increasing doses of H2O2 employed, G1 
and S populations decreased gradually, suggesting that H2O2-induced DNA damage may not 
result in a strong G1/S arrest unlike the response observed following 4NQO exposure. 
Assessing the BrdU incorporation in the H2O2-treated samples by flow cytometry 
substantiated this observation. Exposure of NIH 3T3 cells to H2O2 resulted only in a moderate 
reduction (approximately 30%) of BrdU incorporating cells within 3h of treatment even at the 
highest dose tested here (Figure 4.12). This result seemed to indicate that H2O2 exposure 
primarily induced G2/M accumulation rather than G1 or S, unlike 4NQO-induced cellular 
response. 
 
The G2/M arrest induced by H2O2 remained apparent up to 24h after treatment. By 48h of 
exposure, the DNA profiles of H2O2-treated cells exhibited asynchronous cell distributions, in 
a similar manner to cells treated with a low dose of 4NQO. Thus, the cellular responses to a 
low dose of 4NQO and up to 1mM H2O2 shared a common feature in that they were transient. 
Furthermore, no accumulation of a sub-G1 population was observed up to 48h following 
H2O2-treatment (Figure 4.11), indicating that the majority of the cells were able to effectively 
remove damaged DNA and remain clonogenic. Collectively, these observations emphasised a 
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previous notion that 4NQO and H2O2 exhibit different potencies as DNA damaging agents 
with former potentially being a source of higher levels or more severe forms of DNA damage.  
 
4.2.7 Roles of cyclin D1and p21 in the 4NQO induced cellular response  
In an attempt to identify the roles  cyclin D1 and p21 play in the 4NQO-induced DNA 
damage response, immortalised mouse embryonic fibroblasts lacking  p21 (C57BL p21
-/-
 3T3) 
or cyclin D1 (C57BL cyclin D1
-/-
 3T3) were employed. In the absence of p21, cyclin D1 
exhibited the biphasic response to 4NQO treatment as observed in NIH 3T3 cells (Figure 
4.13a), indicating that the molecular response of cyclin D1 was not dependent on p21. This 
relationship was also true in the reverse situation where an absence of cyclin D1 did not 
interfere with the 4NQO-induced response of p21 (Figure 4.14a). Thus, the molecular 
responses of p21 and cyclin D1 may represent two distinct signalling pathways associated 
with the 4NQO-induced DNA damage.  
 
Investigations of 4NQO-induced cellular responses by flow cytometry uncovered increased 
propensities of the C57BL p21
-/-
 3T3 and C57BL cyclin D1
-/-
 3T3 cells to undergo DNA 
fragmentation, even in the absence of 4NQO-induced DNA damage (Figures 4.13b, 4.14b). 
The C57BL p21
-/-
 3T3 cells appeared particularly sensitive to apoptotic cell death. The 
accumulation of a sub-G1 population observed for this cell line was approximately twice the 
level observed in NIH 3T3 cells at all doses tested here (Figures 4.6b, 4.13c). Exposure to a 
low dose (2.5µM) of 4NQO led to an increase of population in S and G2/M within 24h of 
exposure in C57BL p21
-/-
 3T3 cells, implying either that p21 expression is not required for 
this response or that an alternative pathway was able to compensate for the absence of p21. 
Furthermore, C57BL p21
-/-
 3T3 cells were incapable of restoring a normal distribution of cells 
amongst G1, S and G2/M phases at later time points. Instead, the majority of the cells 
underwent DNA fragmentation at 72-96h after exposure (Figure 4.13b, c). Taken together, 
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these results indicate a protective role for p21 as well as its potential involvement in cell cycle 
recovery during 4NQO-induced response.  In the cells treated with medium (50µM) and high 
(200µM) doses of 4NQO, little change in the distribution of cells was observed after 24h 
other than a slightly increased population of cells in S and G2/M. Whether this was due to cell 
cycle arrests at multiple stages of cell cycle or a lack of response was not determined. 
Strikingly, C57BL p21
-/-
 3T3 cells failed to establish any notable G1 accumulation in response 
to medium and high doses of 4NQO unlike NIH 3T3 cells (Figure 4.13b).  
 
A lack of cyclin D1 expression seemed to have a less profound effect in terms of cellular 
responses induced by 4NQO exposure, compared to a loss of p21. Although slightly perturbed, 
an accumulation of cells in S-G2/M phases following an exposure to a low dose of 4NQO and 
G1 arrests induced by medium and high doses of 4NQO were still detectable (Figure 4.14b). 
The absence of cyclin D1 appeared to sensitise the cells to apoptotic cell death as the majority 
of C57BL cyclin D1
-/-
 3T3 cell population treated with medium and high doses of 4NQO 
underwent DNA fragmentation within 48h of damage as indicated by a dramatic increase in 
the sub-G1 population (Figure 4.14b). Assessing the changes in the levels of other members 
of D-type cyclins, which are capable of complementing cyclin D1 in normal cell cycle, 
following 4NQO exposure revealed that both cyclin D2 and D3 responded in the same way as 
cyclin D1 did (Figures 4.14a, 3.1a). These responses may have contributed to the relatively 
intact cell cycle arrests induced by 4NQO in C57BL cyclin D1
-/-
 3T3 cells. However, the 
responses associated with cyclin D2 and D3 were not able to restore the similar resistance to 
4NQO-induced cell death exhibited by NIH 3T3 cells. Therefore, these observations seemed 
to indicate that cyclin D1 may have a unique role in DNA damage responses associated with 
4NQO.  
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4.3 Discussion 
4.3.1 Cell deaths triggered by the 4NQO-induced DNA damage response 
Whereas DNA damage-induced p21 responses are often shown to persist up to 72-95h post-
damage, cyclin D1 responses are reported to be short-lived or its long-term response is 
frequently not addressed (Di Leonardo et al., 1994; Hiyama and Reeves, 1999; Agami and 
Bernards, 2000; Barnouin et al., 2002). A long-term analysis of the 4NQO-induced molecular 
responses of cyclin D1 and p21 suggested that their dose-dependent responses were 
maintained up to 48h post-exposure (Figure 4.1). This observation substantiated the 
possibility that cyclin D1 as well as p21 may play an important role in regulating cellular 
responses to 4NQO-induced DNA damage.  
 
To determine the cellular responses mounted by NIH 3T3 cells in response to varying doses of 
4NQO, the cellular viabilities of cells were assessed using two assays; PI-exclusion and the 
MTS assays. The PI exclusion assay measured the integrity of cellular membranes whereas 
the MTS assay measured metabolic activities of mitochondria, both of which are 
compromised in dying cells. NIH 3T3 cells were able to maintain membrane integrities in the 
majority of the population throughout the course of the assay following exposure to a low 
dose of 4NQO (Figure 4.2). On the other hand, doses greater than 50µM induced a substantial 
loss of membrane integrity, suggesting that the DNA damage response induced at these doses 
may result in cell death (Figure 4.2). The level of cell death induced by 4NQO appeared 
proportional to the doses and hence the levels of damage imposed to the cells. The analysis of 
mitochondrial activities in 4NQO-treated NIH 3T3 cells seemed to support these observations. 
The mitochondrial activities declined in a dose-dependent manner. and at 200µM, the activity 
was reduced to  approximately 40% of the maximum activity observed in the non-treated cells 
(Figure 4.3).   
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Recent advances in our understanding of the molecular mechanisms governing the cell death 
processes have implicated a number of cell cycle proteins such as CDKs and p21 in the 
induction of apoptosis and an alternative mode of cell death, autophagy (Wang et al., 2008). 
Thus, the 4NQO-induced alterations of cyclin D1 and p21 expression levels could potentially 
play a role in activating a specific type of cell death. The viability assays employed in this 
investigation could not distinguish late apoptotic and necrotic cells. In a physiological 
environment, cell membranes of apoptotic cells begin to display specific ligands on cell 
surface that can be recognised by phagocytic cells to promote their clearance prior to loss of 
membrane integrity whereas necrotic cells instantly loses membrane integrity upon cell death 
(Gregory and Devitt, 2004; Kinchen and Ravichandran, 2007). In the experimental system 
used for the PI exclusion assay, however, such phagocytic cells were not present to remove 
apoptotic bodies. At late stages of apoptosis, cells subsequently became permeable to PI dye 
and became indistinguishable from necrotic cells (Darzynkiewicz, 1997; Vitale et al., 1998). 
On the other hand, mitochondrial deregulation was considered as one of the hallmarks of 
apoptotic cell death, in particular as a downstream signalling to intrinsic sources of apoptotic 
stimuli, including DNA damage and cellular stress (Jin and El-Deiry, 2005; Chowdhury et al., 
2006; Meier and Vousden, 2007). During apoptosis, pro-apoptotic Bcl-2 family proteins 
polymerise and form pores on outer mitochondrial membranes, allowing the release of several 
pro-apoptotic proteins such as cytochrome c and apoptosis protease-activating factor-1 (Apaf-
1) (Joza et al., 2001; Arnoult et al., 2002). This process, known as the mitochondrial 
permeability transition (MPT), also neutralises mitochondrial membrane potential leading to 
abrogation of the electron transport system that is essential for mitochondria to generate cell’s 
energy source, ATP (James and Murphy, 2002; Murphy and Steenbergen, 2007). Interestingly, 
recent studies have identified a mitochondrial protein, cyclophilin D, which induces MPT in a 
Bak/Bax-independent manner, suggesting that there are two distinct mechanisms of MPT 
(Baines et al., 2005; Nakagawa et al., 2005). A mutant cyclophilin D or the presence of its 
inhibitor, cyclosporine A, was shown to abolish an oxidative damage-induced MPT and 
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consequently inhibited necrotic cell death whilst MPT induced by common apoptotic inducers 
such as staurosporine was unaffected. Furthermore, necrotic cell death can also be triggered 
by receptor-ligand interaction and proteases like calpains and cathepsins have been implicated 
in necrotic process, similarly to apoptosis (Golstein and Kroemer, 2007). Overall, these data 
indicate that necrosis may also be a programmed process (Lemasters et al., 2002; Festjens et 
al., 2006; Zong and Thompson, 2006; Golstein and Kroemer, 2007). 
 
Amongst many cellular events shared between apoptosis and necrosis, activation of caspases 
is predominantly associated with apoptotic cell death. Caspase-3 activation has been observed 
in apoptotic cell death induced by various DNA damaging agents (Kimura et al., 1998; Yu and 
Little, 1998; Huang et al., 1999b; Dunkern et al., 2001). In an attempt to differentiate the 
types of cell death, caspase-3 activation in the 4NQO-treated NIH 3T3 cells was monitored by 
immunoblotting assays. Consistent with the lack of cell death features observed from PI 
exclusion and MTS assays, no activation of caspase-3 was observed up to 48h after an  
exposure to a low dose of 4NQO (Figure 4.5), supporting the notion that a low dose of 4NQO 
induced cellular responses other than cell death. In cells treated with medium and high doses 
of 4NQO, activation of caspase-3 took place with different kinetics (Figure 4.5). The active 
form of caspase-3 was detected first at 16h after exposure and increased steadily up to 48h-
time point in a sample treated with a medium dose of 4NQO. On the other hand, a similar 
level of active caspase-3 was detected only at 48h after an exposure to a high dose of 4NQO. 
Prior to this time point, active caspase-3 could be detected but the level of detection was 
much lower than that observed in the cells treated with a medium dose of 4NQO. Caspase-3 is 
involved in the activation of DNA endonucleases responsible for DNA fragmentation 
associated with apoptotic cell death (Sakahira et al., 1998; McIlroy et al., 1999). Indeed, 
analysis of DNA profiles showed an accumulation of a sub-G1 population in samples where 
active caspase-3 was detected (Figure 4.6). DNA profiles of 4NQO-treated NIH 3T3 cells 
obtained at 24-48h after treatment showed less than 5% of the cell population with the DNA 
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content less than that of G1 cells (i.e. < 2N), indicating a very low level of DNA 
fragmentation. The accumulation of a sub-G1 population in cells treated with medium and 
high doses of 4NQO also followed the caspase-3 activation pattern; the sub-G1 population 
began to accumulate earlier in the 50µM sample than in the 200µM sample, corresponding to 
the earlier increase in the level of activated caspase-3 in the 50µM sample (Figures 4.5, 4.6b). 
Therefore, these data seem to imply that DNA damage induced by a medium dose of 4NQO 
was more potent in inducing events associated with apoptotic cell death compared to a high 
dose of 4NQO. Conversely, DNA damage imposed by a high dose of 4NQO seemed to incur a 
greater cytotoxic effect as indicated by the greater loss of membrane integrity and 
mitochondrial activities. Although apoptotic cell death in the absence of DNA fragmentation 
has been reported before (Schulze-Osthoff et al., 1994), the observations above seem to 
indicate that a high dose of 4NQO induced necrotic cell death.  
 
4.3.2 Multiple phase cell cycle arrest 
Analysis of cell cycle progression following 4NQO exposure in asynchronous population of 
NIH 3T3 cells indicated that at low doses, cells induced transient arrests to repair and remove 
damaged DNA and upon completion, a normal cell cycle was resumed. On the other hand, 
treatment with doses greater than 10µM 4NQO induced permanent cell cycle arrests or cell 
death cell death. Perhaps at these doses, overwhelming levels of damage are incurred and the 
damage response favours the removal of these cells. Studying the cell cycle progression of 
synchronous populations of NIH 3T3 cells indicated that cell cycle arrests triggered by 4NQO 
were not confined to one stage of cell cycle. Rather, all 4NQO doses tested induced transient 
or long-term arrests at multiple phases of cell cycle (Figures 4.8-4.10). In response to medium 
and high doses of 4NQO, cells were arrested not only in G1 but also in S and G2/M. These 
arrests were maintained for at least 24h after treatment. A low dose of 4NQO induced an 
attenuated progress of cells in S and G2/M, consistently with what was observed in the 
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asynchronous population of NIH 3T3 cells. However, G1 arrest induced by a low dose of 
4NQO persisted up to 24h after exposure and showed no sign of progression into S phase 
(Figure 4.8b). These observations demonstrated that the DNA damage response mounted by 
cells were, in part, phase specific. The cells in G1 appeared to be most sensitive to DNA 
damage-induced arrest but also most resistant to cell death (Figure 4.8). This seemed 
reasonable as the R-point resides within the late stage of G1 (Blagosklonny and Pardee, 2002). 
Such a DNA damage response would ensure that cells would not be committed to cycle in the 
presence of excessive level of DNA damage. Where cells were committed to cell cycle prior 
to attaining DNA damage, cellular responses seemed to depend largely on 4NQO doses and 
hence the levels of DNA damage incurred.  
   
In response to various doses of H2O2, NIH 3T3 cells responded by transient cell cycle arrest 
primarily in G2/M phase (Figure 4.11). A number of previous studies have demonstrated that 
H2O2 treatment induced an irreversible G1 arrest with phenotypes resembling that of 
replicative senescence, in a p53-dependent manner in human fibroblasts (Chen et al., 1998; 
Chen et al., 2000). In this study, such a strong G1 arrest was not observed, most likely due to 
differences in a number of key variables in the experimental conditions including the cell 
types, cell density, and lengths of H2O2 treatment employed. Here, increasing doses of H2O2 
caused a moderate reduction in BrdU-incorporating cells (Figure 4.12). Furthermore, H2O2-
induced G1 and G2/M arrests in NIH 3T3 cells were both transient and the normal cell cycle 
seemed to be regained within 48h of exposure (Figure 4.11). The comparison of cellular 
responses established in NIH 3T3 cells following exposure to 4NQO and H2O2 supported the 
previous notion that 4NQO is more potent as a DNA damaging agent than H2O2. The cellular 
responses triggered by 2.5µM 4NQO resembled those induced by 250-1000µM H2O2. 
Whereas NIH 3T3 cells treated with 50µM or greater doses of 4NQO resulted in a long-term 
arrests followed by cell death, 1000µM H2O2 triggered a transient arrest with no sign of cell 
death. Taken together, these observations appeared to indicate that the DNA damage imposed 
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by 4NQO is likely to be more debilitating to the cells. Studies by Olive and Johnston (1997) 
indeed demonstrated the superiority of 4NQO as a DNA damaging agent in a number of 
aspects; 4NQO induced double strand DNA breaks 10-fold more efficiently than H2O2, 
repairing 4NQO-imposed single-strand DNA breaks took 10 times longer than that for 
repairing the same number of H2O2-induced breaks, and the lethal dose 50 (LD50) of 4NQO in 
Chinese Hamster cells was 2.6µM compared to 100µM for H2O2 (Olive and Johnston, 1997).  
 
4.3.3 Relationships between molecular and cellular responses  
Due to the multifaceted and somewhat conflicting properties associated with some of the key 
components of cell cycle proteins, the precise mechanisms by which cell cycle proteins 
participate in regulation of DNA damage responses are still under discussion. Investigation of 
the molecular responses associated with the NIH 3T3 cells treated with 4NQO or H2O2 
revealed that whilst expression of the majority of cyclins and CDKs remained unchanged, 
cyclin D1 and p21 responded in a characteristic dose-dependent manner (Figures 3.1, 3.3). 
The use of cell lines defective in expression of cyclin D1 or p21 suggested that their responses 
triggered by 4NQO were not dependent on each other (Figures 4.13a, 4.14a). Therefore, it is 
possible that the molecular responses of these proteins represent the outcomes of two 
independent DNA damage signalling pathways which synergise to bring about appropriate 
cellular responses.  
 
In response to a low dose of 4NQO, NIH 3T3 cells induced multi-phase cell cycle arrests but 
remained resistant to apoptotic cell death up to 48h after treatment. The molecular responses 
observed in this investigation, together with previous reports in literature, indicated a central 
role of p21 in establishing these cellular responses. Following an exposure to a low dose of 
4NQO, p21 expression was found elevated as early as 3h post-exposure (Figure 3.3) and it 
remained high up to 48h after damage (Figure 4.1). In parallel, a 70% reduction of CDK2-
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associated kinase activities (Figure 3.7) and hypophosphorylated form of pRb (Figure 3.6a) 
were also detected. Collectively, these observations suggested that the p21-dependent 
inhibition of CDK2 resulted in activation of pRb, inhibiting E2F-dependent transactivation of 
gene expression required for DNA synthesis and thus resulting in a G1 arrest. A similar 
induction of p21 expression and subsequent G1 arrest has been observed in response to 
various DNA damaging agents including UV, IR and H2O2 (el-Deiry et al., 1993; Canman et 
al., 1994; Di Leonardo et al., 1994; el-Deiry et al., 1994; Chen et al., 1998; Barnouin et al., 
2002). Evidence substantiating the crucial role played by p21 in the DNA damage-induced G1 
arrest was provided from the studies of mice lacking functional p21 which were compromised 
of radiation-induced G1 arrests (Brugarolas et al., 1995; Deng et al., 1995). In addition to G1 
arrest, NIH 3T3 cells treated with a low dose of 4NQO progressed through S and G2/M stages 
of cell cycle at an attenuated rate compared to the non-treated control population (Figures 
4.9b, 4.10b). The expression of most cyclins and CDKs responsible for regulating these stages 
of cell cycle remained unchanged (Figure 3.3), suggesting that their activities were controlled 
either by inhibitors or by covalent modifications. Since p21 is a potent inhibitor of many 
cyclin-CDKs (Gu et al., 1993; Xiong et al., 1993), the elevated level of p21 most probably 
contributed to inhibiting the activities of cyclinA-CDK2 as well as cyclin B-CDK1 complexes 
that are required for DNA replication and mitotic entry.  
 
Alternatively, p21 can attenuate the cell cycle at S phase by interacting with an auxiliary 
factor of DNA polymerase δ, PCNA. Normally, PCNA interacts with replicative proteins such 
as DNA polymerase δ and replication factor C to form a holoenzyme. The binding of p21 to 
PCNA disrupts the formation of this pro-replicative complex and results in an inhibition DNA 
replication (Zhang et al., 1993; Oku et al., 1998; Rousseau et al., 1999; Maga and Hubscher, 
2003). In addition to DNA replication, PCNA is also required for DNA repair (Kelman, 1997; 
Maga and Hubscher, 2003; Corrette-Bennett et al., 2004). The actual effect of interaction 
between p21 and PCNA on DNA repair reported in the literature varies greatly. A number of 
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reports suggest that the binding of p21 to PCNA inhibits DNA repair as well as replication 
(Pan et al., 1995; Cooper et al., 1999; Soria et al., 2006). Bendjennat and colleagues have 
demonstrated that the p21 degradation following UV-induced DNA damage response is 
required to promote DNA repair (Bendjennat et al., 2003). Other studies indicated that DNA 
repair was not affected by p21 and that DNA replication and repair exhibited different 
sensitivity to p21-dependent inhibition (Flores-Rozas et al., 1994; Li et al., 1994; Shivji et al., 
1994). Human fibroblasts and cancer cells lacking the expression of p21 were deficient in 
repairing UV-induced damage, indicating a positive role of p21 in DNA repair (McDonald et 
al., 1996; Stivala et al., 2001). Molecular and kinetic analyses of the DNA repair process 
suggested that the presence of p21 did not affect the recruitment of PCNA to the site of 
damage but rather, a direct interaction of PCNA and p21 promoted the localisation of the 
latter to the site of DNA (Li et al., 1996; Perucca et al., 2006; Cazzalini et al., 2008). The 
effect of DNA damage induced p21 accumulation on DNA repair was not addressed in this 
investigation. However, at 4NQO- or H2O2-doses that resulted in an increased level of p21, 
cells responded by transient arrests and recovery of normal cell cycle, indicating that damaged 
DNA must have been removed and repaired successfully (Figure 3.3a, b). Furthermore, 
C57BL p21
-/-
 3T3 cells were unable to recover from 4NQO-induced arrests (Figure 4.13b). 
Collectively, these results suggested that the repair process was likely to be intact in the 
presence of elevated p21 in response to 4NQO.  
 
An aspect of the cellular responses triggered by a low dose of 4NQO appeared unique in that 
cells remained resistant to cell death (Figure 4.6). Similarly, H2O2-treated NIH 3T3 cells 
survived the exposure and seemed to induce little cell death (Figure 4.11). In both cases, p21 
level was induced whilst responses by cyclin D1 varied. Furthermore, C57BL p21
-/-
 3T3 cells 
were much more susceptible to apoptotic cell death even in the absence of DNA damage, 
suggesting that p21 plays a protective role and promote a survival of the cells (Figure 4.13b). 
In fact, the protective role of p21 is reported in the literature (Gorospe et al., 1996; Asada et 
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al., 1999; Gartel and Tyner, 2002; Sohn et al., 2006). Cytotoxicities of various DNA 
damaging agents including adriamycin, cisplatin and etoposide which are commonly used in 
cancer treatment, can be manipulated by modifying the levels of p21; overexpression of p21 
protected cells from apoptosis whilst reduced p21 expression due to mutations or introduction 
of antisense p21 enhanced lethality of these drugs (Prabhu et al., 1999; Vrana et al., 1999; 
Chan et al., 2000; Gartel and Tyner, 2002; Yu et al., 2005). Molecular mechanisms for the 
anti-apoptotic function of p21 have been suggested to involve inhibitory interactions of p21 
with pro-apoptotic proteins such as apoptosis signal-regulating kinase 1 (ASK1) and pro-
caspase 3 (Suzuki et al., 1998; Asada et al., 1999; Suzuki et al., 1999a; Suzuki et al., 2000; 
Nath, 2005). Interestingly, contrasting evidence indicates that p21 also plays a positive role in 
inducing apoptotic cell death; overexpression of p21 rendered cells hypersensitive to 
radiation- and drug-induced cell death (Kondo et al., 1996; Fotedar et al., 1999; Rieber and 
Strasberg Rieber, 2000; Dong et al., 2005). Furthermore, p21 has been implicated in 
determining the types of cell death where the presence of p21 favours apoptosis rather than 
autophagy (Fujiwara et al., 2008). An involvement of p21 in anti- or pro-apoptotic pathways 
during the DNA damage response seems to depend greatly on cell types and sources of DNA 
damage. It appeared that the anti-apoptotic functions of p21 dominated in the DNA damage 
response triggered by a low dose of 4NQO and up to 1000µM H2O2.  
 
So far, potential function of p21 in the DNA damage response triggered by a low dose of 
4NQO has been discussed. What does cyclin D1 play in such responses? Unlike p21, the level 
of cyclin D1 did not change dramatically following an exposure to a low dose of 4NQO 
(Figure 3.1). Being a positive regulator of cell cycle, maintaining cyclin D1 expression in 
cells which exhibited a great propensity to arrest at multiple stage of cell cycle seemed rather 
puzzling. Analysing the phosphorylation status of CDK4-specific target sites on pRb 
suggested that despite the largely unchanged level of cyclin D1 expression, CDK4-associated 
kinase activity appeared reduced (Figure 3.8). Interestingly, there is evidence demonstrating 
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that cyclin D1 could exert anti-proliferative effects. For instance, cyclin D1 has been shown to 
hold CDK2 in an inactive complex in cells approaching senescence as well as in proliferating 
mammalian cells and cancer cells (Dulic et al., 1993; Higashi et al., 1996; Fukami-Kobayashi 
and Mitsui, 1999). Stacey and colleagues suggested that a repression of cyclin D1 is required 
for progression through the S phase of cell cycle (Stacey, 2003; Yang et al., 2006a). An 
inhibitory activity of cyclin D1 in the S phase was also suggested upon detection of a direct 
interaction of cyclin D1 and PCNA, both in vivo and in vitro (Matsuoka et al., 1994; Pagano 
et al., 1994). Zhang and colleagues revealed that various cyclins and CDKs, PCNA, and p21 
can assemble to form a larger complex in vivo although the functionality of such complexes 
have yet to be determined (Zhang et al., 1993; Gadbois et al., 1995). Whether such 
interactions were present in NIH 3T3 cells treated with a low dose of 4NQO was not 
addressed in my investigation. However, it is possible that the maintenance of cyclin D1 may 
have contributed to cell cycle arrests by augmenting the inhibitory effects of p21.  
 
In response to a medium dose of 4NQO, a dramatic degradation of cyclin D1 resembling that 
reported previously for IR or UV-induced DNA-damage was observed (Agami and Bernards, 
2000; Miyakawa and Matsushime, 2001). In agreement with these reports, flow cytometry 
analyses demonstrated that a degradation of cyclin D1 was associated with G1 arrest (Figures 
4.6, 4.7). Molecular events associated with a G1 arrest such as an accumulation of 
hypophosphorylated pRb (Figure 3.6a) and reduced activities of kinases involved in the 
regulation of G1/S transition (Figures 3.7, 3.8) were observed concomitantly. Unlike cells 
treated with a low dose of 4NQO, no accumulation of p21 was observed. Instead, p21 
expression was reduced to an almost undetectable level similarly to those perceived following 
an exposure to certain doses of UV (Bendjennat et al., 2003; Lee et al., 2006). Thus,  the G1 
arrest triggered by a medium dose of 4NQO are likely to be the result of a  loss of active 
cyclin D1-CDK4/6 complexes due to reduced cyclin D1 expression, as well as a p21-
independent inhibition of cyclin E-CDK2 complexes, leading to activation of pRb. In addition, 
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S and G2/M arrests induced by a medium dose of 4NQO could not be explained by the p21-
dependent mechanisms proposed above. Taken together, these observations advocate the 
presence of p21-independent mechanisms that regulate the long-term arrests induced by a 
medium dose of 4NQO.  
 
DNA damage response involving the family of protein phosphatase, CDC25, represents one 
of the major alternative pathways that can bring about multiphase cell cycle arrests. The first 
indication that CDC25 is involved in DNA damage response was identified in 
Schizosaccharomyces pombe (S.pombe). Funari and colleagues demonstrated that Chk1 
phosphorylates and inhibits CDC25 in response to DNA damage leading to reduced a 
dephosphorylation of Tyr 15  from CDC2, ultimately establishing a G2 arrest (Furnari et al., 
1997; Rhind et al., 1997). In human cells, inactivation of CDC25A, B, and C, is dependent on 
phosphorylation by DNA damage-responsive kinases including Chk1, Chk2 and 
SAPK2/p38
MAPK
 (Sanchez et al., 1997; Matsuoka et al., 1998; Bulavin et al., 2001). The 
damage-induced phosphorylation of CDC25s leads to rapid degradations of these proteins and 
subsequently to reduced activations of cyclin-CDK complexes and thus to cell cycle arrests  
(Mailand et al., 2000; Bartek and Lukas, 2001; Falck et al., 2001; Chen et al., 2002; Mailand 
et al., 2002; Donzelli and Draetta, 2003; Sorensen et al., 2003).  It has been suggested that 
p21 and CDC25s govern distinct damage-induced signalling pathways working in parallel to 
ensure the establishment of appropriate cellular responses (Poon et al., 1996; Garner-Hamrick 
and Fisher, 1998; Chan et al., 2000; Bartek and Lukas, 2001; Taylor and Stark, 2001). It is 
conceivable that the CDC25-dependent pathway was responsible for the establishment of the 
cellular responses associated with medium doses of 4NQO where the p21 expression was 
reduced dramatically.  
 
In addition to cell cycle arrests, exposure to medium doses of 4NQO induced cell death, 
Cytotoxicity assays suggested that within 48h post-exposure, up to 60% of population were 
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non-viable (Figure 4.2) and the multiphase cell cycle arrests were maintained without 
recovery (Figure 4.6). The reduced p21 expression probably promoted apoptotic cell death. 
DNA damage-induced apoptosis often requires an induction of p53 and the activities of its 
target proteins including Bax and GADD45 (Schuler and Green, 2001; Maeda et al., 2002; 
Schuler et al., 2003; Mak and Kultz, 2004). An investigation of molecular mechanisms 
underlying the 4NQO-induced apoptosis in an epidermoid KB carcinoma cells suggested that 
disruption of mitochondrial functionalities, p53-dependent induction of p21 and Bax, and 
subsequent activation of caspase-3 were involved in onset of apoptosis (Han et al., 2007). 
Some of these events were indeed observed in NIH 3T3 cells treated with a medium dose of 
4NQO (Figures 4.3, 4.5). In addition, other molecular events induced in response to a medium 
dose of 4NQO such as cyclin D1 degradation and reduced activities of CDK4 and CDK2 
were also associated with activation of apoptotic pathways. For example, Thoms and 
colleagues demonstrated that aspirin-induced cyclin D1 degradation subsequently caused 
nucleolar translocation of RelA, leading to an inhibition of NFκB signalling, and apoptosis. 
Retention of RelA in the nucleoplasm abrogated a DNA damage-induced apoptosis (Stark and 
Dunlop, 2005; Thoms et al., 2007b). Furthermore, an inhibition of CDK4 was able to mimic 
the events following cyclin D1 degradation, suggesting that an inhibition of cyclin D1/CDK4 
complexes plays a critical role in an activation of apoptosis (Thoms et al., 2007a). Similarly 
to CDK4, depletion of cyclin A-binding CDKs (i.e. CDK2 and CDK1) together with the 
transcriptional cyclin-CDK complexes or an inhibition of CDK2 with a chemical inhibitor 
have been suggested to promote apoptosis (Hahntow et al., 2004; Cai et al., 2006).  Moreover, 
pRb was dephosphorylated in cells treated with a medium dose of 4NQO as can be expected 
from reduced CDK activities. Wang and colleagues have demonstrated that dephosphorylation 
of pRb may regulate the initiation of apoptosis and that protein phosphatase 1α (PP1α) is 
responsible for the dephosphorylation of pRb (Wang et al., 2001). Other evidence suggested 
that PP1α activity is normally inhibited by CDK2 and this inhibition is found attenuated in 
cells treated with DNA damaging agents in an ATM-dependent manner (Dohadwala et al., 
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1994; Tang et al., 2008). Altogether, these observations are supportive of a potential positive 
implication for CDK inhibition in an induction of apoptosis.  
 
Following an exposure to a high dose of 4NQO (200µM), cells were arrested at multiple 
phases during the cell cycle and the majority of the population appeared to undergo cell death, 
similarly to the cells treated with a medium dose of 4NQO (50µM). However, at 200µM, 
dying cells lacked most of apoptotic features. Although caspase-3 activation was observed at a 
late time point, only 20% of population underwent DNA fragmentation (Figures 4.2, 4.6b). 
When comparing the molecular responses associated with cells treated with a medium and a 
high dose of 4NQO, it is evident that the latter failed to trigger some of the pro-apoptotic 
events mentioned previously. For instance, cyclin D1 and p21, both of which are protective of 
cells, were not degraded (Figures 3.1, 3.3a). Moreover, pRb was not fully dephosphorylated 
(Figures 3.6, 3.8). From these observations, it can be envisaged that a high dose of 4NQO 
caused an overwhelming level of DNA damage and thus abrogated at least a part of DNA 
damage response in NIH 3T3 cells and hence was unable to induce apoptosis. As described 
before, the metabolic activation 4NQO can generate reactive oxygen species which can cause 
damages to proteins and lipid as well as DNA (Buechter, 1988; Cabiscol et al., 2000). At a 
high dose of 4NQO, such damages may have directly altered the functionalities of DNA 
damage proteins or caused membrane disruption. With an increasing interest in the 
application of DNA damaging agents as anti-cancer drugs, it is imperative to characterise and 
understand the dose-dependent induction of the damage signalling and their outcomes in order 
to develop effective treatment.  
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Figure 4.1 Long-term responses of cyclin D1 and p21 in 4NQO-treated NIH 3T3 
cells 
Asynchronously growing NIH 3T3 cells were treated with varying doses of 4NQO and lysed 
at indicated time points. The levels of cyclin D1 and p21 expression were assessed by 
immunoblotting. The level of α-tubulin was also examined to monitor protein loading.  
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Figure 4.2  Assessment of viabilities of 4NQO-treated NIH 3T3 cells by PI 
exclusion assay 
Asynchronously growing NIH 3T3 cells were treated with none, low (2.5µM), medium 
(50µM) and high (200µM) doses of 4NQO and harvested 3, 24, and 48h post-treatment. Cells 
were stained with PI and analysed by flow cytometry immediately. 10,000 events for each 
sample were collected. The levels of cell death are indicated in the bar chart as the proportion 
of PI positive cells. The error bars represent standard errors calculated from three independent 
experiments.  
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Figure 4.3  Investigation of viability of 4NQO treated NIH 3T3 cells by MTS assay 
NIH 3T3 cells were seeded at 2000 cells per well on a 96-well tissue culture plate. 
Asynchronously growing NIH 3T3 cells were exposed to a range of doses of 4NQO, 24h 
post-plating. 3h after exposure, the MTS solution was added and incubated for further 2h. 
Viability of the cells was assessed by the MTS assays following the manufacturer’s 
instructions (Promega). The graph and standard error bars are representative of six 
independent experiments.  
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Figure 4.4 Observation of nuclear condensation induced by 4NQO in NIH 3T3 
cells 
NIH 3T3 cells were plated for 4NQO treatment as described (Materials and Methods) in 
dishes containing a coverslip. Cells were treated with indicated doses of 4NQO and their 
nuclei were stained with DAPI at indicated time points. The stained cells were visualised and 
the images were captured using the Axiocam software on a Zeiss Axiovert 200M inverted 
microscope. The scale bar represents 20µm.  
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Figure  4.5  Activation of caspase-3 following 4NQO exposure in NIH 3T3 cells 
Asynchronously growing NIH 3T3 cells were treated with 4 doses of 4NQO and harvested for 
immunoblot at 3, 8, 16, 24, and 48h post-treatment. Protein samples were separated on 15% 
SDS-PAGE gel and the presence of full-length caspase-3 (procaspase-3) and truncated 
caspase (active caspase-3) was detected using pan-caspase-3 antibody. These protein samples 
are the same as those from in Figure 4.1 and thus the α-tubulin blot was not repeated.  
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Figure 4.6  Cell cycle analysis of 4NQ- treated NIH 3T3 cells by flow cytometry 
For description see below. 
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Figure 4.6 cont. Cell cycle analysis of 4NQO treated NIH 3T3 cells by flow 
cytometry 
(a) Asynchronously growing NIH 3T3 cells were treated with indicated doses of 4NQO. Cells 
were fixed and stained with PI for flow cytometry analysis as described (Materials and 
Method). 10,000 events were collected, using appropriate gates to omit debris and doublets 
from the analysis. DNA profiles were analysed using the FlowJo programme (TreeStar). For 
the ease of detecting changes in distribution of cells along the X-axis (i.e. DNA content), the 
Y-axis is presented as a percentage of maximum cell number in each population rather than 
the actual cell numbers. The profiles are representative of typical results obtained from 3 
independent experiments. (b) Proportion of the cells containing below G1 DNA content (i.e. 
sub-G1 population) was quantified using the FlowJo programme. The bar chart and the 
standard error bars represent results from 3 independent experiments.  
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Figure 4.7  BrdU incorporation assay of 4NQO-treated NIH 3T3 cells by flow 
cytometry. 
Asynchronously growing NIH 3T3 cells were treated with 0, 2.5, 50 and 200µM 4NQO. Cells 
were incubated for 3h with last 30minutes in the presence of 10µM BrdU. Cells were 
processed and stained with FITC-conjugated BrdU antibody (Invitrogen) as described 
(Materials and Methods), prior to being analysed by flow cytometry. The BrdU positive 
population was quantified with FlowJo programme. The mean values of 9 independent 
experiments are presented in the bar charts with standard error bars.  
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Figure 4.8  Cell cycle analysis of G1 phase-enriched population of NIH 3T3 
following exposure to 4NQO 
NIH 3T3 cells were synchronised by serum starvation for 72hours. Cells were transferred into 
a complete media for 10h, allowing the accumulation of cells in the G1 phase of cell cycle. 
The G1 phase–enriched population of cells were exposed to (a) none, (b) 2.5µM, (c) 50µM 
and (d) 200µM as previously described (Materials and Methods). Cells were harvested at 
indicated time points and processed for PI staining. DNA content was analysed by flow 
cytometry. 10,000 events were collected using appropriate gating to remove doublets and 
debris.  
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Figure 4.9  Cell cycle analysis of S phase-enriched population of NIH 3T3 cells 
following 4NQO exposure 
NIH 3T3 cells were synchronised by serum starvation for 72hours. Cells were transferred into 
a full media for 18h, allowing the accumulation of cells in the S phase of cell cycle. The S 
phase–enriched population of cells were exposed to (a) none, (b) 2.5µM, (c) 50µM and (d) 
200µM as previously described (Materials and Methods). Cells were harvested at indicated 
time points and processed for PI staining. DNA content was analysed by flow cytometry. 
10,000 events were collected using appropriate gating to remove doublets and debris. 
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Figure 4.10  Cell cycle analysis of G2/M phases-enriched population of NIH 3T3 
cells following 4NQO exposure 
NIH 3T3 cells were synchronised by serum starvation for 72hours. Cells were transferred into 
a full media for 22h, allowing the accumulation of cells in the G2/M phases of cell cycle. The 
G2/M phase–enriched population of cells were exposed to (a) none, (b) 2.5µM, (c) 50µM and 
(d) 200µM as previously described (Materials and Methods). Cells were harvested at 
indicated time points and processed for PI staining. DNA content was analysed by flow 
cytometry. 10,000 events were collected using appropriate gating to remove doublets and 
debris.  
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Figure 4.11  Cell cycle analysis of H2O2-treated NIH 3T3 cells by flow cytometry 
Asynchronously growing NIH 3T3 cells were treated with indicated doses of H2O2. Cells 
were fixed and stained with PI for flow cytometry analysis as described (Materials and 
Method). 10,000 events were collected, using appropriate gates to omit debris and doublets. 
DNA profiles were analysed using the FlowJo programme (TreeStar) to determine the 
proportion of cells in G1, S and G2/M phases of cell cycle. For the ease of detecting changes 
in distribution of cells along the X-axis (i.e. DNA content), the Y-axis is presented as a 
percentage of maximum cell number in each population rather than the actual cell numbers.   
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Figure 4.12  BrdU incorporation assay of H2O2-treated NIH 3T3 cells by flow 
cytometry 
Asynchronously growing NIH 3T3 cells were treated with 0, 25, 100, 250 and 1000µM H2O2. 
Cells were incubated for 3h with last 30minutes in the presence of 10µM BrdU. Cells were 
processed and stained with FITC-conjugated BrdU antibody (Invitrogen) as described 
(Materials and Methods), prior to being analysed by flow cytometry. 20,000 events were 
collected using appropriate gating to remove debris and doublets.  
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Figure 4.13  4NQO induced molecular and cellular responses in C57BL p21
-/-
 3T3 
cells 
Asynchronously growing C57BL p21
-/-
 3T3 cells were treated with various doses of 4NQO.  
(a) Cells were harvested 3h post-exposure and the levels of cyclin D1 and p21 were assessed 
by immunoblotting assay. α-tubulin level was used to monitor protein loading. Lysate of 
asynchronously growing NIH 3T3 cells were used as a positive control for p21 blot.  
 (b) Cells were harvested at 24 and 48h after 4NQO treatment and fixed for PI staining. Cells 
treated with a low dose (i.e. 2.5µM) of 4NQO were incubated up to 72, and 96h post-
exposure. DNA profile of each sample was obtained by flow cytometry. 10,000 events per 
sample were collected using appropriate gating. X-axis indicates DNA content and Y-axis 
represents number of cells carrying a specific DNA content as a percentage of the maximum 
cell number.  
(c) The sub-G1 population was quantified using the FlowJo programme. The bar chart and the 
range is representative of two independent experiments.  
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Figure 4.13 cont.  4NQO induced molecular and cellular responses in C57BL p21
-/-
 
3T3 cells 
For legend, see previous page. 
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Figure 4.14  4NQO-induced molecular and cellular responses in C57BL cyclin D1
-/-
 
3T3 cells 
Asynchronously growing C57BL cyclin D1
-/-
 3T3 cells were treated with none, 2.5µM , 50µM, 
and 200µM 4NQO.  
(a) Cells were harvested 3h post-exposure and the levels of cyclin D1 and p21 were assessed 
by immunoblotting assay. α-tubulin levels were monitored to monitor protein loading.  
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Figure 4.14 cont. 4NQO-induced molecular and cellular responses in C57BL cyclin 
D1
-/-
 3T3 cells 
 
(b) Cells were harvested at 24 and 48h after 4NQO exposure and fixed for PI staining. DNA 
profile of each sample was obtained by flow cytometry. 10,000 events per sample were 
collected using appropriate gating. Proportion of sub-G1 population is indicated.  
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Chapter 5:   Molecular mechanisms regulating DNA damage-
induced degradation of cyclin D1 
5.1 Introduction 
Within the past decade, a number of studies have demonstrated that cyclin D1 is rapidly 
degraded in response to genotoxic stress such as IR, UV and H2O2 (Hiyama and Reeves, 1999; 
Agami and Bernards, 2000; Miyakawa and Matsushime, 2001; Barnouin et al., 2002; 
Fasanaro et al., 2006). A number of mechanisms have been suggested for each case but the 
upstream and downstream signalling molecules governing such DNA damage-induced cyclin 
D1 degradation have not been established. In the previous chapters, I have demonstrated that 
exposure of mammalian cells to the UV mimetic, 4NQO, also triggered cyclin D1 degradation 
in a dose-dependent manner (Figure 3.1). A comparison of molecular and cellular responses 
associated with 4NQO-induced DNA lesions suggested that cyclin D1 may play a protective 
role against apoptosis alongside with p21 (Chapter 4). Given its central role in cell cycle 
regulation and its potential role in protection against apoptosis, it is imperative to understand, 
at a molecular level, the regulation of cyclin D1 during DNA damage response.  
 
5.2 Results 
5.2.1 4NQO-induced cyclin D1degradation is dependent on the proteasome 
In an effort to discover the molecular mechanisms responsible for cyclin D1 degradation 
induced by DNA damage, a derivative of NIH 3T3 cells expressing FLAG-tagged human 
cyclin D1 under IPTG-inducible promoter (D1 inducible 3T3); Child and Mann (2001); was 
employed. First, the D1 inducible 3T3 cells were exposed to a range of 4NQO doses and 
changes in endogenous and exogenous cyclin D1 expression were assayed by immunoblotting 
in the absence of IPTG, to demonstrate that a stable transfection of an expression vector in the 
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cells had no effect on the 4NQO-induced cyclin D1 degradation (Figure 5.1a). Although a low 
level of exogenous cyclin D1 expression was detected in the absence of IPTG, endogenous 
cyclin D1 exhibited the characteristic biphasic response following exposure to 4NQO as 
observed in NIH 3T3 cells (Figures 5.1a, 3.1). Upon induction with IPTG, the expression of 
exogenous cyclin D1 increased by approximately 10-fold, validating the integrity of the 
IPTG-inducible promoter (Figure 5.1b). The dose-dependent change of cyclin D1 triggered by 
4NQO treatment was exhibited by both endogenous and exogenous cyclin D1 in the presence 
of IPTG (Figure 5.1b). These observations demonstrate that the levels of cyclin D1 expression 
were regulated post-transcriptionally during a 4NQO-triggered response.  
 
During cell cycle, cyclin D1 expression is regulated by the balance between Ras-dependent 
cyclin D1 accumulation and rapid proteolysis via proteasome-dependent pathways (Udvardy, 
1996; Diehl et al., 1997; Diehl et al., 1998; Lin et al., 2006). However, it was also suggested 
that cyclin D1 proteolysis depends on another protease, calpain (Choi et al., 1997). To 
determine the enzyme responsible for the 4NQO-induced degradation of cyclin D1, NIH 3T3 
cells were pre-incubated with a 26S proteasome specific inhibitor, MG132, or a broad 
specificity inhibitor, N-Acetyl-L-leucyl-L-leucyl-L-norleucinal (ALLN), which inhibits both 
proteasomes and calpain (Mellgren, 1997), prior to exposure to 4NQO. Both inhibitors 
protected cyclin D1 from 4NQO-induced degradation (Figure 5.2a). Interestingly, MG132 
was able to inhibit cyclin D1 degradation as well as ALLN (Figure 5.2b), indicating that 
cyclin D1 degradation is likely to be mediated by a proteasome-dependent pathway. The 
impact of MG132- or ALLN-mediated inhibition of cyclin D1 degradation on the 4NQO-
induced inhibition of DNA synthesis was assessed by BrdU incorporation. In the absence of 
proteasome inhibitors, BrdU incorporation was maintained in response to 2.5µM 4NQO but 
eliminated following exposure to 50 and 200µM 4NQO (Figure 5.3). Interestingly, the 
presence of neither MG132 nor ALLN was able to restore a normal level of DNA synthesis in 
cells treated with 50 and 200µM 4NQO (Figure 5.3), implying that a degradation of cyclin D1 
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was dispensable for the 4NQO-induced inhibition of DNA synthesis.  
 
5.2.2 Investigation of amino acid residues involved in the regulation of 4NQO-
induced cyclin D1 degradation.  
A number of different amino acids and motifs were shown to regulate cyclin D1 stability 
during normal cell cycle and in stress-induced responses. T286 is located at the C-terminus of 
cyclin D1 within the PEST region (Figure 5.4) that has been implicated in a stress-induced 
degradation of a cyclin homolog, Ume3p in S. cerevisiae (Cooper et al., 1997). In mammalian 
cells, phosphorylation of T286 is associated with destabilisation of cyclin D1 during normal 
proliferation (Stacey, 2003; Guo et al., 2005b; Yang et al., 2006a; Alao, 2007), osmotic stress 
(Casanovas et al., 2000), replicative stress (Mukherji et al., 2008) and upon treatment with 
various chemotherapeutic agents including all trans-retinoic acids (Ma et al., 2005) and 
inhibitors of histone deacetylases (HDAC) (Alao et al., 2006b). In addition, Cooper et al. 
(1997) suggested that the RxxL motif was also required in Ume3p degradation. Following this 
report, Agami and Bernard (2000) identified a putative RxxL motif at the N-terminus of 
cyclin D1 (Figure 5.4) and demonstrated that a point mutation in this motif can abrogate IR-
induced cyclin D1 degradation. To determine whether these motifs were involved in the 
4NQO-induced cyclin D1 degradation, recombinant plasmids encoding a double mutant 
R29A/L32A (mutations of the RxxL motif) and a single mutant T286A were constructed 
(Materials and Methods). In addition, T156A substitution mutant, which act as a dominant 
negative mutant of cyclin D1/CDK4 by sequestering the complex in the cytoplasm (Diehl and 
Sherr, 1997), was also generated in order to determine whether an altered subcellular 
localisation would affect the response of cyclin D1 (Materials and Methods). Initially, these 
cyclin D1 mutants were transiently expressed in NIH 3T3 cells to investigate the impact of 
these mutations on 4NQO-induced cyclin D1 response. However, for all three mutants tested, 
a high level of ectopic expression achieved by this method appeared to desensitise both 
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exogenous and endogenous cyclin D1 to 4NQO-induced degradation (data not shown). As an 
alternative approach, cyclin D1 mutants were stably co-transfected with a plasmid encoding a 
gene conferring puromycin resistance. Individual colonies of NIH 3T3 cells successfully 
carrying the recombinant plasmids were selected for puromycin resistance and the stable cell 
lines expressing the exogenous cyclin D1 at a similar or lower level than the endogenous 
cyclin D1 were employed for the investigation (Appendix).  
 
5.2.2.1 RxxL double mutant cyclin D1 
Agami and Bernard (2000) demonstrated that single mutations R29Q or L32A of the RxxL 
motif, when expressed transiently, abolished cyclin D1 degradation induced by 20Gy IR. 
Unlike this report, however, when the NIH 3T3-derived cell lines stably expressing a FLAG-
tagged wild type cyclin D1 (D1 wt 3T3) or a FLAG-tagged human cyclin D1 R29A/L32A 
double mutant (D1 RxxL 3T3) were irradiated with > 20Gy IR, both ectopically expressed 
wild type and the double mutant cyclin D1 were degraded similarly to endogenous cyclin D1 
(Figure 5.5a). Although R29 was mutated to alanine rather than gulutamine, the double 
mutant generated in this investigation maintained the L32A point mutation which was shown 
to inhibit IR-induced degradation of cyclin D1 (Agami and Bernards, 2000). Since the 
previous investigation employed MCF-7 cells which has a moderately increased expression of 
cyclin D1 without gene amplification (Buckley et al., 1993), it is plausible that the regulation 
governing cyclin D1 expression in this cancer cell line differed from that of NIH 3T3 cells. 
Nevertheless, the results presented here demonstrated that degradation of endogenous cyclin 
D1 and an accumulation of p21 occurred in exposure to IR in the D1 wt 3T3 and D1 RxxL 
3T3 cell lines, indicating that the experimental system was sound. Furthermore, the behaviour 
of the double mutant cyclin D1 indicated that the IR-induced cyclin D1 degradation was 
independent of proteolysis mediated by the RxxL motif, at least in NIH 3T3 cells. To 
determine whether the 4NQO-induced cyclin D1 degradation was dependent on RxxL-
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mediated proteolysis, D1 RxxL 3T3 cells were treated with a range of 4NQO doses and 
harvested 3h later for immunoblotting assays. Following exposure to 4NQO, the endogenous 
cyclin D1 and p21 expression responded in a dose-dependent manner as observed in NIH 3T3 
cells previously (Figure 5.5b). Similarly to the endogenous cyclin D1, the R29A/L32A double 
mutant of cyclin D1 also responded in a dose-dependent manner where its expression was 
maintained following exposure to low and high doses of 4NQO whereas it was degraded 
dramatically in response to medium doses of 4NQO (Figure 5.5b). When D1 wt 3T3 and D1 
RxxL 3T3 cells were irradiated with increasing doses of UV, similar results were obtained 
(Figure 5.5 c & d). Collectively, the data presented here suggest that cyclin D1 responses to 
4NQO-, UV- and IR-induced DNA damage were independent of the RxxL motif on cyclin D1 
in NIH 3T3 cells.  
 
5.2.2.2 T156A mutant 
T156 is a residue located next to the well conserved cyclin box in the central domain of cyclin 
D1 (Figure 5.4). Unlike the other two motifs chosen for the mutagenesis studies in this 
investigation, T156 has not been implicated in the regulation of cyclin D1 stability. However, 
Diehl and Sherr (1997) demonstrated that the integrity of this residue is essential for the 
activation of cyclin D1-CDK4 complexes by CAK and T156A cyclin D1 competes with the 
wild type protein to form an abortive complex with CDK4 when expressed in mammalian 
cells. To investigate whether the integrity of this residue is also important in the DNA 
damage-induced cyclin D1 response, NIH 3T3 cells stably expressing FLAG-tagged cyclin 
D1 with a point mutation of T156A, named D1 T156A 3T3, was constructed as described 
above. To verify that the cyclin D1 T156A mutant in the D1 T156A 3T3 cell line generated 
here behaved in the same manner as observed previously, the subcellular localisation of 
endogenous cyclin D1 and ectopically expressed T156A mutant cyclin D1 were determined 
by immunostaining (Figure 5.6). Endogenous cyclin D1 was detected using mouse-specific 
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cyclin D1 antibody (72-13G; Santa Cruz) whilst mutant cyclin D1 was visualised by probing 
for its FLAG-tag to distinguish the two.  Endogenous cyclin D1 co-localised with DAPI-
stained nuclei in up to 80% of the D1 T156A 3T3 cell population, which was similar to that 
observed in the parental NIH 3T3 cells (Figure 5.6a, c). This suggested that the presence of 
mutant cyclin D1 did not affect the localisation of endogenous cyclin D1. In line with a 
previous report (Diehl and Sherr, 1997), the majority of the mutant cyclin D1 was found in 
cytoplasm and less than 10% of D1 T156A 3T3 cells showed a marked FLAG-staining in 
their nuclei (Figure 5.6b, c).  
 
When D1 T156A 3T3 cells were exposed to increasing doses of 4NQO, endogenous cyclin 
D1 and p21 responded as in parental NIH 3T3 cells (Figure 5.7a). Expression of cyclin D1 
T156A mutant seemed low even in the absence of 4NQO-induced damage and most D1 
T156A 3T3 clones isolated by puromycin selection showed relatively weak ectopic 
expression (Appendix). Following exposure to medium doses of 4NQO, cyclin D1 T156A 
was degraded similarly to endogenous cyclin D1 (Figure 5.7a). The maintenance of cyclin D1 
T156A mutant following exposure to low and high doses of 4NQO seemed impeded 
compared to that of endogenous cyclin D1. This may be reflective of an enhanced 
accessibility of proteolytic components of cells to the mutant cyclin D1 due to its cytoplasmic 
localisation. As in the case with the RxxL mutant, mutating the T156 residue did not affect the 
response of cyclin D1 to IR or UV either (Figure 5.7b, c).  Altogether, these results indicated 
that the integrity of T156 does not affect the cyclin D1 stability following exposure to 4NQO, 
UV or IR.  
 
5.2.2.3 T286A mutant 
As mentioned above, phosphorylation of T286 residue plays an important role in cyclin D1 
degradation in response to stress-induced responses as well as in cell cycle. Mutating this 
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residue has been shown to inhibit nuclear export of cyclin D1 and stabilises the protein 
greatly without affecting its ability to activate CDK4 (Diehl and Sherr, 1997; Diehl et al., 
1997). Indeed, mutation at this site has been found in human cancer cells, indicating that T286 
may hold a key to the oncogenic property of cyclin D1 (Alt et al., 2000; Benzeno et al., 2006). 
To assess whether T286 was also involved in cyclin D1 degradation induced by 4NQO and 
UV, NIH 3T3 cells ectopically expressing FLAG-tagged human cyclin D1 T286A, named D1 
T286A 3T3, were generated as described before. In D1 T286A 3T3 cells, endogenous cyclin 
D1 was predominantly localised in nucleus (Figure 5.6a, c). All cells staining positive for 
FLAG had nuclear cyclin D1 although around 50% of the population displayed no FLAG 
staining (Figure 5.6b, c). This observation demonstrated that cyclin D1 T286A mutant 
localises in nuclei of cells, consistent with the previous observations (Diehl et al., 1997; Alt et 
al., 2000). Furthermore, it appears that although the stable line was derived from a single 
colony of cells following transfection and thus should contain a homogeneous population of 
cells, approximately 40-50% of cells appeared to have lost the expression of mutant cyclin D1 
during the course of investigation.   
 
Following exposure to a range of doses of 4NQO and UV, cyclin D1 T286A mutant 
expression was maintained at all doses tested unlike endogenous cyclin D1 expression which 
was destabilised in response to medium doses of 4NQO and UV (Figure 5.8a, b). These 
observations implied that an intact T286 is required for 4NQO- and UV-induced cyclin D1 
degradation. When D1 T286A 3T3 cells were irradiated with > 20 Gy of IR, cyclin D1 T286A 
mutant appeared to be protected from destabilisation (Figure 5.8c). This observation was 
unexpected as Agami and Bernard (2000) demonstrated that T286A mutation cannot 
overcome the IR-induced degradation of cyclin D1. To check whether this is due to a 
difference in the sensitivities of DNA damage responses associated different cell lines, D1 
T286A 3T3 cells were irradiated with up to 65.79Gy IR. Whereas endogenous cyclin D1 was 
gradually degraded with increasing doses of IR, cyclin D1 T286A expression remained as 
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high as in the non-treated control sample (Figure 5.8d). Thus, it appeared that intact T286 is 
indeed required for the degradation induced by IR as well as 4NQO and UV, at least in NIH 
3T3 cells.  
 
5.2.3 Upstream regulators of cyclin D1 degradation 
5.2.3.1 Involvement of GSK3β and SAPK2/p38MAPK in cyclin D1 regulation during 
DNA damage response 
Amongst the three conserved motifs/residues on cyclin D1, a point mutation T286A was able 
to abrogate cyclin D1 degradation induced by 4NQO, UV and IR in my experimental system. 
T286 of cyclin D1 is best characterised as a phosphorylation target site of glycogen synthase 
kinase 3 β (GSK3β). GSK3β is a downstream target of the PI3K-PKB/Akt signalling, whose 
activity regulates the subcellular localisation as well as stability of cyclin D1 during normal 
cell cycle (Diehl et al., 1997; Diehl et al., 1998). Since GSK3β-dependent phosphorylation of 
T286 on cyclin D1 has also been implicated in stress- or drug-induced cyclin D1 degradation, 
a potential role of GSK3β in 4NQO-induced cyclin D1 degradation was assessed by using a 
GSK3β inhibitor, Li+ (Stambolic et al., 1996). To minimise the possibility that a proposed-
ability of LiCl to deplete cellular myo-inositol from affecting the cyclin D1 response (Atack et 
al., 1995), cells were pre-treated with 100µM myo-inositol before addition of LiCl. The 
presence of Li
+
 did not affect the dose-dependent response of cyclin D1 induced by 4NQO 
(Figure 5.9a). In addition, the dose-dependent response of p21 was also intact, indicating that 
GSK3β activity is neither responsible for degradation of cyclin D1 nor p21 following 
exposure to 4NQO. This observation was further confirmed using a Swiss 3T3 derivative cell 
line, designated Swiss-PI3K, which was engineered to express a constitutively active PI3K. It 
was shown that in the Swiss-PI3K cell line, protein kinase B/Akt – negative regulator of 
GSK3β - was constantly active and cyclin D1 expression was stabilised even in the absence of 
mitogenic stimuli (Prasad, 2003). Following exposure to 4NQO, cyclin D1 in both SWISS 
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3T3 and SWISS-PI3K cells were destabilised to similar extent (Figure 5.9b). In other words, 
this result indicated that the 4NQO-induced degradation of cyclin D1 was independent of 
GSK3β.  
 
An alternative kinase implicated in the phosphorylation of cyclin D1 T286 is SAPK2/p38
MAPK
. 
In response to osmotic stress which predominantly causes strand breaks (Dmitrieva et al., 
2005), rapid degradation of cyclin D1 was observed. A detailed analysis demonstrated that 
SAPK2/p38
MAPK
 was able to phosphorylate T286 of cyclin D1 and an equivalent site in cyclin 
D3 (T283), directing them to a proteasomal degradation (Casanovas et al., 2000; Casanovas et 
al., 2004). Furthermore, SAPK2/p38
MAPK
 was also shown to play a role in regulating 
transcription of cyclin D1 (Lavoie et al., 1996). Therefore, the potential involvement of this 
kinase in the 4NQO-induced cyclin D1 response was analysed by using SAPK2/p38
MAPK
 
inhibitor, SB203580. In the presence of SB203580, cyclin D1 degradation induced by NaCl 
was abolished (Figure 5.10a), verifying the efficacy of this inhibitor. 4NQO-induced 
degradation of cyclin D1 and p21, on the other hand, were intact even in the presence of 
SB203580, indicating that SAPK2/p38
MAPK 
was unlikely to be responsible for the regulation 
of cyclin D1 or p21 expression following 4NQO-induced DNA damage response.  
 
5.2.3.2 Potential roles of p53- and pRb-dependent signalling in DNA damage-
induced cyclin D1 responses 
pRb and p53 proteins are two fundamental tumour suppressors whose activities govern the 
two main arms of cell cycle regulatory signalling pathways (Schafer, 1998; Stewart et al., 
2001). By interacting with members of E2F transcription factor, pRb plays a critical role in 
controlling cell cycle progression through the restriction point (Dyson, 1998; Blagosklonny 
and Pardee, 2002). pRb has also been implicated in DNA damage-induced cell cycle arrest as 
well as the regulation of apoptosis (Harrington et al., 1998; Kasten and Giordano, 1998; 
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Harbour and Dean, 2000b). p53, on the other hand, is itself a transcription factor which is 
activated in response to genotoxic stress (Horn and Vousden, 2007). Activation of p53 results 
in upregulation of target proteins such as p21, BAX, and GADD45, whose activities are 
known to subsequently induce cell cycle arrest, particularly at G1 phase, and apoptosis 
(Hickman et al., 2002; Oren, 2003; Lim et al., 2007).  Defects in p53 and pRb often culminate 
in genomic instability and indeed, many human cancer cells exhibit loss of p53 and/or pRb 
functions. To determine whether cyclin D1 plays a part of pRb- and p53-mediated damage 
response, a cell line expressing a heat labile simian virus 40 (SV40) large T-antigen (T-Ag), 
named SVts8, was employed (Tsuyama et al., 1991; Tahara et al., 1995). SV40 T-Ag is a viral 
oncoprotein which binds and inactivates pRb and p53 simultaneously, dismantling two of the 
main “guardians” of the genome in cells (Lee et al., 1992; Ali and DeCaprio, 2001). When 
Svts8 cells are cultivated at the non-permissive temperature (38.5
o
C), T-Ag is inactive and 
hence p53- and pRb-dependent pathways remain intact. At this temperature, cyclin D1 
expression exhibited the characteristic biphasic response to increasing doses of 4NQO (Figure 
5.11). The sensitivity of the cyclin D1 response observed in Svts8 cells cultured at 38.5
o
C 
somewhat differed from NIH 3T3 cells as cyclin D1 was maintained up to 25µM rather than 
2.5µM 4NQO. Cyclin D1 level declined dramatically in response to 50-100µM 4NQO and at 
a high dose, 200µM 4NQO, cyclin D1 was maintained (Figure 5.11). On the other hand, the 
p21 response lacked the rapid induction that was observed in response to 2.5µM 4NQO in 
NIH 3T3 cells. Instead, p21 expression appeared elevated in the non-treated cells which may 
have hindered any additional induction of p21 following a 4NQO-exposure. When SVts8 cells 
were grown at the permissive temperature (34
o
C), where T-Ag was active and thus p53 and 
pRb were inactive, both cyclin D1 and p21 expression levels declined with increasing doses 
of 4NQO and both proteins were almost undetectable at the highest dose tested here (Figure 
5.11). The maintenance of cyclin D1 expression following exposure to high doses of 4NQO 
was abrogated. Taken together, these results indicated that cyclin D1 and p21 degradation 
induced by 4NQO did not require functional p53 or pRb but the maintenance of cyclin D1 and 
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p21 following exposure to a high dose of 4NQO, as well as p21 induction observed in 
response to a low dose of 4NQO require functional p53 and or pRb.  
 
Since the ability of 4NQO to impose damage to DNA relies on its cellular metabolism which 
converts 4NQO to an active damage-inducing form, Ac-4HAQO, changes in the temperature 
at which cells were cultured during the investigation may have altered the actual level of 
DNA damage induced by a particular dose of 4NQO. If this is the case, at a permissive 
temperature, 200µM 4NQO may have only caused a level of DNA damage equivalent to that 
induced by lower doses of 4NQO when incubated at 37
o
C. To avoid the variability arising 
from a differing level of damage induced by a particular concentration of 4NQO due to a 
variable temperature, the experiment was repeated using an SV40-immortalised normal 
human fibroblast, MRC5 CV1.  
 
In response to increasing doses of 4NQO, cyclin D1 levels declined dramatically up to 
100µM 4NQO in MRC5 CV1 cells (Figure 5.12a), suggesting that the destabilisation of 
cyclin D1 was not mediated by pRb or p53. At 200µM 4NQO, cyclin D1 expression appeared 
higher compared to that in the cells exposed to 25- 100µM 4NQO despite a reduced α-tubulin 
level (Figure 5.12a). In fact, cyclin D1 expression was relatively unchanged in the 200µM 
sample. Induction of p21 after treatment with a low dose of 4NQO was still absent in MRC5 
CV1, indicating that functional p53 and/or pRb were required for this molecular response 
(Figure 5.12a). Furthermore, the biphasic response of cyclin D1 was also intact in MRC5 
CV1 cells treated with UV (Figure 5.12b). These observations seemed to suggest that the 
difference in the temperature at which SVts8 cells were cultured during the investigation had 
an impact on the 4NQO-induced cyclin D1 response. Taken together, it appeared that pRb 
and/or p53 were dispensable for 4NQO- and UV-induced cyclin D1 response and the 
degradation of p21. However, functional p53 and/or pRb are required for the upregulation of 
p21 observed following an exposure to a low dose of 4NQO. Figure 5.12c represents the IR-
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induced responses of cyclin D1 and p21 in MRC5 CV1 cells. Unlike 4NQO- or UV-induced 
responses, exposure to IR did not trigger detectable responses from either cyclin D1 or p21, 
providing further evidence that the expression of cyclin D1 and p21 following IR exposure 
are regulated differently from that observed following 4NQO- and UV-treatment.  
 
The molecular responses of cyclin D1 and p21 following exposure to 4NQO, UV or IR were 
probed further in two other SV40-immortalised cell lines, XP12RO and AT5BI VA, derived 
from individuals with xeroderma pigmentosum (XP) and ataxia telangiectasia (A-T), 
respectively. XP12RO cells lack the expression of XP group A protein (XP-A) and are 
defective of NER, the major repair pathway for DNA damage imposed by UV and 4NQO 
(Wolff et al., 1977; Jones et al., 1992; Afzal et al., 1995; de Laat et al., 1999). XP-A was long 
considered to act as a sensor for damaged DNA in NER. However, this model was challenged 
by evidence which implicated replication protein A (RPA) and XP-C as the damage sensing 
elements (Satokata et al., 1992; de Laat et al., 1999; Lehmann, 2003; Rademakers et al., 
2003). Nevertheless, with its ability to interact with various repair factors and its preferential 
affinity to damaged DNA, XP-A remains likely to be a key regulator of NER. When XP12RO 
cells were treated with a range of doses of 4NQO or UV, expression levels of cyclin D1 and 
p21 exhibited similar changes to those observed in MRC5 CV1 cells (Figure 5.13a, b). In 
addition, IR irradiation did not induce any response of cyclin D1 or p21 most probably due to 
the presence of T-Ag (Figure 5.13c). Collectively, these observations suggested that cyclin D1 
and p21 responses to 4NQO- and UV-induced DNA damage were unlikely to be involved in 
the repair pathway or be downstream targets of XP-A-dependent pathways. The other SV40-
immortalised cell line, AT5BI VA, has mutations in the gene encoding ATM (Gilad et al., 1996; 
Gately et al., 1998). ATM belongs to a family of PI3K-related kinases (PIKKs) (Abraham, 
2001; Shiloh, 2001) and has been shown to regulate the initiation of IR-induced DNA damage 
responses as well as repair of double strand DNA breaks (Kurz and Lees-Miller, 2004). As 
can be expected, mutations in this protein confer cells hypersensitive to radiation in particular 
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to IR (Lavin, 1999; Kuhne et al., 2004; Kurz and Lees-Miller, 2004). In AT5BI VA, no 
changes in cyclin D1 or p21 expression were observed following exposure to various doses of 
IR (Figure 5.14c), in line with the previously reported association of ATM to IR-induced DNA 
damage (Suzuki et al., 1999b; Shiloh, 2001). Furthermore, cyclin D1 and p21 responses to 
treatment with 4NQO or UV appeared intact (Figure 5.14b, c), suggesting that ATM was 
dispensable for 4NQO- and UV- induced responses.  
 
5.2.3.3 Moving up the signalling pathways: ATM/ATR and Chk1/Chk2 
So far, a number of cell lines defective in some of the major DNA damage proteins were used 
to investigate the involvement of these proteins as upstream regulators of responses by cyclin 
D1- and p21-responses induced by DNA damaging agents. Apart from the lack of p21 
induction following exposure to low doses of 4NQO and UV probably due to abrogation of 
p53 by T-Ag, other aspects of the molecular responses were unaffected in these cell lines. To 
identify upstream damage signalling molecules that regulate cyclin D1 and p21, a number of 
chemical inhibitors were employed to specifically inhibit the activities of the known upstream 
signalling molecules.  
 
As described before the DNA damage response is an intricate network of multiple signalling 
cascades comprised of signalling molecules organised in a hierarchical order. Most damage 
signalling cascades are principally regulated by the apical kinases, ATM and ATR (ataxia-
telangiectasia mutated and Rad3-related), which subsequently promote activation of the 
transducer proteins, Chk1 and Chk2 (Abraham, 2001; Shiloh, 2001; Chen and Poon, 2008). 
To determine whether these upstream kinases were also involved in regulating the responses 
of cyclin D1 and p21 observed following an exposure to 4NQO in NIH 3T3 cells, the 
immunoblotting assays were repeated after treatment of cells with different chemical 
inhibitors. Caffeine is a radiosensitising agent widely employed as an inhibitor of ATM and 
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ATR (Sakahira et al., 1998; Blasina et al., 1999; Hall-Jackson et al., 1999; Foukas et al., 
2002) and its presence was shown to abrogate DNA damage-induced cell cycle arrest 
particularly at S and G2 phases of cell cycle (Kaufmann et al., 2003; Ravi et al., 2008). To 
investigate the effect of caffeine, NIH 3T3 cells were pre-treated with 20mM caffeine for 
30min prior to treatment with 4NQO. The expression levels of cyclin D1 and p21 were 
assessed by immunoblotting as before. The presence of caffeine dramatically abolished the 
cyclin D1 degradation observed previously in response to medium doses of 4NQO (Figure 
5.15). It also inhibited the induction of p21 following exposure to 2.5µM 4NQO, as was 
observed in SV40-immortalised cells. However, reduced expression of p21 in response to 
medium doses of 4NQO was unaffected by caffeine (Figure 5.15), suggesting that the 
degradation of cyclin D1 and p21 were likely to be regulated by separate signalling pathways. 
Next, the effect of Chk1 and Chk2 inhibitors, SB218078 and 2-(4-(4-Chlorophenoxy)phenyl)-
1H-benzimidazole-5-carboxamide (called Chk2 inhibitor II hereafter), respectively, were 
examined in 4NQO-treated NIH 3T3 cells. In the presence of one of the inhibitors, 4NQO 
treatment induced a normal dose-dependent response of cyclin D1 as observed before (Figure 
5.16a,b, c). To eliminate the possibility of Chk1 and Chk2 complementing each other, the 
experiment was repeated in the presence of both inhibitors. However, even with both 
inhibitors present, cyclin D1 degradation induced by a medium dose of 4NQO could not be 
abolished (Figure 5.16d), indicating that Chk1 and Chk2 were not required for 4NQO-induced 
damage-dependent degradation of cyclin D1. Whilst the responses of p21 to medium and high 
doses of 4NQO were unaffected by the presence of the inhibitors, p21 accumulation triggered 
by a low dose of 4NQO showed differential sensitivities to these inhibitors. In the presence of 
SB218078, the difference between the p21 expression in the control and 2.5µM samples 
remained similar to that of α-tubulin, indicating that the p21 was not markedly induced in the 
latter (Figure 5.16b). The Chk2 inhibitor, on the other hand, seemed not to affect the p21 
induction greatly (Figure 5.16c). In the presence of both inhibitors, an attenuation of p21 
induction was observed at the similar level achieved by the presence of SB219078 alone 
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(Figure 5.16d). Taken together, these observations indicated that a low dose of 4NQO is likely 
to activate p21 accumulation via pathway sensitive to caffeine and Chk1 inhibitor.   
 
 
5.3 Discussion 
5.3.1 Cyclin D1 expression is regulated at a post-transcriptional level in NIH 3T3 
cells following an exposure to 4NQO 
In an endeavour to delineate the molecular mechanism regulating 4NQO-induced degradation 
of cyclin D1, a number of cell lines expressing either wild type or mutant exogenous cyclin 
D1 proteins were generated in this investigation. Use of the D1 inducible 3T3 cells 
demonstrated that a 4NQO-induced degradation of cyclin D1 was post-transcriptionally 
regulated (Figure 5.1b). Miyakawa and Matsushime (2001) previously suggested that a cyclin 
D1 degradation triggered by UV, which imposes similar types of DNA damage as 4NQO, is 
regulated by changes of protein and mRNA stabilities. In particular, they proposed that the 3’-
untranslated region of cyclin D1 mRNA was required for the altered mRNA stability in 
response to UV exposure, contributing to a reduction of cyclin D1 expression. The expression 
plasmids used to generate the stable cell lines for this investigation only contained the coding 
region of cyclin D1. However, both endogenous and exogenous cyclin D1 were degraded in 
response to 4NQO, UV and IR. Thus, although the mechanisms proposed by Miyakawa and 
Matsushime (2001) may have contributed to the response, the results obtained in this 
investigation demonstrated that the 3’-untraslated region of cyclin D1 mRNA was dispensable 
for the genotoxic stress-induced cyclin D1 degradation observed in NIH 3T3. Rather, damage-
induced destabilisation of cyclin D1 was sensitive to the presence of proteasome inhibitors 
(Figure 5.2), indicating the involvement of post-translational regulation. Agami and Bernard 
(2000) demonstrated that inhibition of cyclin D1 degradation led to a failure to inhibit DNA 
synthesis and hence a lack of G1 arrest in response to an exposure to IR. In contrast to this 
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report, experiments herein demonstrated an inhibition of cyclin D1 degradation by a 
proteasome inhibitor was unable to restore DNA synthesis following exposure to medium and 
high doses of 4NQO (Figure 5.3). It is either that cyclin D1 degradation is dispensable for 
4NQO-induced G1 arrest or alternative pathways such as the CDC25-dependent pathway as 
described previously may be able to compensate for the loss of cyclin D1 response.  
 
5.3.2 T286 of cyclin D1 is required for degradation induced by genotoxic stress in 
NIH 3T3 cells 
To understand the molecular mechanisms of proteasome-dependent cyclin D1 degradation 
induced by 4NQO, three conserved motifs/residues RxxL (R29/L32), T156 and T286 of 
cyclin D1 were chosen for the site-directed mutagenesis studies. They were chosen as all three 
motifs have previously been implicated in regulation of cyclin D1 functionalities as explained 
above. Whilst the double mutant, R29A/L32A and the dominant negative mutant, T156A, 
responded similarly to the endogenous cyclin D1 (Figures 5.5a,b, 5.7), the T286A mutant 
resisted degradation induced by 4NQO, UV and IR (Figure 5.8a, b, c). This observation partly 
contradicted the findings of Agami and Bernards (2000), which suggested that T286 was 
dispensable for the IR-induced destabilisation of cyclin D1 but the RxxL motif was not and 
thus dependent on the activity of anaphase promoting complex (APC). Such a discrepancy is 
likely to be due to a difference in experimental approach used in the previous publication and 
this investigation; Agami and Bernards investigated the effect of cyclin D1 mutations by 
transient transfection in a breast cancer cell line, MCF-7, as opposed to using a stable 
transfection in an immortalised mouse fibroblast, NIH 3T3 cells. MCF-7 cells are known to 
have elevated levels of D-cyclins. An investigation by Russell and colleagues has suggested 
that this was mainly due to a defect in proteolysis of D-cyclins  (Russell et al., 1999). They 
demonstrated that protein stabilities of D-type cyclins in MCF-7 cells were approximately 3-
fold higher than that in other cancer cell lines, as well as having a slightly raised mRNA level. 
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Furthermore, it was shown that MCF-7 cells lack the expression of αB-crystallin, a co-factor 
of the F-box protein, Fbx4, which comprises the E3 ligase, SCF complex, responsible for 
cyclin D1 degradation (Chelouche-Lev et al., 2004; Barbash et al., 2007). Elimination of αB-
crystallin was shown to disrupt the interaction between cyclin D1 phosphorylated at T286 and 
the SCF complex in vivo (Lin et al., 2006). It is plausible that MCF-7 cells have adapted to 
such defect by utilising an alternative E3 ligases such as APC, which normally regulates the 
expression of cyclins involved in late phases of cell cycle (Blanco et al., 2000). Nevertheless, 
the results obtained in my investigation implied that 4NQO, UV and IR induced cyclin D1 
degradation via a mechanism which required an intact T286 in NIH 3T3 cells. 
 
In the past, a number of kinases such as GSK3β or SAPK2/p38MAPK have been implicated in 
stress/damage-induced destabilisation of cyclin D1 (Casanovas et al., 2000; Ma et al., 2005; 
Alao, 2007; Mukherji et al., 2008). GSK3β has long been thought to act as the central kinase 
that negatively regulates the expression level of cyclin D1 at a post-translational level during 
cell cycle (Diehl et al., 1997; Diehl et al., 1998; Takahashi-Yanaga and Sasaguri, 2008). It 
also inhibits cyclin D1 at a transcriptional level by interfering with growth factor-induced 
MAPK cascades (Boyle et al., 1991; Doble and Woodgett, 2003; Liu et al., 2004). 
Incidentally, the activity of GSK3β has been linked with a number of UV-responsive events. 
For instance, mouse or human embryonic fibroblasts with GSK3β deletion were unable to 
activate stress-responsive MAPK kinase kinase 1 (MEKK1) or c-Jun N-terminal kinase (JNK) 
in response to UV irradiation (Kim et al., 2003; Liu et al., 2004). Further evidence for the 
involvement of GSK3β in the UV-induced DNA damage response was provided by Lee and 
colleagues who demonstrated that GSK3β-dependent phosphorylation of p21 at S114 directs 
degradation of p21 downstream of ATR (Lee et al., 2007). Despite its activation by DNA 
damage and its involvement in cyclin D1 degradation, inhibition of GSK3β by chemical 
inhibitions (Li+) or biochemical pathway (activated PI3K) failed to alter the cyclin D1 
response in 4NQO-treated cells (Figure 5.9). Another candidate for a cyclin D1 kinase is 
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SAPK2/p38
MAPK
. It belongs to the MAPK superfamily which is known to be activated in 
response to cellular stresses caused by oxidative and osmotic shock as well as various 
cytokines (Doble and Woodgett, 2003; Roux and Blenis, 2004). Whilst its activity is often 
associated with immune responses, it fulfils a role in signal transduction during DNA damage 
responses induced by both UV and IR-associated (Yang et al., 2003; Reinhardt et al., 2007). 
One of the best established DNA damage components targeted by SAPK2/p38
MAPK
 is p53. A 
number of studies demonstrated that SAPK2/p38
MAPK
 positively regulates p53 by 
phosphorylating it at S389 (S392 in human p53) in response to UV but not IR (Kapoor and 
Lozano, 1998; Lu et al., 1998; Huang et al., 1999a; Keller et al., 1999). Moreover, 
SAPK2/p38
MAPK
 was shown to mediate the phosphorylation of T286 and destabilise cyclin D1 
as a part of the stress-induced response (Casanovas et al.2000; Alao, 2007). However, once 
again, my investigation failed to detect any associations between changes in cyclin D1 
expression induced by 4NQO and the activity of this enzyme (Figure 5.10).  
 
These observations gave rise to two possible explanations; multiple kinases are able to target 
this residue for phosphorylation during DNA damage response and thus inhibition of one 
enzyme is complemented by another or there is a yet unidentified kinase responsible for the 
phosphorylation of cyclin D1 T286. As discussed previously, cross-talk between protein 
kinases of the DNA damage response is common and has been observed between apical 
kinases, ATM and ATR or checkpoint kinases, Chk1 and Chk2 (Gatei et al., 2003; Wang et al., 
2006; Zaugg et al., 2007). Furthermore, Reinhardt and colleagues have demonstrated that 
Chk1 and SAPK2/p38
MAPK
 were activated independently in response to various DNA 
damaging agents and converged downstream to downregulate Cdc25 family of proteins, 
exemplifying the presence of parallel signalling pathways elicited during the DNA damage 
response (Reinhardt et al., 2007).  Should GSK3β and SAPK2/p38MAPK be a part of two 
independent signalling cascades induced by 4NQO responsible for cyclin D1 destabilisation, 
inhibiting one is unlikely to cause a dramatic change in cyclin D1 response. Recently, Kwak 
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and colleagues demonstrated that a member of IκB kinases (IKKs), IKKα, plays a critical role 
in regulating cellular level of cyclin D1 (Kwak et al., 2005). They showed that in cells lacking 
an expression of IKKα, cyclin D1 was stabilised and was predominantly nuclear, similar to 
the behaviour of cyclin D1 T286A mutant observed in this investigation as well as others 
(Figure 5.6b) (Diehl et al., 1998). Further analyses indicated that IKKα was able to physically 
interact with cyclin D1 and that it directly phosphorylated cyclin D1 at T286 in vivo and in 
vitro. Although the activity of IKKα has not been implicated in the DNA damage response, 
IKKα is a regulator of a UV-responsive transcription factor NFκB (Ravi et al., 2008) and thus 
it may display dual functionalities in cells. Incidentally, T286 is located within a minimal 
motif, S/T-P, for CDKs and MAPK due to the presence of proline residue. To my knowledge, 
no CDKs have been linked to T286 phosphorylation. Further investigation is essential to 
identify the kinase responsible for phosphorylating cyclin D1 following 4NQO exposure to 
trigger its degradation.  
 
5.3.3 Upstream regulators of cyclin D1 during DNA damage response  
The tumour suppressors, pRb and p53, comprise two of the main effectors of DNA damage 
responses that are frequently found mutated in human cancers (Williams et al., 1994; 
Hickman et al., 2002). Whilst pRb is predominantly implicated in DNA damage-induced G1 
arrest (Slebos et al., 1994; Harrington et al., 1998; Bosco and Knudsen, 2005), p53 has been 
widely shown to function in G1 and G2/M arrests as well as apoptosis (Agarwal et al., 1995; 
Aloni-Grinstein et al., 1995; Hermeking et al., 1997; Bunz et al., 1998; Geyer et al., 2000; 
Seidita et al., 2000). The roles of pRb and p53 in the DNA damage response appear to largely 
depend on the type of DNA damaging agents employed as well as on the genotypes of the 
affected cells. Evidence suggests that pRb is in fact involved in many aspects of the DNA 
damage response including an inhibitory regulation of apoptosis (Jacks et al., 1992; Lee et al., 
1992; Haas-Kogan et al., 1995; Kasten and Giordano, 1998), DNA repair (Bosco et al., 2004; 
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Latonen and Laiho, 2005) and G2/M arrest (Niculescu et al., 1998; Naderi et al., 2002; 
Jackson et al., 2005; Eguchi et al., 2007). Furthermore, it was shown that lack of pRb or 
inhibition of pRb by various oncoproteins down-regulates cyclin D1 expression (Muller et al., 
1994; Takebayashi et al., 2003). Investigations carried out using a number of SV40-
immortalised mammalian cells suggested that 4NQO- or UV-induced changes in cyclin D1 
expression were independent of the activities of p53 and/or pRb. On the other hand, 
degradation of cyclin D1 induced by IR was abolished in these cell lines indicating that 
functional p53 and/or pRb are required. 
 
The responses of cyclin D1 following 4NQO and UV also remained intact in XP12RO and 
AT5BI VA, implying that the repair protein, XP-A, and the apical kinase, ATM, were also 
dispensable (Figures 5.13a,b, 5.14a,b). XP-A is a repair protein which becomes incorporated 
into NER complexes at sites of DNA damage (Volker et al., 2001). A kinetic study of XP-A 
recruitment to NER complex showed that XP-A was immobilised within 5 min of UV 
exposure and thus is likely to compose an upstream regulator of the sensor pathways 
(Rademakers et al., 2003). The data presented here demonstrate the cyclin D1 response is 
independent of XP-A. AT5BI VA cells express a defective apical kinase, ATM and are 
defective in repairing DNA double strand breaks (Kysela et al., 1995; Gately et al., 1998; 
Kuhne et al., 2004). As expected, IR-induced responses of cyclin D1 and p21 were abrogated 
in this cell line (Figure 5.15c). Amongst the two apical kinases, ATM and ATR, the response 
to IR has been associated primarily with ATM activation whilst the response to UV with ATR 
(Abraham, 2001; Shiloh, 2001). Considering the extent of the similarities between the 
molecular responses caused by UV and 4NQO observed in this investigation, it appeared 
likely that 4NQO induced an ATR-dependent response. To support this speculation, 4NQO-
induced cyclin D1 response was unaffected in AT5BI VA cells but sensitive to the presence of 
caffeine which abrogates both ATM and ATR (Figures 5.14a, 5.15). It is worth noting that the 
understanding of molecular mechanisms by which caffeine affects damage responses are yet 
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to be fully understood. Although widely employed as an inhibitor of ATM and ATR, its 
inhibitory effect is not specific to these kinases and myriad other targets have been identified 
including, DNA-PK (Foukas et al., 2002; Yang et al., 2003), alkaline phosphatases (Wharton 
and Goz, 1979) and phosphodiesterase (Beavo et al., 1970). Much of direct evidence for 
caffeine’s ability to inhibit ATM and ATR has been based on studies in vitro. Various groups 
have demonstrated that immunopurified ATM and ATR were inhibited by caffeine in the low 
milli molar range of concentration (Sakahira et al., 1998; Blasina et al., 1999; Hall-Jackson et 
al., 1999; Foukas et al., 2002). The main link between caffeine and these kinases in vivo was 
provided by observations that caffeine was able to override various damage-induced S and 
G2/M arrests that were dependent on expression of functional ATR or ATM (Heffernan et al., 
2002; Kaufmann et al., 2003; Shechter et al., 2004). A number of groups have demonstrated 
that expression of kinase-dead forms of ATR or Chk1 mimicked the effect of caffeine on UV-
induced S phase checkpoint (Nghiem et al., 2001; Heffernan et al., 2002). Similarly, a study 
in S. pombe demonstrated that caffeine abrogated Cds1 (homologous to human Chk2) and 
Chk1 phosphorylation due to a lack of Rad3 (homologous to human ATM/ATR) activation 
(Moser et al., 2000). However, Cortez (2003) demonstrated that the presence of caffeine did 
not abolish autophosphorylation and a subsequent activation of ATM in response to IR 
irradiation, disagreeing with previous reports. Furthermore, treatment with hydroxyurea in the 
presence of caffeine enhanced phosphorylation of Chk1, Chk2 and p53 at residues known to 
activate these proteins in a ATM/ATR-dependent manner (Cortez, 2003). This observation 
was supported by another group and raised the hypothesis that caffeine inhibits checkpoint 
response without affecting ATM/ATR directly (Cortez, 2003; Kaufmann et al., 2003). 
Assessing the true effect of caffeine is further complicated by the fact that caffeine could 
directly contribute to an accumulation of DNA damage and chromosomal aberrations by 
intercalating in DNA as well as interfering with DNA repair (Tohda and Oikawa, 1988; 
Tornaletti et al., 1989; Selby and Sancar, 1990).  
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ATR is a Ser/Thr-kinase which targets a cluster of S/T-Q motifs (Traven and Heierhorst, 
2005). The amino acid sequence of cyclin D1 does not contain such a motif (Figure 5.4), 
suggesting that ATR is unlikely to phosphorylate cyclin D1 directly but likely to promote the 
activation of a cyclin D1-kinase. Primary targets of ATR include Chk1, Chk2 and p53 (Lakin 
and Jackson, 1999; Tibbetts et al., 1999; Zhao and Piwnica-Worms, 2001; Heffernan et al., 
2002; Wang et al., 2006). Since the cyclin D1 response appeared to be independent of p53, the 
requirements for the activities of Chk1 and Chk2 were tested using their inhibitors. However, 
neither the presence of a single inhibitor nor the presence of both Chk1 and Chk2 inhibitors 
were able to reverse 4NQO-induced cyclin D1 degradation (Figure 5.16). These observations 
seemed to point towards the presence of a yet unidentified damage signalling molecule which 
is activated by ATR. Taken together, the following facts have been revealed in this 
investigation (Table 5).   
 
Table 5  Summary of the results of investigation on the molecular mechanisms 
underlying the 4NQO-induced cyclin D1. 
 0µM 
2.5 µM 
(low) 
50 µM 
(medium) 
200 µM 
(high) 
Normal response Expressed 
Minimal 
reduction 
Dramatically  
degraded 
Minimal 
reduction 
Proteasome 
inhibitor 
Stabilised Stabilised Stabilised Stabilised 
R29A/L32A 
double mutant 
Expressed 
Minimal 
reduction 
Dramatically 
degraded 
Minimal 
reduction 
T156A mutant Expressed 
Minimal 
reduction 
Dramatically 
degraded 
Minimal 
reduction 
T286A mutant Expressed Stabilised Stabilised  Stabilised 
GSK3β inhibition Unaffected Unaffected Unaffected Unaffected 
SAPK2/p38
MAPK
 
inhibition 
Unaffected Unaffected Unaffected Unaffected 
Inhibition of 
p53/pRb by T-Ag 
Unaffected Unaffected Unaffected Unaffected 
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XP-A  Not required Not required Not required Not required 
ATM Not required Not required Not required Not required 
Caffeine  Unaffected Stabilised Stabilised Stabilised 
Chk1/2 inhibitors Unaffected  Unaffected Unaffected Unaffected 
 
5.3.4 Regulation of DNA damage-induced p21 response in NIH 3T3 cells 
As established in Chapter 3, p21 expression changes in response to 4NQO exposure in a dose-
dependent manner (Figure 3.3a). In particular, its expression level changed dramatically 
following exposure to low and medium doses of 4NQO where a low dose of 4NQO (2.5µM) 
induced a strong accumulation of p21 whilst a medium dose (50µM) triggered a dramatic loss 
of p21 to an undetectable level. A number of cell lines and inhibitors employed to investigate 
the molecular mechanisms underlying 4NQO-induced cyclin D1 degradation also provided 
useful information for identifying potential regulatory proteins required for eliciting such a 
response by p21. Induction of p21 is a well-established response to IR and has also been 
observed following exposure to UV (Di Leonardo et al., 1994; el-Deiry et al., 1994; Poon et 
al., 1996; Jabbur et al., 2000). This response is thought to be primarily mediated by a p53-
dependent pathway although in some instances it has also been observed in p53 defective 
cells (Michieli et al., 1994; Loignon et al., 1997; Haapajarvi et al., 1999; Geyer et al., 2000; 
Murphy et al., 2002; Wang et al., 2008). Damage-induced expression of p21 was found 
associated with phosphorylation of p53 at S15 and S20 which subsequently activated p53 as a 
transcription factor (Siliciano et al., 1997; Jabbur et al., 2000; Garner and Raj, 2008). S15 and 
S20 of p53 are known targets of upstream regulators, ATM/ATR and Chk1/Chk2, respectively 
(Canman et al., 1994; Chehab et al., 1999; Lakin and Jackson, 1999; Tibbetts et al., 1999; 
Shieh et al., 2000; Saito et al., 2002; Chen and Poon, 2008). Taken together, these 
components of the damage response come together to constitute a signalling cascade; 
ATM/ATR-Chk2/Chk1-p53-p21. The results presented above seem to support the 
involvement of this proposed pathway for the 4NQO-triggered response in p21. Firstly, the 
p21 induction was abrogated in SV40-immortalised cells, implying that the response required 
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functional p53 and/or pRb (Figures 5.11-13). Secondly, it was also sensitive to the presence of 
caffeine (Figure 5.15), which is capable of inhibiting ATM and ATR, as discussed above. 
Finally, an inhibitor of Chk1 (but not Chk2) was able to attenuate 4NQO-induced p21 
induction (Figure 5.16).  
 
Downregulation of p21 has been observed following exposure to UVC in a dose-dependent 
manner, in various cell lines (Allan and Fried, 1999; Wang et al., 1999; Bendjennat et al., 
2003; Soria et al., 2006). However, the exact doses at which UVC triggered p21 degradation 
appeared to vary greatly with cell type and the molecular mechanisms underlying these 
differences are not well understood (Bendjennat et al., 2003; Itoh and Linn, 2005; Lee et al., 
2006). In the results presented above,  it was shown that 4NQO-induced p21 degradation was 
not eliminated by (i) inhibition of GSK3β (Figure 5.9), (ii) inhibition of SAPK2/p38MAPK 
(Figure 5.10), (iii) the presence of SV40 T-Ag (Figures 5.11,5 12), (iv) defective XP-A or 
ATM (Figures 5.13,5 14), (v) caffeine (Figure 5.15), and finally (vi) inhibitors of Chk1 or 
Chk2 (Figure 5.16). These observations indicated that many of the key DNA damage 
regulating proteins were dispensable for the p21 degradation. Furthermore, proteasome 
inhibitors attenuated p21 degradation but did not completely abrogate the response (data not 
shown). Many reports have highlighted the importance of damage-induced p21 
downregulation in efficiently activating DNA repair and apoptosis in order to maintain 
genomic stability in multicellular organisms (McKay et al., 1998; Allan and Fried, 1999; 
Fotedar et al., 1999; Izumaru et al., 2004; Soria et al., 2006). Thus, it appears that much 
remains to be learnt about the regulation of p21 expression in the DNA damage response.   
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Figure 5.1  Response of endogenous and ectopically expressed cyclin D1 following 
exposure to various doses of 4NQO in cyclin D1 inducible 3T3 cell line 
An asynchronous population of D1 inducible 3T3 cells was seeded at a cell density of 1 x 10
6
 
cells / φ90mm dish and an expression of exogenous cyclin D1 was induced with 1mM IPTG. 
24h post-induction, cells were treated with varying doses of 4NQO and lysed 3h later. 
Expression levels of endogenous and exogenous cyclin D1 were separated on 10% SDS-
PAGE and detected using antibodies against mouse cyclin D1 (72-13G; Santa Cruz) and 
FLAG (M-2; Sigma) or human cyclin D1 (A-12; Santa Cruz), respectively. Protein loading 
was monitored by assessing α-tubulin expression levels.  
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a. 
 
 
b. 
 
 
Figure 5.2   Changes of cyclin D1 expression in NIH 3T3 cells treated with 4NQO 
in the presence and absence of proteolysis inhibitors 
Asynchronously growing NIH 3T3 cells were pre-incubated with 50µM of (a) DMSO 
(control), (b) MG132 or ALLN for 30min prior to treatment with 4NQO. Cells were harvested 
3h post-4NQO exposure and expression levels of cyclin D1 were observed. The level of p27 
was elevated in cells treated with proteasome inhibitors, verifying the efficacy of the 
inhibitors. The level of α-tubulin was monitored as a control for protein loading.  
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Figure 5.3  Effect of chemical inhibitors, MG132 or ALLN, on BrdU incorporation 
following exposure to 4NQO  
Asynchronous populations of NIH 3T3 cells were pre-treated with 50µM of proteasome 
inhibitors, MG132 or ALLN. Cells were exposed to 4 doses of 4NQO and incubated for 3h. 
10µM BrdU was added 30min prior to harvest. Fixed samples were processed for BrdU 
incorporation assays and analysed by flow cytometry. 20,000 events per sample were 
collected and BrdU positive population was scored as described (Materials and Methods).  
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Figure 5.4   Amino acid sequence alignment of human and mouse cyclin D1 
Amino acid sequences of human (AAH00076) and mouse (NP_031657) cyclin D1 were 
aligned using Basic Local Alignment Search Tool (BLAST). The conserved motifs and 
residues targeted for mutagenesis studies in this investigation are highlighted; RxxL motif 
(yellow), T156 (blue) and T286 (red). The C-terminal region rich in an acidic amino acid, 
glutamate (E), is highlighted in green.   
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a. 
 
b. 
 
Figure 5.5  Analysis of ectopically expressed cyclin D1 wt and RxxL mutant in 
response to DNA damaging agents in stably transfected NIH 3T3 cell lines  
NIH 3T3 cells stably transfected with FLAG-tagged cyclin D1 wild type (D1 wt 3T3) or 
cyclin D1 R29A/L32A mutant (D1 RxxL 3T3) were treated with (a) IR, (b) 4NQO or (c) UV  
as described (Materials and Methods). 3h after treatment, cells were lysed and expression 
levels of endogenous and FLAG-epitope tagged exogenous cyclin D1 as well as p21 were 
assessed by immunoblotting. Levels of α-tubulin were monitored as a control for protein 
loading.   
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c. 
 
d. 
 
Figure 5.5 cont.  Analysis of ectopically expressed cyclin D1 wt and cyclin D1 RxxL 
mutant in response to DNA damaging agents in stably transfected NIH 3T3 cell 
lines 
Where both exogenous and endogenous cyclin D1 were detected simultaneously, black and 
white triangles are used to indicate them, respectively (c & d). To aid the observation of UV-
induced dose-dependent response by exogenous and endogenous cyclin D1 in D1 RxxL 3T3 
cells, two blots with different exposure times are presented (d).   
 N. Suwaki 
Page | 158  
 
 
Figure 5.6  Determining the subcellular localisation of endogenous and exogenous 
cyclin D1 in stable cell lines by immunostaining  
For legend, see following page.  
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c. 
 
Figure 5.6 cont.  Determining subcellular localisation of endogenous and 
exogenous cyclin D1 in stable cell lines by immunostaining 
NIH 3T3, D1 T156A 3T3 and D1 T286A 3T3 cell lines were plated onto coverslips and 
stained for (a) cyclin D1 and (b) FLAG expression 24-48h post-plating. The stained cells were 
visualised and the images were captured using the Axiocam software on a Zeiss Axiovert 
200M inverted microscope. The scale bar represents 20µm. (c) The staining was quantified by 
counting the number of cyclin D1 and FLAG stained nuclei and expressing this as a 
percentage of the total number of cells counted per well. 200 cells were counted for each cell 
type and different type of staining. The mean values of positively stained population from 
three independent experiments are presented in the bar chart. The error bars indicate standard 
errors.  
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Figure 5.7  Analyses of molecular responses following exposure of D1 T156A 3T3 
cell lines to various DNA damaging agents 
NIH 3T3 cells stably expressing cyclin D1 T156A mutant (D1 T156A 3T3) were exposed to 
(a) 4NQO, (b) IR, or (c) UV. Expression levels of endogenous cyclin D1, ectopically 
expressed cyclin D1 mutant and p21 were assessed by immunoblotting. Level of α-tubulin 
expression was monitored as a control for protein loading. Where both exogenous and 
endogenous cyclin D1 expression can be observed simultaneously, black and white triangles 
are used to indicate them, respectively.  
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Figure 5.8  Analyses of molecular responses in D1 T286A 3T3 cells following 
exposure to various DNA damaging agents  
NIH 3T3 cells stably expressing cyclin D1 T1286A mutant (D1 T286A 3T3) were exposed to 
indicated doses of (a) 4NQO, (b) UV, or (c)-(d) IR. Expression levels of endogenous cyclin 
D1, ectopically expressed cyclin D1 mutant and p21 were assessed by immunoblotting. Level 
of α-tubulin expression was monitored as a control for protein loading. Where both exogenous 
and endogenous cyclin D1 expression can be observed simultaneously, black and white 
triangles are used to indicate them, respectively.  
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Figure 5.9  Effect of GSK3β inhibitor, Li+, on 4NQO-induced cyclin D1 and p21 
responses  
(a) NIH 3T3 cells were pre-treated with 100µM myo-inositol for 15min and exposed to 20mM 
LiCl or 20mM KCl (as a control). 30min after the addition of salts, cells were treated with 
indicated doses of 4NQO as previously described (Materials and Methods). (b) Swiss 3T3 and 
Swiss PI3K cells were exposed to indicated doses of 4NQO. 4NQO-treated cells were lysed 
3h later. Expression levels of cyclin D1 and p21 were assessed by immunoblotting. α-tubulin 
level was assessed as a loading control.  
 N. Suwaki 
Page | 163  
 
a. 
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Figure 5.10  Effect of SAPK2/p38
MAPK
 inhibitor, SB203580, on 4NQO-induced 
responses by cyclin D1 and p21. 
NIH 3T3 cells were pre-treated with 10µM SB203580 or DMSO (control) for 30min prior to 
incubation with (a) 180mM NaCl for 1.5h or (b) indicated doses of 4NQO for 3h as described 
(Materials and Methods). Responses of cyclin D1 and p21 were examined by immunoblotting 
assays. The α-tubulin expression was also monitored as a loading control.  
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Figure 5.11   Effect of SV40 T-Ag expression on the responses of cyclin D1 and p21 
to 4NQO 
SVts8 cells plated for 4NQO treatment and cultured at the permissive (34
o
C) and non-
permissive temperature (38.5
o
C) for 15h prior to exposure. Cells were harvested 3h post-
exposure and lysates were resolved on a 12% SDS PAGE and immunoblotting assays were 
performed. Blots were probed using antibodies against human cyclin D1, p21 and α-tubulin.  
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Figure 5.12  Molecular responses of cyclin D1 and p21 in SV40-immortalised 
MRC5 cell line (MRC5 CV1 ) to DNA damaging agents 
MRC5 CV1 cells were exposed to indicated doses of (a) 4NQO, (b) UV, and (c) IR. Cells 
were collected in 2X SDS loading buffer 3h following exposure. Protein samples were 
resolved on 12% SDS PAGE and expression levels of cyclin D1 and p21 were assessed by 
immunoblotting assays. α-tubulin level was detected as a loading control.   
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Figure 5.13  Molecular responses of cyclin D1 and p21 in SV40-immortalised XP 
cell line, XP12R, to DNA damaging agents 
XP12RO cells were exposed to indicated doses of (a) 4NQO, (b) UV, and (c) IR. Cells were 
lysed in 2X SDS loading buffer 3h post-exposure. Cell lysates were separated on 12% SDS 
PAGE and expression levels of cyclin D1 and p21 were assessed by immunoblotting assays. 
α-tubulin level was detected as a loading control.   
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Figure 5.14  Molecular responses of cyclin D1 and p21 in SV40-immortalised A-T 
cell line, AT5BI VA, to DNA damaging agents 
AT5BI VA cells were treated with indicated doses of (a) 4NQO, (b) UV, and (c) IR. Cells were 
lysed in 2X SDS loading buffer 3h post-exposure. Cell lysates were separated on 12% SDS 
PAGE and immunoblotting assays were performed using antibodies against human cyclin D1, 
p21 and α-tubulin.  
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Figure 5.15  Effect of caffeine on the responses of cyclin D1 and p21 in 4NQO-
treated NIH 3T3 cells  
NIH 3T3 cells were pre-treated with 20mM of caffeine 30min prior to treatment with 
indicated doses of 4NQO. 3h after treatment, cells were collected in 2X SDS loading buffer. 
Cell lysates were resolved on 12% SDS PAGE and cellular level of cyclin D1 and p21 were 
analysed by immunoblotting assays. α-tubulin level was monitored as a control for protein 
loading. In the absence of caffeine, a normal cyclin D1 and p21 responses were observed (as 
shown in Figures 3.1, 3.3). 
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Figure 5.16  Effect of Chk1 and Chk2 inhibitors on the responses of cyclin D1 and 
p21 in 4NQO-treated NIH 3T3 cells 
NIH 3T3 cells were pre-treated with (a) DMSO (control), (b) 1µM Chk1 inhibitor, (c) 1µM 
Chk2 inhibitor and (d) 1µM Chk1 and Chk2 inhibitors for 30min. Cells were then exposed to 
indicated doses of 4NQO as described (Materials and Methods). Cells were lysed 3h post-
exposure and resolved on 12% SDS PAGE. Cellular levels of cyclin D1, p21 and α-tubulin 
were assessed by immunoblotting assays.  
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Chapter 6:  D-type cyclins 
6.1 Introduction 
Recent studies using D-cyclin deficient mice and single D-cyclin expressing mice suggested 
that the three members of D-type cyclins are largely redundant at an early stage of 
development (Ciemerych et al., 2002; Kozar et al., 2004; Ciemerych et al., 2008). However, 
at late stages of development and in adult cells, cell specific distributions of distinct D-cyclin 
were observed and the lack of a single D-cyclin expression resulted in unique phenotypic 
abnormalities (Sun et al., 1996; Sherr and Roberts, 2004; Kaplan et al., 2005; Kozar and 
Sicinski, 2005; Yang et al., 2006b). For instance, loss of cyclin D1 caused defective 
developments of retina and mammary glands (Fantl et al., 1995; Sicinski et al., 1995; Fantl et 
al., 1999). Whilst the absence of cyclin D2 or cyclin D3 was predominantly associated with 
impaired maturation of B- and T-lymphocytes, respectively (Sicinski et al., 1996; Lam et al., 
2000; Sonoki et al., 2001; Sicinska et al., 2003; Chiles, 2004; Kowalczyk et al., 2004). The 
execution of different functions by each D-cyclin can be envisioned from the association of 
distinct types of cancer with defects in particular D-cyclins. Aberrant expression of cyclin D1 
is observed in a wide range of cancers including those of breast, neck and head (de Jong et al., 
1998; de Jong et al., 1999; Hardisson, 2003) whereas the deregulation of cyclins D2 or D3 
has been strongly implicated in lymphocytic malignancies and a number of pancreatic and 
ovarian cancers (Delmer et al., 1995; Sonoki et al., 2001; Weng and Aster, 2003; Chiles, 2004; 
Clappier et al., 2006; Sakuma et al., 2007). Thus, understanding the mechanisms underlying 
the activity of individual D-cyclin is of great importance in providing a molecular description 
of many cancers.  
 
Studies on D-cyclins and the DNA damage response have so far been mostly focused on the 
roles of cyclin D1. To address this issue, the molecular responses of all three members of the 
D-cyclin family associated with distinct DNA damaging agents were investigated in various 
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mammalian cell lines.  
 
6.2 Results 
6.2.1 Differential response of D-cyclins to distinct DNA damaging agents in 
mammalian cells 
First, changes of cyclin D2 and D3 expression in response to DNA damaging agents were 
probed by immunoblotting assays. Four DNA damaging agents, 4NQO, UV, H2O2 and IR, all 
of which induced substantial degradation of cyclin D1 in NIH 3T3 cells as shown previously 
(Chapter 4), were employed. Figure 6.1 shows that D-cyclins exhibited differential responses 
to these agents. Treatment of NIH 3T3 cells with up to 50µM 4NQO caused a dramatic 
clearance of all three D-cyclins (Figure 6.1a) as did UV exposure up to 1000J/m
2 
(Figure 
6.1b). Cyclin D2 and D3 expression did not change following treatment with up to 250µM 
H2O2 or exposure to up to 21.2Gy IR whereas the cyclin D1 level diminished in both cases 
(Figure 6.1c, d). In line with some of the results presented in Chapter 4, p21 expression 
exhibited distinct changes following exposure to 4NQO or UV compared to H2O2 or IR 
(Figure 6.1).  
 
Although NIH 3T3 cells appear to express all three D-cyclins often mammalian cell lines 
show expression of distinct combinations of D-cyclins. To determine whether D-cyclin 
responses observed in NIH 3T3 cells were cell-specific, their expression levels following 
exposure of five different mammalian cell lines to UV, H2O2 and IR were investigated by 
immunoblotting assays. All three D-cyclins were detected in mouse embryonic fibroblast 
(C57BL MEF) and human osteosarcoma cells (U2OS). The other cell lines; immortalised 
cyclin D1 knockout mouse fibroblast (C57BL cyclin D1
-/-
 3T3), normal human fibroblast 
(WI38) and human cervical carcinoma cells (HeLa); expressed only two of the D-cyclins. 
Treatment of cells with up to 1000J/m
2
 UV caused degradation of D-cyclins in all mammalian 
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cell lines examined here (Figure 6.2).  In comparison to UV-induced changes in expression, 
H2O2 and IR doses that caused cyclin D1 degradation failed to induce any marked changes in 
the levels of cyclin D2 and D3 in all five cell types employed (Figures 6.3. 6.4).  
 
Amongst the mammalian cell lines tested, the expression level of p21 was generally increased 
following exposure to either H2O2 or IR whilst p21 accumulated after exposure to 15J/m
2
 UV 
but was present at reduced levels after 3h treatment with high doses (Figures 6.2 – 6.4). The 
two cancer cell lines, HeLa and U2OS, exhibited attenuated accumulation of p21 in 
comparison to the other cell lines, indicating that the cancerous cells may have acquired 
mutations that deregulate the DNA damage-induced p21 response.  
 
6.2.2 Characterisation of UV-induced degradation of D-cyclins in NIH 3T3 cells 
The degradation of each D-cyclin induced by UV treatment was further investigated in NIH 
3T3 cells. To compare the kinetics at which each D-cyclin expression was altered following 
UV exposure, NIH 3T3 cells were treated with various doses of UV (Materials and Methods) 
and were lysed 10, 30, 60, 120 and 180min after the exposure. The expression levels of each 
D-cyclin were examined by immunoblotting assays. Cyclin D1 and D2 expression diminished 
at 60min post-exposure whereas cyclin D3 expression showed minimal change at this time 
point (Figure 6.5). A reduction in cyclin D3 expression became apparent at 120min following 
exposure. Pre-incubation of NIH 3T3 cells with a proteasome inhibitor, MG132, prior to UV 
exposure protected all three D-cyclins from downregulation (Figure 6.6a). This observation 
suggested that the effect of UV on D-cyclins was at least partly dependent on a proteasome-
mediated degradation pathway. The use of NIH 3T3 cells carrying a plasmid encoding for 
FLAG-tagged cyclin D3 under an IPTG-inducible promoter (D3 inducible 3T3) showed that 
both endogenous and exogenous cyclin D3 expression was similarly affected after UV 
exposure (Figure 6.6b), providing another indication that post-transcriptional regulation was 
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involved.  
 
6.2.3 Effect of loss of cyclin D1 expression in the DNA damage response following 
exposure to UV or H2O2 
The immunoblotting assays presented above collectively demonstrated that the UV and 
4NQO-associated DNA damage responses triggered reductions in all three D-cyclins whereas 
H2O2 and IR-treatment only affected a single D-cyclin, namely cyclin D1. Moreover, the 
expression levels of D-cyclins seemed to change with different kinetics after UV treatment, 
suggesting that each D-cyclin may be a downstream target of regulatory pathways triggered 
by different DNA damaging agents.  To investigate potential differential roles of D-cyclins in 
the DNA damage response, the impact of an absence of cyclin D1 expression on cellular 
responses induced by UV and H2O2 were assessed in an immortalised mouse fibroblast (NIH 
3T3),  or a wild type primary mouse fibroblast (C57BL MEF) and its cyclin D1 knockout 
variant, C57BL cyclin D1
-/-
 MEFs. Each type of cell line was treated with UV or H2O2 and 
harvested and fixed at 24h or 48h post-exposure for flow cytometry.  
 
The DNA profiles of C57BL MEFs showed minimal changes in distribution of cell 
populations amongst the different phases of cell cycle after UV exposure, most probably due 
to multiple arrests established at the points of damage (Figure 6.7a). A moderate accumulation 
in the sub-G1 population was observed in a dose-dependent manner at 48h post-exposure. A 
quantitative analysis revealed that 1000J/m
2
 UV triggered apoptotic cell death in 
approximately 25% of the total population (Figure 6.7a, c). A lack of cyclin D1 appeared to 
sensitise C57BL cyclin D1
-/-
 MEFs to apoptosis induced by UV treatment despite intact 
responses from cyclin D2 and D3 (Figure 6.7b). More than 50% cells underwent apoptosis at 
48h-post exposure to UV doses greater than 50J/m
2 
(Figure 6.7c). This is reminiscent of the 
enhanced sensitivity exhibited by C57BL cyclin D1
-/-
 3T3 following exposure to 4NQO 
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(Figure 4.14). On the other hand, multi-phase cell cycle arrests seemed to be intact in C57BL 
cyclin D1
-/-
 MEFs (Figure 6.7b). Interestingly, at a lower dose, 15J/m
2
 UV, C57BL cyclin D1
-/-
 
MEFs remained as resistant to apoptosis as the wild type C57BL MEFs (Figure 6.7c). This 
may be a consequence of p21 induction (Figure 6.2) which is known to have a protective role 
against DNA damage-induced cell death (Gorospe et al., 1996; Gartel and Tyner, 2002; 
Janicke et al., 2007).  
 
When NIH 3T3 cells were treated with H2O2, no accumulation in the sub-G1 population was 
visible by flow cytometry at either 24 or 48h post-exposure (Figure 6.8a, c). It appeared that 
the anti-apoptotic activity of p21 induced following H2O2 or alternatively the presence of 
cyclin D2 and D3 were sufficient to protect C57BL cyclin D1
-/-
 MEFs from H2O2-induced cell 
death with only a marginal increase in the sub-G1 population (Figure 6.8b, c). NIH 3T3 cells 
seemed to induce a stronger G2/M arrest than the cyclin D1 deficient C57BL cyclin D1
-/-
 
MEFs after 250µM H2O2 treatment (Figure 6.8 a, b). However, it could not be determined 
whether this was solely due to the lack of cyclin D1 response or due to the difference in the 
origin of the cells. This experiment could not be repeated using C57BL MEFs due to the non-
availability of the cells.  
 
6.2.4 The cellular response of a single-D-cyclin expressing cell line to the  DNA 
damage response induced by 4NQO and H2O2 
Molt-4 cells are human T-lymphocyte leukaemia cells that express cyclin D3 but not cyclin 
D1 or D2. Considering the UV-triggered cyclin D3 degradation was somewhat delayed 
compared to those of cyclin D1 and D2 in NIH 3T3 cells (Figure 6.5), it seems likely that 
cyclin D3 is regulated by a different pathway compared to cyclin D1 and D2. Thus, with no 
detectable level of expression of cyclins D1 and D2, their roles in the DNA damage response 
should become apparent in the cellular responses associated with Molt-4 cells. First, changes 
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in the expression of cyclin D3 following exposure to 4NQO or H2O2 were examined by 
immunoblotting. At 3h post-4NQO exposure, cyclin D3 expression was reduced (Figure 6.9a) 
albeit in much less dramatic manner than that observed in other mammalian cell lines 
including NIH 3T3 and WI38 (Figure 6.2). On the other hand, the level of cyclin D3 remained 
unchanged following treatment with H2O2 (Figure 6.9b). In terms of cellular responses, Molt-
4 cells responded similarly to both 4NQO and H2O2 treatment (Figure 6.9c, d). There was a 
linear correlation between the doses of damaging agents employed and the increase in G1, S 
and the sub-G1 populations (Figure 6.9c, d). In particular, Molt-4 cells exhibited the highest 
sensitivity to H2O2 exposure amongst all cell lines tested. This seemed to support the 
possibility that cyclin D1 may participate in the DNA damage response as an anti-apoptotic 
signalling molecule.  
 
6.3 Discussion 
Amongst D-type cyclins, the roles of cyclin D1 following DNA damage have been of a 
particular interest whereas those of cyclin D2 and D3 have not been studied greatly. Even the 
limited information on cyclin D2 and D3 responses currently available is conflicting. A 
number of groups have reported a concomitant reduction of cyclin D1 and cyclin D3 
following DNA damage (Im et al., 2001; Barnouin et al., 2002; Ichikawa et al., 2008) whilst 
another study demonstrated an accumulation of cyclin D3 trigger by adriamycin treatment 
(Nishizuka et al., 2008). To my knowledge, the differential regulation of D-cyclins has been 
best characterised in the studies using retinoic acid. Retinoic acids are vitamin A derivatives 
that have been used successfully for chemoprevention and treatment of cancer (Freemantle et 
al., 2003). Although not a DNA damaging agent, retinoic acids induce a diverse array of 
intracellular signalling upon binding to their receptors and ultimately regulate cell cycle 
progression and cell death, similarly to the DNA damage response (Dragnev et al., 2003). 
Retinoic acid treatment triggered a reduction in the protein levels of cyclins D1 and D3 whilst 
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cyclin D2 expression was only affected at the mRNA level (Dragnev et al., 2004; Ma et al., 
2005). They also showed that both cyclin D1 and D3 were degraded in a phosphorylation-
directed proteasome-dependent manner. 
 
With the aim to identify DNA damage-induced responses for each D-type cyclin, NIH 3T3 
cells were treated with four different DNA damaging agents and the expression levels each D-
cyclin was probed by immunoblotting 3h post-treatment. Interestingly, 4NQO and UV, both of 
which predominantly incur DNA damage by forming bulky DNA adducts triggered 
degradation of all three D-cyclins (Figure 6.1 a, b). On the other hand, the major strand-break 
inducers, H2O2 and IR, only destabilised cyclin D1 expression in a dose-dependent manner 
whilst cyclin D2 and D3 expression remained unaffected (Figure 6.1 c, d). These observations 
were consistent in five other mammalian cells (Figure 6.2, 6.3, 6.4). D-type cyclin responses 
were not interdependent since a number of cell lines lacked expression of one of the D-type 
cyclins but it did not seem to affect the response of the others. Their responses were sensitive 
to the presence of a proteasome inhibitor, indicating that post-transcriptional regulation was 
involved (Figure 6.6). A report suggested that a phosphorylation of cyclin D3 at T283 residue 
destabilises the protein by directing it towards proteasome degradation (Casanovas et al., 
2004). This residue is conserved in all three D-cyclins. T286 of cyclin D1 has been implicated 
in the regulation of cyclin D1 expression during normal proliferation as described before 
(Diehl et al., 1997; Casanovas et al., 2000). In addition, 4NQO- and UV-induced cyclin D1 
degradation was abrogated by mutating the T286 residue (Figure 5.8). It is possible that both 
cyclin D2 and D3 may be phosphorylated at this conserved residue by kinases regulated by 
distinct signalling pathways. Further investigation is required to decipher the molecular 
mechanisms governing the DNA damage-induced alteration of D-cyclin expression. However, 
to the best of my knowledge, this is the first study which systematically examines the DNA 
damage-induced responses of individual members of D-type cyclins family in various 
mammalian cells.  
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The analysis of cellular responses presented here provided an indication that cyclin D1 may 
play a protective role against damage-induced apoptotic cell death that could not be 
complemented by the activities of cyclins D2 or cyclin D3. For instance, C57BL cyclin D1
-/-
 
MEFs were more sensitive to UV-induced apoptotic cell death than C57BL MEFs where p21 
accumulation was not observed (Figure 6.2). At doses greater than 250J/m
2
 where cyclin D1 
expression was normally undetectable, the loss of cyclin D1 appeared to have an impact on 
cellular responses. It is possible that cells sense the change in the cellular level of cyclin D1 
over time to determine the subsequent response rather than the presence or absence of the 
protein at one particular moment. The cellular responses were also probed in another cell line, 
Molt-4. The preliminary data on Molt-4 presented here showed that this cell line, which only 
expresses a single D-cyclin, cyclin D3, has a greater susceptibility to cell death induced by 
both 4NQO and H2O2 (Figure 6.9). However, interpretation of the data is difficult at this stage 
as Molt-4 is considerably different from the other cell lines employed in this project where 
molecular and cellular responses have been studied extensively. There are a number of 
possibilities that could be the cause of Molt-4’s increased sensitivity to both UV and H2O2. 
For instance, no detectable p21 expression was observed at 3h post-damage at any dose tested 
here (data not shown). Although there has been a report suggesting an induction of p21 
following IR-treatment at later stages, it appeared to be involved in cell cycle arrest rather 
than apoptosis (Morita et al., 2006). Thus, the lack of p21 expression would likely contribute 
to the increased propensity of cells to die. Furthermore, another study revealed that Molt-4 
cells exhibited a high radiosensitivity partly due to their inability to activate a damage protein, 
Nijmegen breakage syndrome 1 (Nbs1), in response to IR-exposure (Rezacova et al., 2008). 
Nbs1 is an upstream regulator of DNA damage response which acts as a sensor by forming 
MRN complexes (Uziel et al., 2003; Kobayashi et al., 2004; Lee and Paull, 2005; Paull and 
Lee, 2005) or as a signal transducer by being a substrate of ATM (Gatei et al., 2000; Lim et 
al., 2000; Wu et al., 2000; Zhao et al., 2000). Its function is primarily associated with DSB-
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ATM-dependent pathways, but a requirement of Nbs1 in UV-induced ATR-dependent 
pathway has also been suggested (Robison et al., 2004; Stiff et al., 2005). Collectively, these 
properties of Molt-4 cells can hinder the identification of the true impact of having a single D-
cyclin.  
 
Looking forward, it would be of a great interest to utilise cell lines with unique genotypes to 
reveal the insight into the roles of D-type cyclins in DNA damage response. For instance, 
C57BL cyclin D1
-/-
 MEFs can be transfected with a functional cyclin D1 to assess whether it 
can restore a normal sensitivity exhibited by a wild type C57BL MEFs after exposure to DNA 
damaging agents. Furthermore, transfecting a degradation- resistant mutant of cyclin D1 and 
examining its effect on the cellular responses could provide critical information to explore the 
signalling pathways regulating D-cyclin expression during damage responses. Those MEFs 
derived from mice expressing none (Kozar et al., 2004), a single or distinct combinations of 
D-cyclins (Ciemerych et al., 2002; Ciemerych et al., 2008) could be powerful tools to probe 
differential functionalities of D-cyclins. I am hopeful that the advancement of such 
investigation can lead to the identification of novel targets for cancer therapy in the future.    
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Figure 6.1  Expression levels of D-cyclins and p21 in NIH 3T3 cells treated with 
DNA damaging agents 
NIH 3T3 cells were seeded at the density of 1x10
6
 cells per φ 90mm dish and treated with 
indicated doses of (a) 4NQO for 30minutes, (b) 254nm UV (c) H2O2 for 30minutes or (d) IR,  
24hours post-plating, as described (Materials and Methods). Cells were further incubated for 
3hours and harvested and were subjected to SDS-PAGE. Blots were probed using antibodies 
against cyclin D1, D2, D3 and p21, to determine the changes in their expression levels. α-
tubulin blot served to monitor protein loading.  
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Figure 6.2 Responses of D-cyclins and p21 in various mammalian cells exposed to 
UV 
Five different mammalian cell lines, C57BL 3T3, C57BL cyclin D1
-/-
 3T3, WI38, HeLa and 
U2OS, were treated with indicated doses of UV as described (Materials and Methods). Cells 
were lysed 3h post-irradiation and proteins were separated on SDS-PAGE. Expression levels 
of cyclin D1, D2, D3 and p21 were assessed by immunoblotting. α-tubulin level was also 
monitored as loading control.  
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Figure 6.3 Expression of D-cyclins and p21 in mammalian cells treated with H2O2 
Five different mammalian cell lines, C57BL 3T3, C57BL cyclin D1
-/-
 3T3, WI38, HeLa and 
U2OS, were treated with indicated doses of H2O2 for 30min as described (Materials and 
Methods). Cells were lysed 3h post-exposure and proteins were separated on SDS-PAGE. 
Expression levels of cyclin D1, D2, D3 and p21 were assessed by immunoblotting. α-tubulin 
level was assessed to monitor protein loading.  
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Figure 6.4 Responses of D-cyclins and p21 in mammalian cells exposed to IR 
Five different mammalian cell lines, C57BL 3T3, C57BL cyclin D1
-/-
 3T3, WI38, HeLa and 
U2OS, were treated with indicated doses of IR as described (Materials and Methods). Cells 
were collected 3h post-irradiation and proteins were separated on SDS-PAGE. Expression 
levels of cyclin D1, D2, D3 and p21 were assessed by immunoblotting. α-tubulin level was 
also detected to monitor protein loading.  
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Figure 6.5 Short-term response of D-cyclins following exposure to UV in NIH 3T3 
cells 
Asynchronously growing NIH 3T3 cells were irradiated with indicated doses of UV as 
described (Materials and Methods). Cells were collected at 10, 30, 50, 120, and 180min 
following irradiation. Samples were subjected to SDS-PAGE and expression levels of cyclin 
D1, D2 and D3 were assessed by immunoblotting. α-tubulin level was also examined to 
monitor protein loading.  
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Figure 6.6  Post-transcriptional degradation of D-cyclins in NIH 3T3 cells 
following treatment with UV 
(a) NIH3T3 cells were prepared for UV irradiation as before. 24hours post-plating, cells were 
pre-incubated with 50µM MG132 for 30minutes. Cells were irradiated with indicated doses of 
UV and harvested 3hours later. Protein profiles of D-type cyclins were obtained by 
immunoblotting. Equal α-tubulin level indicate equal loading. (b) Cyclin D3 inducible 3T3 
cells were plated for UV irradiation. Ectopic expression of cyclin D3 was induced with 1µM 
IPTG for 24hours. Cells were exposed to UV-C and harvested 3hours post-irradiation. 
Expression of exogenous (black triangle) and endogenous cyclin D3 (white triangle) was 
detected by immunoblotting.  
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Figure 6.7  Sub-G1 analysis of UV-treated C57BL MEFs and C57BL cyclin D1
-/-
 
MEFs 
Asynchronously growing (a) C57BL MEFs and (b) C57BL cyclin D1
-/-
 MEFs were plated for 
UV irradiation as described before (Materials and Methods). Cells were exposed to indicated 
doses of UV and fixed in 70% ethanol at 24h and 48h post-irradiations. Cells were processed 
for PI staining and the DNA profiles were analysed by flow cytometry. (c) Accumulations of 
sub-G1 populations were quantitatively analysed using the FlowJo programme and presented 
as bar charts.  
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Figure 6.7 cont.  Sub-G1 analysis of UV-treated C57BL MEFs and C57BL cyclin 
D1
-/-
 MEFs 
For legend, see previous page.  
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Figure 6.7 cont.  Sub-G1 analysis of UV-treated C57BL MEFs and C57BL cyclin 
D1
-/-
 MEFs 
For legend, see previous page.   
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Figure 6.8  Sub-G1 analyses of H2O2 treated NIH 3T3 and C57BL cyclin D1
-/-
MEFs 
Asynchronously growing (a) NIH 3T3 and (b) C57BL cyclin D1
-/-
 MEF were plated for H2O2 
treatment as described before (Materials and Methods). Cells were exposed to H2O2 for 
30minutes and fixed in 70% ethanol at 24h and 48h post-irradiations. Cells were processed 
for PI staining and the DNA profiles were analysed by flow cytometry.  
(c) Accumulations of sub-G1 populations were quantitatively analysed using FlowJo 
programme and presented as bar charts.  
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Figure 6.8 cont.   Sub-G1 analyses of the H2O2 treated NIH 3T3 and C57BL cyclin 
D1
-/-
MEFs 
For legend, see previous page.   
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Figure 6.9 Molecular and cellular responses of 4NQO- or H2O2- treated Molt-4 
cells 
Asynchronously growing Molt-4 cells were seeded at a cell density of 5x10
5
 cells per ml and 
were treated with (a) 4NQO or (b) H2O2 at indicated doses for 30min, at 24h post-plating. 
Cells were harvested 3h later and expression levels of D-cyclins were examined by SDS-
PAGE and immunoblotting. Only cyclin D3 protein expression was detected in both cases. 
Cellular responses of (c) 4NQO- and (d) H2O2-treated Molt-4 cells were assessed by 
collecting samples at 24h and 48h post-treatment. Fixed cells were stained with PI and their 
DNA profiles were collected by flow cytometry The distribution of cell population is 
presented. Y-axis indicates cell number as a percentage of maximum number and X-axis 
represents DNA content of cells. (e) The population of sub G1 in each sample was quantified 
using the FlowJo and presented as bar charts.  
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Figure 6.9  cont.  Molecular and cellular responses of 4NQO or H2O2 treated Molt-
4 cells 
For legend, see previous page.  
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Figure 6.9  cont.  Molecular and cellular responses of 4NQO or H2O2 treated Molt-
4 cells 
For legend, see above.  
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Chapter 7:  Investigation of azaferrocene and related 
compounds 
7.1 Introduction 
Cancer cells are frequently defective in one of more components of the DNA damage 
response. As a result, they are unable to mount protective-responses upon development of an 
aberrant DNA structure or lesions. This property makes them more susceptible to DNA 
damage-induced cell death compared to non-cancerous cells. A successful example of anti-
cancer drugs that exploits such defects is cisplatin (cis-[PtCl2(NH3)2]). It is a transition metal 
complex that can effectively induce DNA damage and subsequent cell death (Rosenberg et al., 
1969; Siddiqi and Bothe, 1987; Pabla et al., 2008). In addition to cisplatin, a number of 
ferrocene based compounds were reported to show anti-tumour activities (Kopf-Maier et al., 
1984; Osella et al., 2000; Tabbi et al., 2002). In vitro DNA cleavage assays showed that 
ferrocenium cations (oxidised form of ferrocene) could induce DNA strand breaks possibly by 
generating ROS such as ·OH (Tamura and Miwa, 1997). In collaboration with a chemistry 
research group led by Professor N. Long at Imperial College London, I have characterised a 
series of novel derivatives of azaferrocene (a heteroanalogue of ferrocene) for their 
cytotoxicity and abilities to induced DNA cleavage. Our findings led to two publications and 
the outcomes of biochemical investigation are presented below (Kowalski et al., 2006; 
Kowalski et al., 2007).   
 
7.2 Results 
7.2.1 Assessment of cytotoxic properties of 2,5-dimethylazaferrocenyl phosphonates 
Two novel azaferrocene salts (Figure 7.1; compound 2 and 3) were synthesised and 
chemically characterised as described Kowalski et al. (2006). To assess whether these 
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compounds exhibited antitumour activities, effects of these novel compounds and their 
parental compound (Figure 7.1; compound 1) on cellular viability was examined in two cell 
lines; the non-tumourigenic immortalised mouse fibroblast cell line NIH 3T3 (Jainchill et al., 
1969) and the human cervical carcinoma transformed with Human Papilloma virus, HeLa 
(Boshart et al., 1984). Cytotoxicity was analysed by assessing the metabolic conversion of a 
tetrazolium salt to a formazan product by spectrophotometric detection as described above 
(MTS assay, Materials and Methods). Treatment with up to 1mM of the parental compound 
failed to cause any marked metabolic toxicity in NIH 3T3 cells (Figure 7.1a). However, it 
induced a statistically significant reduction of cell viability in HeLa cells (Figure 7.1a; P < 
0.05). When these experiments were repeated using two novel phosphonate derivatives, 
compound 2 and 3, the former was unable to trigger any significant changes in neither of the 
cell lines employed (Figure 7.1b). On the other hand, compound 3 induced a statistically 
significant metabolic toxicity in HeLa cells but not NIH 3T3 cells (Figure 7.1c; P < 0.05).  
 
7.2.2 In vitro DNA cleaving activity of azaferrocene derivatives  
It was suggested that the cytotoxicity associated with ferrocenium cations depended upon 
their ability to induce DNA scission by promoting the generation of free radicals (Tamura and 
Miwa, 1997). To determine whether azaferrocene derivatives were also capable of promoting 
such events, a series of novel azaferrocene- and ferrocene-based compounds (Figure 7.2) were 
screened for their activities towards plasmid DNA in vitro (Kowalski et al., 2007). The DNA 
cleaving ability of the compounds was monitored using native agarose gel electrophoresis to 
follow the conversion of super-coiled plasmid (Form I) to the relaxed forms (Form II) with its 
subsequent fragmentation. A range of concentrations for each compound was tested in the 
presence and absence of thiourea (a free radical scavenger) or dithiothreitol (DTT) (a 
potentiator of free-radical-dependent DNA cleavage) (Tamura and & Miwa, 1997).  
First, plasmid DNA was treated with either ferrocene (5) or its cationic derivative, ferrocene 
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tri-iodide (6). In agreement with previous observations by Tamura and Miwa (1997), 5 
exhibited no DNA cleaving activity whereas 6 showed a moderate activity, leading to an 
accumulation of the relaxed form of DNA (II) with increasing doses of the compound (Figure 
7.3a, b). Thiourea counteracted this effect whilst DTT dramatically enhanced the scission and 
induced degradation of plasmid DNA (Figure 7.3b). Azaferrocene (3), on the other hand, 
caused minimal accumulation of form II DNA but resulted in a degradation of form I DNA to 
smaller fragments in a dose-dependent manner. This effect was slightly attenuated by thiourea 
and greatly increased by DTT (Figure 7.3c). Assessing the DNA cleaving activities of 
azaferrocene derivatives;  2,5-dimethylazaferrocene (2), N-methylazaferrocene iodide (3), N-
methyl-2,5-dimethylazaferrocene iodide (4) and 3,3’,4,4’-tetramethyl-1,1’-
diphosphaferrocene (7); demonstrated that 3 and 4 were able to induce a substantial level of 
DNA degradation even at the lowest concentration tested. In both cases, the presence of 
thiourea hardly attenuated their abilities whereas DTT strongly potentiated DNA scission 
(Figure 7.4 b, c). In contrast to 3 and 4, 2 and 7 showed much more moderate activities. Their 
cleaving activities did not seem to be affected by thiourea although they were very strongly 
potentiated by the presence of DTT (Figures 7.4a, 7.5). Taken together, these results indicated 
that the compounds had the following order of potency as DNA cleaving agent; 3 > 4 > 1 > 2 
= 7 > 6 > 5.  
 
The cationic species tested here generally showed greater potency, in comparison to their non-
charged counterparts. Thus we hypothesised that the charge interaction between these 
compounds and DNA backbone may play a role in promoting DNA cleavage was investigated. 
To do so, the DNA cleavage assays were repeated using compounds 2 and 4 in the presence 
and absence of 250mM NH4Cl. Figure 7.6 clearly demonstrates that the presence of NH4Cl, as 
a source of an excess ionic species, was able to protect plasmid DNA almost completely from 
the cleaving activities of 2 and 4. It seems possible that NH4
+
 cations shielded DNA from 
forming electrostatic interactions with azaferrocene cations and hence attenuating cleavage 
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activity.  
 
7.3 Discussion  
Our investigation of these azaferrocene-based compounds demonstrated for the first time the 
potential of azaferrocene-related compounds as DNA damaging agents. Cytotoxicity assays 
demonstrated that phosphonate-derivatives of azaferrocene compounds preferentially 
exhibited cytotoxicity to cancerous HeLa cells rather than non-tumourigenic NIH 3T3 cells 
albeit at a relatively high doses. Furthermore, in vitro DNA cleavage assays showed that these 
compounds were able to induce DNA scission more effectively than ferrocene-based 
compounds. Previously, it was suggested that the abilities of ferrocenium cations to induce 
DNA cleavage depended on having the iron centre with +3 oxidation state and its ability to 
promote radical generation (Tamura and Miwa, 1997; Osella et al., 2000; Tabbi et al., 2002). 
The azaferrocene-based compounds investigated herein, mostly contained +2 iron centres but 
were still able to efficiently trigger DNA degradation. Moreover, thiourea was only effective 
in reducing DNA scission in a number of cases, indicating that a mechanism other than 
generation of ROS might be responsible for the induction of DNA cleavage. The results of 
experiment using NH4Cl appeared to support our speculation that the charge interaction 
between plasmid DNA and the compounds may be important.  Altogether, the results 
presented here provided preliminary indications that metallocene-based compounds other than 
ferrocenium cations may be employed as a precursor to designing effective anticancer drugs. 
Further mechanistic analysis would likely to give useful information to develop novel tools in 
understanding bioorganometallic chemistry.  
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Figure 7.1 Effect of azaferrocenes on cell viability of NIH 3T3 and HeLa cells 
NIH 3T3 (grey bar) and HeLa (black bar) cells were treated with vehicle, 0.5 or 1mM of (a) 
N-methyl-2,5-dimethylazaferrocee iodide (compound I), (b)/(c) two phoshonate derivatives of 
compound I designated compound II and III, respectively. Cells were exposed to the 
compound for 30min, washed briefly and re-fed with complete medium. After 15h of 
incubation, cell viability was determined using the MTS assay. Data were normalised to 
untreated controls and represent the means of 4 – 6 independent experiments. The error bars 
show standard errors.  
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Figure 7.2 Structures of novel azaferrocene and ferrocene derivatives tested in DNA 
scission assays 
(a) Molecular structures of novel azaferrocene-based compounds and ferrocene derivatives 
tested for DNA scission assays. (b) Chemical names of the compounds are shown. 
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Figure 7.3  DNA cleavage activities associated with ferrocene (5), ferrocenium tri-
iodide (6) and azaferrocene (1) 
DNA cleavage activities associated with (a) ferrocene (5), ferrocenium tri-iodide (6), and (c) 
azaferrocene (1) were examined by incubation of supercoiled plasmid DNA with each 
compound at indicated concentrations. Reaction product was resolved by agarose gel 
electrophoresis as described above (Materials and Methods). Effect of 1mM thiourea or DTT 
on DNA cleaving activities of 6 and 1 were also tested (b, c). Amount of supercoiled DNA (I) 
and relaxed DNA (II) was visualised under UV illumination.  
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Figure 7.4  DNA cleavage activities 2,5-dimethylazaferrocene(2), N-
methylazaferrocene iodide(3) and N-methyl-2,5-dimethylazaferrocene iodide(4) 
Supercoiled plasmid DNA was treated with (a) 2,5-dimethylazaferrocene(2), N-
methylazaferrocene iodide(3) or (c) N-methyl-2,5-dimethylazaferrocene iodide(4) in the 
presence and absence of 1mM thiourea or DTT. Reaction product was resolved by agarose gel 
electrophoresis as described above (Materials and Methods). Amount of supercoiled DNA (I) 
and relaxed DNA (II) was visualised under UV illumination.  
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Figure 7.5 DNA  scission by 3,3’,4,4’-tetramethyl-1,1’-diphosphaferrocene (7) 
Supercoiled plasmid DNA was treated with 3,3’,4,4’-tetramethyl-1,1’-diphosphaferrocene (7) 
in the presence and absence of thiourea or DTT. Reaction product was resolved by agarose gel 
electrophoresis as described above (Materials and Methods). Amount of supercoiled DNA (I) 
and relaxed DNA (II) was visualised under UV illumination.  
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Figure 7.6  Effect of NH4Cl on the DNA cleavage caused by compound 2 and 4 
Supercoiled DNA was treated with either (a) compound 2 or (b) compound 4 in the presence 
and absence of 250mM NH4Cl as a source of excess ionic species. The reaction products were 
subjected to agarose gel electrophoresis and the formation of form I (supercoiled) and II 
(relaxed) DNA was viewed by UV illumination.   
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Chapter 8:  Summary and General Discussion 
The ability of cells to perturb their cell cycle to ensure that the initiation of late events occurs 
only after the completion of early events is referred to as regulation by “checkpoints” 
(Hartwell and Weinert, 1989). DNA damage responses often result in alterations to cell cycle 
progression to allow for DNA repair or cell death to take place and thus can be refer to as 
DNA damage checkpoint. Since the introduction of this concept, the signalling pathways 
involved have come under intense scrutiny (Kastan and Bartek, 2004; Ishikawa et al., 2006; 
Harper and Elledge, 2007). The importance of understanding these cellular events was 
realised from the close association between a number of severe cancer-prone human disorders 
and mutations of genes encoding for damage-responsive proteins. For instance, rare genetic 
disorders like ataxia telangiectasia (A-T), Nijmegen breakage syndrome (NBS), A-T like 
disorder (A-TLD), and Li-Fraumeni Syndrome (LFS) are related to defect in ATM, Nbs1, 
Mre1, and p53/Chk1/Chk2, respectively, all of which have been implicated in damage-sensing 
and upstream signal transduction during DNA damage response (Weinert and Lydall, 1993; 
Hall and Angele, 1999; Kastan and Lim, 2000; Wang, 2000; Vahteristo et al., 2001). Although 
our understanding of the DNA damage response and its regulation has made great strides 
forward, further effort is required to fully understand the pathways and  utilise our findings to 
develop effective treatment for such debilitating diseases.  
 
This study aimed to characterise the DNA damage response triggered by 4NQO-induced DNA 
lesions at both molecular and cellular levels, with a particular focus on the role of cyclin D1. 
Amongst the proteins examined, cyclin D1 and p21 were the two components of the cell cycle 
machinery whose expression levels consistently changed in a dose-dependent manner 
following an exposure to 4NQO in NIH 3T3 cells (Figure 3.1, 3.3a). The changes of their 
expression levels took place in three stages; (1) at a low dose (2.5µM), cyclin D1 expression 
was maintained whilst p21 accumulated dramatically, (2) at an intermediate range of 4NQO 
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doses (10-75µM), both cyclin D1 and p21 levels diminished to undetectable levels, (3) at 
doses 100µM and above, cyclin D1 and p21 expression appeared largely unchanged (Figure 
3.1, 3.3a). Exposure to UV also triggered similar alterations of cyclin D1 and p21 levels in a 
dose-dependent manner whereas, these responses could not be reproduced even with a range 
of doses of other sources of genotoxic stress such as H2O2 or IR (Figures 3.2, 3.3b, 3.5). 
Where cyclin D1 was detectable, pRb was found phosphorylated, particularly at the cyclin 
D1-CDK4-specific sites (Figures 3.6a, 3.8). A novel species of pRb that migrated in between 
hypo- and hyer-phosphoylated forms of pRb was identified in cells treated with a high dose 
(200µM) of 4NQO (Figure 3.6a). This pRb with a unique electrophoretic mobility was not 
observed in cells treated with H2O2 (Figure 3.6b). These observations indicated that there 
were at least two distinct damage-induced signalling pathways; one that responds 
predominantly to DNA adduct formation such induced by UV and 4NQO and another that 
responds to strand breaks primarily associated with H2O2 and IR.  
 
The DNA damage response activated by 4NQO treatment caused multi-phase cell cycle 
arrests at all doses tested here (Figures 4.8-4.10). Although cyclin D1 has been implicated in a 
number of cell cycle regulatory roles other than the activation of CDK4/6, such as formation 
of inactive complex with CDK2 (Higashi et al., 1996) and a potential inhibition of DNA 
replication by binding to PCNA (Fukami-Kobayashi and Mitsui, 1999), these functionalities 
alone could not describe the cellular responses observed here. Comparing the molecular and 
cellular responses associated with different doses of 4NQO suggested that the cell cycle 
arrests observed were most probably the cumulative result of several damage-induced 
pathways such as ATM/ATR-Chk2/Chk1-CDC25 and p53-dependent regulation of p21 as 
discussed above (Section 4.3.3). Interestingly, there appeared to be a correlation between the 
presence of cyclin D1 and the lack of apoptotic cell death (Section 4.2.3), indicating a 
potential protective role of cyclin D1 during the DNA damage response. A greater 
accumulation of the sub-G1 population in cells lacking cyclin D1 expression (Figure 4.14) 
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seemed to support this hypothesis.  
 
Previously, a number of components of the cell cycle machinery have been implicated in 
apoptotic regulation. However, the literature on their actual roles during apoptosis has been 
rather confused. In fact, diametrically opposing roles of various cell cycle proteins have been 
reported. For example, it has been shown that apoptotic cells exhibit increased activities of 
CDK1 and dominant negative mutants of CDK1, 2 and 3 suppressed apoptosis induced by 
tumour necrosis factor α (Shi et al., 1994; Kasten and Giordano, 1998; Mirzayans et al., 
1999). On the other hand, others suggested that an inhibition or depletion of cyclin A-CDK2/1 
or cyclin D-CDK4 promote apoptosis (Hahntow et al., 2004; Cai et al., 2006; Thoms et al., 
2007a; Thoms et al., 2007b). Similarly, contrasting evidence for pRb’s roles in the DNA 
damage response was found; several lines of evidence suggested that pRb acts as a negative 
regulator of apoptosis by inhibiting E2F-1-dependent transcription of pro-apoptotic genes  
which contradicts the suggestion that the dephosphorylation of pRb promotes apoptosis 
(Haas-Kogan et al., 1995; Berndt et al., 1997; Kasten and Giordano, 1998; Lin et al., 2001; 
Wang et al., 2001; Stevens et al., 2003; Rogoff and Kowalik, 2004). Inevitably, differences in 
the genotypes of cell lines used as well as the precise experimental procedures employed 
could play a role in creating these discrepancies. However, the primary source of such 
conflicting observations appears to be our limited understanding of the functional diversity 
endorsed by covalent modifications of these proteins. As discussed previously (Introduction), 
phosphorylation of cell cycle proteins, such as CDKs, plays a critical role in regulating their 
activities and subsequently the cell cycle progress. Often, a single protein contains multiple 
phosphorylation sites and individual modification is associated with particular functions. For 
instance, a phosphorylation of pRb at S780 disrupts its interaction with E2F transcription 
factors whilst phosphorylation at T821 and T826 regulates interactions between pRb and 
LxCxE motif-containing proteins (Kitagawa et al., 1996; Knudsen and Wang, 1996). 
Differential phosphorylation of p21 and p27 regulates their abilities to act as inhibitors or 
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activators of G1- cyclin-CDK complexes (Child and Mann, 2006; James et al., 2008). A 
recent report identified a novel regulatory pathway where a PI3K-responsive kinase, Akt, was 
shown to phosphorylate CDK2. Although a transient activation of Akt during normal cell 
cycle promotes cell survival, a constitutive activation of Akt and the subsequent 
phosphorylation of CDK2 observed during damage response was shown to promote apoptosis 
(Maddika et al., 2008). As can be seen, a single phosphorylation can act as a “molecular 
switch” for various cellular proteins. Other covalent modifications, including acetylation and 
ubiquitination may further increase the functional diversity of the cellular proteins. Thus, 
understanding the consequences associated with different modification of proteins could be 
the key for reconciling the discrepancies in the literature.  
 
The results presented above suggested that cyclin D1 is likely to be regulated by 
phosphorylation during damage-responses. A dramatic degradation of cyclin D1 following 
exposure to 4NQO, UV or IR required an intact T286 (Figure 5.8), the residue which has been 
shown to instigate cyclin D1 destabilisation when phosphorylated (Diehl et al., 1997; Alt et 
al., 2000; Alao, 2007). The cyclin D1 destabilisation associated with 4NQO exposure was 
caffeine sensitive yet intact in immortalised A-T cells (AT5BI VA) suggesting that it is most 
likely dependent on ATR (Figures 5.14, 5.15). However, it was independent of Chk1 (Figure 
5.16b), Chk2 (Figure 5.16c), p53 and pRb (Figure 5.12a), some of which are known to be the 
downstream targets of ATR (Lakin and Jackson, 1999; Tibbetts et al., 1999; Guo et al., 2000; 
Zhao and Piwnica-Worms, 2001; Wang et al., 2006). Furthermore, neither GSK3β nor 
SAPK2/p38
MAPK
 were required for the 4NQO-induced cyclin D1 degradation (Figures 5.9, 
5.10) although a number of groups have previously suggested that their activities were 
responsible for stress-induced T286 phosphorylation and subsequent degradation of cyclin D1 
(Diehl et al., 1998; Casanovas et al., 2000). While preparing this thesis, Hitomi and 
colleagues reported that the T286-phosphorylation directed degradation of cyclin D1 in 
response to UV and during S phase of cell cycle and that this was dependent on the activities 
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of ATR. The ATR homologue, ATM, mediates this response following the induction of DSB 
(Hitomi et al., 2008). They showed that depletion of ATR expression by small interference 
RNA (siRNA) can attenuate UV-induced destabilisation of cyclin D1. The T286 
phosphorylation induced by DSB was sensitive to an ATM inhibitor. My findings presented 
above appear to be consistent with their observations. In order to extend our knowledge on the 
role of cyclin D1 in the DNA damage response, it is essential to identify cyclin D1 T286 
kinases that are responsive to ATR and ATM. Recently, a number of groups have complied 
profiles of ATM and ATR substrates phosphorylated in response to DNA damage. They 
showed that these kinases alone can target several hundreds of phosphorylation sites most of 
which have not been characterised before (Matsuoka et al., 2007; Stokes et al., 2007).  One of 
these unidentified targets could be the kinase responsible for cyclin D1 phosphorylation. 
Further investigation is required to decipher this signalling pathway. Amongst the ATR-
responsive proteins, Roche and colleagues have demonstrated that a forkhead associated 
(FHA) domain-containing protein, Smad nuclear interacting protein 1 (SNIP1), is required for 
cell proliferation and is able to regulate the activities of cyclin D1 promoter in a p53-
independent manner (Roche et al., 2004). The FHA domain mediates protein-protein 
interaction especially via motifs containing phospho-threonine residues (Durocher and 
Jackson, 2002). It is commonly found in DNA damage proteins such as Chk2 and MDC1  
(Lee and Chung, 2001; Goldberg et al., 2003), indicating a possibility that SNIP1 may also 
have a function in the DNA damage response. Indeed, it was suggested that SNIP1 is 
phosphorylated and its activity is required for ATR-dependent damage signalling following 
UV exposure (Roche et al., 2007). Although no direct link has been examined, it is possible 
that SNIP1 may contribute to a regulation of damage-induced changes of cyclin D1 
expression at a transcriptional regulation.  
 
As our understanding of DNA damage signalling has advanced, a single protein stands out 
from the rest for its exceptional ability to interact with a wide range of DNA damage 
 N. Suwaki 
Page | 208  
 
responsive proteins as well as those involved in other fundamental cellular events; BRCA1. 
BRCA1 was cloned in 1994 as a 220kDa protein whose loss of function was responsible for 
up to 50% of familial breast cancer (Miki et al., 1994; Easton et al., 1995). It consists of an 
amino-terminal RING (really interesting new gene) domain, two nuclear localisation signals 
and tandem C-terminal repeats known as BRCT (Brca1 C-terminus). The RING domain of 
BRCA1 mediates an interaction with its binding partner, BARD1 (BRCA1 associated RING 
domain 1), which also contains a RING motif. The resulting BRCA1-BARD1 heterodimer 
exhibits E3 ubiquitin ligase activity (Lorick et al., 1999; Brzovic et al., 2001; Baer and 
Ludwig, 2002; Xia et al., 2003; Morris and Solomon, 2004). The BRCT-domain, on the other 
hand, is a phospho-protein binding domain (Manke et al., 2003; Yu et al., 2003). It is 
conceivable that BRCA1 recruits a phosphorylated substrate of BRCA1-BARD1 complex via 
its BRCT domain for ubiquitination. BRCA1 is an extremely versatile protein which mediates 
numerous cellular processes by interacting directly or indirectly with cell cycle regulators, 
transcriptional regulators, DNA repair proteins and tumour suppressors (Brodie and Deng, 
2001; Yoshida and Miki, 2004). It has also been implicated in DNA damage-induced cell 
cycle arrests at G1, S, and G2/M phases via physical and functional associations with the 
upstream components of DNA damage signalling such as ATR, ATM, Chk1, Chk2 and MRN 
complex (Scully et al., 1997; Lee et al., 2000; Tibbetts et al., 2000; Xu et al., 2001; Yarden et 
al., 2002; Scully et al., 2004; Deng, 2006). These proteins were shown to regulate BRCA1 by 
inducing differential phosphorylation at multiple target sites although biological consequences 
of these phosphorylation are largely uncharacterised (Cortez et al., 1999; Lee et al., 2000; Xu 
et al., 2002; Lin et al., 2004; Ouchi, 2006). In addition, BRCA1 is required for the regulation 
of the downstream components of the DNA damage response. For instance, BRCA1-BARD1 
complex was shown to be required for IR-induced G1/S arrest via p53 whilst BRCA1-
dependent induction of GADD45 was shown to play a part in establishing G2/M arrest in 
response to Taxol treatment (Mullan et al., 2001; Fabbro et al., 2004).  Just under a decade 
ago, a concept of Brca1-associated surveillance complex (BASC) was introduced by Wang 
 N. Suwaki 
Page | 209  
 
and colleagues. They isolated 40 proteins that interact with BRCA1 following exposure to IR 
by immunoprecipitation (Wang et al., 2000b). It was suggested that BASC may translocate 
various sub-complexes in response to the presence of DNA damage and activate downstream 
signalling (Futaki and Liu, 2001).  
 
Incidentally, several functional relationships between the protein of the interest to this thesis, 
cyclin D1, and BRCA1 have been reported. For instance, BRCA1 was shown to interact with 
various cyclins and CDKs and its expression is regulated in a cell cycle-dependent manner 
(Chen et al., 1996; Wang et al., 1997). Indeed, the BRCA1 promoter contains a binding site 
for E2F-1 and thus BRCA1 expression was stimulated by ectopic expression of cyclin D1 and 
CDK4 as their activities can relieve the E2F-inhibitory function of pRb (Wang et al., 2000a). 
Additionally, BRCA1 was shown to cause growth arrest in a pRb-dependent manner, 
indicating possible negative feedback regulation (Aprelikova et al., 1999). Interestingly, 
BRCA1 and cyclin D1 appear to have opposing effects in terms of their cellular 
functionalities. For instance, cyclin D1 acts as an antagonist of BRCA1 as it competes for the 
binding with estrogen receptor α (ERα) and subsequently interferes with BRCA1-mediated 
repression of ERα-dependent gene expression (Wang et al., 2005). Another study suggested 
that cyclin D1 inhibits recruitment of BRCA1 to a subset of promoters by phosphorylation 
(Kehn et al., 2007). BRCA1 is also phosphorylated by other CDKs such as CDK2, which may 
affect the functional relationships between cyclin D1 and BRCA1 (Ruffner et al., 1999).  
Furthermore, BRCA1 was shown to promote DNA damage repair whilst the presence of 
cyclin D1 was suggested to be inhibitory towards DNA repair due to its ability to associated 
with PCNA (Pagano et al., 1994; Burma et al., 2006; Shrivastav et al., 2008). Although there 
has been no direct evidence linking BRCA1 and cyclin D1 during DNA damage response to 
my knowledge, their functionalities as described above seem to point towards a presence of 
counteractive relationships between BRCA1 and cyclin D1 during DNA damage response. 
Very recently, Kranz et al. (2008) proposed that BRCA1 and a histone acetyltransferase, 
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Tip60, regulate distinct pathways that converge to induce apoptotic cell death in response to a 
low dose (20J/m
2
) of UV. In this study, they demonstrated that a pre-induction of p53 by a 
non-genotoxic drug or reduction of MDM2 expression led to an induction of p21 and 
subsequent down-regulation of BRCA1, promoting cell survival. On the other hand, knocking 
down Tip60 diminished UV-induced apoptosis even in cells lacking p53, indicating that the 
Tip60-dependent response is not affected by p53 (Kranz et al., 2008). As presented above, my 
results suggested that cyclin D1 antagonise pro-apoptotic signalling and its ATR-dependent 
destabilisation was associated with the onset of apoptotic events such as caspase 3 activation 
(Figures 4.5, 5.15) and the accumulation of sub-G1 population (Figure 4.6). For 4NQO- and 
UV-treated cells, p21 accumulation was induced at low doses (2.5µM and 15J/m
2
, 
respectively), which was abrogated in SV40-immortalised cells, indicating that it was at least 
partly p53-dependent (Figure 5.12). Taken together with the findings of Kranz et al. (2008), I 
propose a model where BRCA1 acts as an upstream regulator of cyclin D1 in response to 
4NQO/UV-induced DNA damage signalling, as illustrated in Figure 8.1. The DNA damage 
induced by UV or 4NQO activates ATR. In response to damage associated with low doses of 
these agents, cells preferentially induce a p53-dependent induction of p21 (Figure 8.1; the 
pathway designated 1). The findings by Kranz et al. (2008) suggested that this leads to the 
downregulation of BRCA1. According to the model proposed in Figure 8.1, this will result in 
the maintenance of cyclin D1 expression, agreeing with my results presented in this thesis. 
Cyclin D1 subsequently cooperates with p21 to promote cell survival. In response to damages 
caused by intermediate doses of UV or 4NQO, cells activate pro-apoptotic signalling where 
ATR-dependent activation of p53 leads to upregulation of pro-apoptotic proteins such as Bax 
(Figure 8.1; the pathway designated 2a). A lack of p21 upregulation leaves BRCA1 
expression intact which is then subjected to phosphorylation by ATR (Figure 8.1; the pathway 
designated 2b). Currently, the functional consequences of BRCA1 phosphorylation by ATR 
are largely unknown (Ouchi, 2006). Considering the presence of the BRCT domain that 
would allow BRCA1 to recognise phospho-protein and the E3 ligase activity associated with 
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the RING domain of BRCA1, it is possible that BRCA1 may act as a regulator of cyclin D1 
expression during the DNA damage response. Perhaps, ATR-dependent phosphorylation of 
BRCA1 promotes down-regulation of cyclin D1 phosphorylated at T286 residue via 
proteasome-dependent pathway.  As a result, anti-apoptotic effect of cyclin D1 is relieved and 
thus resulting in the activation of apoptotic cell death. The observation that BRCA1 is 
required for caspase-3 activation seems to fit the proposed model (Martin and Ouchi, 2005). 
Conceivably, cyclins D2 and D3 (that were also down-regulated in response to UV) may be 
regulated in a similar manner.  
 
In order to test the proposed role of BRCA1 as a regulator of cyclin D1 expression during the 
DNA damage response, the 4NQO-induced changes in cyclin D1 needs to be established in 
BRCA1-null cell lines such as HCC1937 (BRCA1-null human breast cancer cell line)  or 
UWB1.289 (BRCA1-null human ovarian cancer cell line) (Yarden et al., 2002; DelloRusso et 
al., 2007). Should the response of cyclin D1 be altered in these BRCA1-null cells, the 
changes in cellular responses such as incidence of apoptotic cell death and cell cycle 
progression need to be assessed. So far, the investigations in the BRCA1-null cell lines have 
reported that a lack of BRCA1 rendered cells more susceptible to IR-induced DNA damage 
due to defective S and G2/M checkpoint responses. It would be interesting to see whether 
BRCA1-null cells would also exhibit an increased susceptibility towards 4NQO-induced 
DNA damage. In order to directly compare the consequence of BRCA1-null mutation on the 
4NQO-induced DNA damage response with the results presented in this thesis, it would be 
ideal to use a BRCA1
-/-
 mouse cell line as most studies here were carried out in NIH 3T3 cells. 
However, the access to such cell line is currently limited as BRCA1 null mutation causes 
embryonic lethality (Hakem et al., 1998; Brodie and Deng, 2001). It is worth noting that 
BRCA1 knockout mice exhibit developmental defect in mammary glands, eyes and 
cerebellum, similarly to those observed in cyclin D1 knockout mice. A potential problem of 
using the BRCA1-null cancer cell lines is that they frequently exhibit increased chromosomal 
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abnormalities. In particular, BRCA1-linked cancer cells commonly show p53 mutations 
(Scully et al., 2004; Deng, 2006). Considering p53 is one of the key components of the DNA 
damage response, a lack of functional p53 could dramatically affect the molecular and cellular 
responses of a cell line following an exposure to a DNA damaging agent. Thus, the 
experiments should be complemented with a use of small interference RNA (siRNA) to knock 
down the expression of BRCA1 from normal cell lines and observe its effect on the 4NQO-
induced DNA damage response. Furthermore, the ability of the wild type BRCA1 expression 
to restore a normal DNA damage response in the BRCA1-null or siRNA knocked down cells 
should also be analysed. 
 
In addition to investigating the potential role of BRCA1 in regulation of cyclin D1, it would 
be of our interest to further our understanding of the functions of cyclin D1 in the DNA 
damage response. The questions that remain to be answered include whether the roles of 
cyclin D1 in the DNA damage response require CDK4/6 activities and the identity of the 
kinase that is responsible for phosphorylating cyclin D1 at T286 residue following 
4NQO/UV-induced DNA damage. Moreover, establishing whether similar dose-dependent 
responses of cyclin D1 and p21 are observed following treatments with commonly used 
chemotherapeutic drugs such as doxorubicin, vincristine and methotrexate may allow us to 
identify a new biomarker for cancer treatment. Considering the oncogenic properties of D-
type cyclins and the detrimental consequences associated with the defects in DNA damage 
responses, it is essential that we understand the functions and regulation of these proteins in 
molecular detail. This study has revealed novel dose-dependent changes in cyclin D1 
expression following exposure to 4NQO or UV. The investigation of molecular and cellular 
events surrounding the changes in cyclin D1 expression led to a hypothetical signalling 
pathway as proposed in Figure 8.1. Furthermore, cyclins D2 and D3 exhibited differential and 
previously reported responses to distinct DNA damaging agents. With critical roles as sensors 
of extracellular stimuli during cell proliferation and potential anti-apoptotic functions, D-type 
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cyclins are undoubtedly one of the most promising targets for developing cancer treatment. 
By fully appreciating the roles of D-type cyclins in DNA damage response, it may become 
possible to develop treatment tailored to induce a specific cellular response in cancer cells, 
perhaps by using DNA damage-inducing agents like azaferrocene-based compounds.  
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Figure 8.1  A hypothetical signalling pathway regulating cyclin D1 expression 
Kranz et al. (2008) suggested that Tip60 and BRCA1 compose two distinct pathways through 
which cells induce apoptotic cell death. Whereas BRCA1-dependent pathway appears to be 
regulated by p53-dependent induction of p21, the Tip60-dependent pathway was proposed to 
be independent of p53. Combined with the results presented in this thesis, it was proposed 
that cyclin D1 expression maybe regulated by BRCA1. For the details, refer to the text above.  
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Appendix 
Plasmids carrying cyclin D1 mutants were stably co-transfected with a plasmid encoding a 
gene conferring puromycin resistance. Individual colonies of NIH 3T3 cells successfully 
carrying the recombinant plasmids were selected for puromycin resistance. The stable cell 
lines expressing the exogenous FLAG-tagged cyclin D1 (black triangles) at a similar or lower 
level than the endogenous cyclin D1 (white triangles) were employed for the investigation 
and these clones are indicated in bold letters below.  
 
